 
 
 
 
 
Protocol Title  
E- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination  of 
Elotuzumab,  Lenalidomide  and Dexamethasone  in High -Risk Smoldering Multiple Myeloma  
 
NCT #: [STUDY_ID_REMOVED]  
 
IRB Appro val Date: 04/09/2021  
  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
1  
 Local  Protocol #: 14-338 
Bristol -Myers  Squibb  Protocol  #: CA 204-119 
Celgene  Protocol  #: RV-CL-MM-PI-004473  
 
TITLE: E - PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of 
Combination  of Elotuzumab,  Lenalidomide  and Dexamethasone  in High -Risk  
Smoldering Multiple Myeloma  
 
Coordinating  Center:  Dana -Farber  Cancer  Institute  
450 Brookline Avenue  
Boston,  MA 02115  
Phone:  617-632-4198  
Fax: 617-582-8608  
 
 
Principal  Investigator  (PI):   Irene  M. Ghobrial,  MD 
Dana -Farber Cancer Institute 
Irene_Ghobrial@dfci.harvard.edu  
 
Statist ician:  Project  Manager:  
Lorenzo Trippa  Alexandra  Savell  
Dana -Farber  Cancer  Institute  Dana -Farber  Cancer  Institute  
Ltrippa@jimmy.harvard.edu  Asavell@partners.org  
 
 
 
Agent(s):  Elotuzumab,  Bristol -Myers  Squibb 
Lenalidomide, Celgene 
Dexamethasone, commercial  
 
 
IND #: 122322  
 
 
Amendment  10/ 10.0/  April  9th, 2021  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
2  
 CYCLES  1-2 
• 
• 
• Elotuzumab  days 1, 8, 15, 22 
Lenalidomide  days 1-21 
Dexamethasone  days 1, 8, 15, 22 Cycle  Length:  28 days  
CYCLES  3-8 
• 
• 
• Elotuzumab  days 1, 15 
Lenalidomide  days 1-21 
Dexamethasone  days 1, 8, 15 Cycle  Length:  28 days  
MAINTENANCE  (CYCLES  9-24) 
• Elotuzumab  Day 1 
• Lenalidomide  Days  1-21 
• Dexamethasone  Day 1 
Cycle  Length:  28 days  
Stop  
Therapy  **At any time 
• Progression  to Active  Myeloma  
• Unacceptable  Toxicity  
• Refusal  
• Alternative  Therapy  REGISTRATION*  
Event 
Monitoring 
up to 3  SCHEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Disease  Assessment : Day 1 of each cycle  *Stratify  based on age  and cytogenetics:  
• Age ≥65 years  
• High  Risk Cytogenetics  based  on t(4:14), 
t(14:16), 17p deletion, or p53 mutation, 
and 1q amplification  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
3  
  
 
TABLE OF CONTENTS  
SCHEMA  ................................ ................................ ................................ ................................ .........  2 
SYNOPSIS  ................................ ................................ ................................ ................................ ....... 6 
1. OBJECTIVES  ................................ ................................ ................................ ......................  9 
1.1 Study  Design  ................................ ................................ ................................ ............  9 
1.2 Primary  Objectives  ................................ ................................ ................................ . 10 
1.3 Secondary  Objectives  ................................ ................................ .............................  10 
2. BACKGROUND  ................................ ................................ ................................ ................  10 
2.1 Multiple  Myeloma  ................................ ................................ ................................ .. 10 
2.2 MGUS  and SMM  consistently  precedes  multiple  myeloma  ................................ .. 11 
2.3 Molecular  studies  in MGUS  and SMM  ................................ ................................ .. 11 
2.4 Definition  of SMM  ................................ ................................ ................................ . 13 
2.5 Definitions  of high-risk SMM  ................................ ................................ ................  14 
2.6 Treatment  of high risk SMM  ................................ ................................ ..................  14 
2.7 Elotuzumab ................................ ................................ ................................ .............  15 
2.8 Ration ale for Elotuzumab  in SMM  ................................ ................................ ........  15 
2.9 Rationale  for dose and schedule  of Elotuzumab  ................................ ....................  16 
2.10 Trial  Rationale  ................................ ................................ ................................ ........  21 
2.11 Correlative  Studies  Background  ................................ ................................ .............  22 
3. PARTICIPANT  SELECTION  ................................ ................................ ...........................  23 
3.1 Eligibility  Criteria  ................................ ................................ ................................ .. 23 
3.2 Exclusion Criteria  ................................ ................................ ................................ ... 25 
3.3 Inclusion  of Women and Minorities  ................................ ................................ ....... 26 
4. REGISTRATION PROCEDURES  ................................ ................................ ....................  26 
4.1 General  Guidelines  for DF/HCC  and DF/PCC  Institutions  ................................ .... 26 
4.2 Registration  Process  for DF/HCC  and DF/PCC  Institutions  ................................ .. 26 
4.3 General  Guidelines  for Other  Investigative  Sites  ................................ ...................  27 
4.4 Registration  Process  for Other  Investigative  Sites  ................................ .................  27 
5. TREATMENT PLAN  ................................ ................................ ................................ ........  27 
5.1 Treatment  Regimen  ................................ ................................ ................................  27 
5.2 Pre-Treatment  Criteria  ................................ ................................ ............................  30 
5.3 Agent  Administration  ................................ ................................ .............................  31 
5.4 General  Concomitant  Medication  and Supportive  Care  Guidelines  ......................  33 
5.5 Criteria  for Taking  a Participant  Off Protocol  Therapy  ................................ .........  34 
5.6 Duration  of Follow  Up ................................ ................................ ...........................  35 
5.7 Criteria  for Taking  a Participant  Off Study  ................................ ............................  36 
6. DOSI NG DELAYS/DOSE  MODIFICATIONS  ................................ ................................  36 
6.1 Elotuzumab ................................ ................................ ................................ .............  36 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
4  
 6.2 Lenalidomide  ................................ ................................ ................................ ..........  36 
6.3 Dexamethasone  ................................ ................................ ................................ ...... 40 
6.4 Guidelines  for Elotuzumab  Infusion  in Subjects  with Infusion  Reactions  .............  42 
7. ADVERSE  EVENTS:  LIST  AND  REPORTING  REQUIREMENTS  .............................  44 
7.1 Expected  Toxicities  ................................ ................................ ................................  44 
7.2 Adverse  Event  Characteristics  ................................ ................................ ................  46 
7.3 Expedited  Adverse  Event  Reporting  ................................ ................................ ...... 46 
7.4 DF/HCC  Expedited  Reporting  Guidelines  ................................ .............................  46 
Overdose  of Lenalidomide  ................................ ................................ ................................ . 49 
7.5 Expedited  Reporting  to the Food  and Drug  Administration  (FDA)  .......................  49 
7.6 Expedited  Reporting  to Bristol -Myers  Squibb  (BMS)  ................................ ...........  49 
7.7 Expedited  Reporting  to Celgene  ................................ ................................ ............  49 
7.8 Expedited  Reporting  to Hospital  Risk Management  ................................ ..............  50 
7.9 Routine  Adverse  Event  Reporting  ................................ ................................ ..........  50 
8. PHARMACEUTICAL  INFORMATION  ................................ ................................ ..........  50 
8.1 Elotuzumab ................................ ................................ ................................ .............  50 
8.2 Lenalidomide  ................................ ................................ ................................ ..........  52 
8.3 Dexamethasone  ................................ ................................ ................................ ...... 54 
9. BIOMARKER,  CORRELATIVE,  AND  SPECIAL  STUDIES  ................................ .........  56 
9.1 Bone  Marrow  Aspirate  Samples  ................................ ................................ .............  57 
9.2 Peripheral  Blood  Samples  ................................ ................................ ......................  58 
10. STUDY  CALENDAR  ................................ ................................ ................................ ........  61 
11. MEASUREMENT  OF EFFECT  ................................ ................................ .........................  62 
11.1 Development  of symptomatic  disease  ................................ ................................ .... 62 
11.2 Antitumor  Effect  ................................ ................................ ................................ .... 63 
12. DATA  REPORTING  / REGULATORY  REQUIREMENTS  ................................ ...........  70 
12.1 Data  Reporting  ................................ ................................ ................................ ....... 70 
12.2 Data  Safety  Monitoring  ................................ ................................ ...........................  70 
13. STATISTICAL  CONSIDERATIONS.  ................................ ................................ ..............  70 
13.1 Study  Design/Endpoints  ................................ ................................ .........................  70 
13.2 Sample  Size,  Accrual  Rate and Study  Duration  ................................ .....................  72 
13.3 Stratification  Factors  ................................ ................................ ..............................  72 
13.4 Interim  Monitoring  Plan ................................ ................................ .........................  72 
13.5 Stopping  Rule  for Safety  ................................ ................................ ........................  72 
14. PUBLICATION  PLAN  ................................ ................................ ................................ ...... 73 
15. REFERENCES  ................................ ................................ ................................ ...................  74 
APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  ................................ .............................  78 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
5  
 APPENDIX  B: PREPARATION  AND  ADMINISTRATION  OF ELOTUZUMAB  ...................  79 
APPENDIX  C: 14-338 SPECIMEN  COLLECTION  SCHEDULE  ................................ ..............  82 
APPENDIX  D: 14-338 SPECIMEN  REQUISITION  ................................ ................................ .... 84 
APPENDIX  E: DF/HCC  MULTI -CENTER  DATA  AND  SAFETY  MONITORING  PLAN  ...... 85 
1. INTRODUCTION  ................................ ................................ ................................ ..............  89 
1.1 Purpose  ................................ ................................ ................................ ...................  89 
1.2 Multi -Center  Data  and Safety  Monitoring  Plan Definitions  ................................ ... 89 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  ................................ ................................  90 
2.1 DF/HCC  Sponsor  ................................ ................................ ................................ ... 90 
2.2 Coordinating  Center  ................................ ................................ ...............................  91 
2.3 Participating  Institution  ................................ ................................ ..........................  91 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  ..............................  92 
3.1 Protocol  Distribution  ................................ ................................ ..............................  92 
3.2 Protocol  Revisions  and Closure s ................................ ................................ ............  92 
3.3 Informed Consent Requirements  ................................ ................................ ............  93 
3.4 IRB Documentation  ................................ ................................ ................................  93 
3.5 IRB Re -Approval  ................................ ................................ ................................ ... 93 
3.6 Participant  Confidentiality  and Authorization  Statement ................................ ....... 94 
3.7 DF/HCC  Multi -Center  Protocol  Registration  Policy  ................................ .............  94 
3.8 DF/HCC  Protocol  Case  Number  ................................ ................................ ............  95 
3.9 Safety  Assessments  and Toxicity  Monitoring  ................................ ........................  96 
3.10 Data  Management  ................................ ................................ ................................ .. 97 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  ................................ ..........................  97 
5. MONITORING:  QUALITY  CONTROL  ................................ ................................ ..........  98 
5.1 Ongoing  Monitoring  of Protocol  Compliance  ................................ ........................  98 
5.2 Monitoring  Reports  ................................ ................................ ................................  99 
5.3 Accrual  Monitoring  ................................ ................................ ................................  99 
6. AUDITING:  QUALITY  ASSURANCE  ................................ ................................ ............  99 
6.1 Audit  Plan:  DF/HCC  Sponsored  Trials  ................................ ................................ .. 99 
6.2 Audit  Notification  ................................ ................................ ................................ ... 99 
6.3 Audit  Reports  ................................ ................................ ................................ ........  100 
6.4 Participating  Institution  Performance  ................................ ................................ ... 100 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
6  
 SYNOPSIS  
 
 
 
 
 
Study  Rationale  Early therapeutic interventions in patients with smoldering MM will 
prevent/delay progression to overt MM. Recent studies of a phase III trial of 
lenalidomide and dexamethasone vs. placebo showed improved response, 
progression free survival and overall sur vival in patients with high risk  
SMM compared to placebo control. Therefore, there is a need to examine 
novel therapeutic combinations in patients with high risk smoldering MM. 
Based on the activity of lenalidomide and dexamethasone in patients with 
high r isk SMM and based on the safety and activity profile of elotuzumab 
and lenalidomide in patients with relapsed MM, we propose to examine the 
activity  of elotuzumab  and lenalidomide  in patients  with high risk SMM.  We 
will identify the role of early intervent ion on prevention of progression in 
patients with high -risk SMM who have a 50% rate of progression at 2 years.  
 
 
 
Products  Elotuzumab is a humanized recombinant monoclonal IgG1 antibody 
product directed to human SLAMF7 (CD2 -subset -1, also known as 
CRACC),  a cell surface  glycoprotein  that is highly  expressed  in MM cells.  
Lenalidomide  (REVLIMID®),  a thalidomide  analogue,  is an 
immunomodulatory agent with antiangiogenic properties.  
Dexamethasone  is a synthetic  adrenocortical  steroid.  
 
 
 
 
 
 
Study 
Objectives  Primary  Objectives  
• To determine the proportion of high risk smoldering multiple 
myeloma  patients  who are progression  free at 2 years  after receiving 
elotuzumab, lenalidomide and dexamethasone combination therapy  
Secondary  Objectives  
• To assess the response rate  of the combination in these  patients  
• To assess time to progression  
• To assess duration of response  
• To assess overall  survival  
• To assess  safety  of the combination  
• To examine molecular  evolution of  the tumor cells 
• To determine  the role of immune  cells in the progression  of 
smoldering MM  
• To determine minimal  residual  disease (MRD)  
Efficacy 
Endpoints  Response  will be assessed  using  the IMWG  criteria  for response  in Multiple 
Myeloma.  
Safety 
Endpoints  AEs will be evaluated  during the  treatment  period  using  CTCAE v4.03.  
Study  Design  This is a phase II study using the combination of elotuzumab, lenalidomide 
and dexamethasone  in patients  with high-risk smoldering  multiple  myeloma.  
 
Dosing  Regimen  Each  Cycle  = 28 days 
Cycle 1 & 2  
• Elotuzumab  (IV):  Days  1, 8, 15 ,22 
• Lenalidomide  (oral):  Day 1-21 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
7  
  
 • Dexamethasone:  (oral  and IV): Days  1, 8, 15, 22 
Cycles  3-8 
• Elotuzumab  (IV):  Days  1 and 15 
• Lenalidomide  (oral):  Day 1-21 
• Dexamethasone:  (oral  and IV): Days  1, 8, 15 
Cycles  9-24 (maintenance)  
• Elotuzumab  (IV):  Days  1 
• Lenalidomide  (oral):  Day 1-21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Select  Inclusion 
Criteria  • Age  18 years.  
• Must have smoldering myeloma with high risk markers based on the 
Mayo  OR the Spanish  criteria  and including  the new criteria  for SMM  as 
described below:  
o Monoclonal  protein  in the serum  of  3gm/dL  and >10%  plasma 
cells in the bone marrow with a free light chain ratio outside the 
range of 0.125 to 8  
OR 
o Ratio or abnormal to normal bone marrow plasma cells greater 
than or equal  to 95 perce nt or at least one immunoglobulin  level 
lower than the normal range  
• No evidence  of CRAB  criteria  or new criteria  of overt  MM which 
includes the following:  
o Increased  calcium  levels  (corrected  serum  calcium  >0.25  mmol/L 
(>1mg/dL) above the upper limit of normal OR >2.75 mmol/L 
(>11mg/dL)  
o Renal  insufficiency  (attributable  to myeloma);  
o Anemia  (Hgb  2g/dL  below  the lower  limit  of normal  or 
<10g/dL);  
o Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with 
compression  fractures)  
o No evidence of the following new criteria for active MM 
including the following:  Bone marrow plasma cells ≥60%, 
Serum  involved/uninvolved  FLC ratio ≥100,  and MRI  with more 
than one focal lesion (>5mm)  
• ECOG  Performance  Status  (PS) 0, 1, or 2. (Appendix  A) 
• The following laboratory  values obtained   21days  prior to registration:  
o ANC   1000/ L 
o PLT  50,000/ L 
o Total  bilirubin  ≤ 2.0 mg/dL  (If total is elevated  check  direct  and 
if normal patient is eligible.)  
o AST   3 x institutional  upper limit  of normal  (ULN)  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
8  
  
 o ALT   3 x institutional  upper limit  of normal (ULN)  
• Estimated  creatinine clearance   60mL/min  or a creatinine  2.2 mg/dL  
 
 
 
 
Select  Exclusion 
Criteria  • Symptomatic  Multiple  Myeloma  or any evidence  of CRAB  criteria.  Any 
prior  therapy  for active  Myeloma  should  also be excluded.  Prior  therapy 
for smoldering  myeloma  is not an exclusion  criteria.  Concurrent  therapy 
with bisphosphonates are not excluded.  
• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any 
ancillary therapy considered investigational. Prior therapy with 
bisphosphonate is allowed. Prior radiation therapy to a solitary 
plasmacytoma  is allowed. Prior clinical trials for smoldering MM or 
MGUS  are allowed  as long as the last therapy  was at least 2 months  prior 
and there was no improvement in M spike.  
Study  Duration  60 months  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
9  
 1. OBJECTIVES  
The paradigm of therapy in Smoldering Multiple Myeloma (SMM) is changing as we develop 
better therapeutic agents that prevent end organ damage and improve survival of patients with 
multiple myeloma (MM)1-3. Indeed, recent studies of a phase III trial of le nalidomide and 
dexamethasone  versus  placebo  showed  improved  response,  progression  free survival  and overall 
survival in patients with high risk smoldering MM compared to placebo control4. Therefore, 
there is a need to examine novel therapeutic combinations in patients with high risk smoldering  
MM.  Based  on the activity  of lenalidomide  and dexamethasone  in patients  with high risk SMM 
and based on the safety and activity profile of elotuzum ab and lenalidomide in patients with 
relapsed  MM5-8, we propose  to examine  the activity  of elotuzumab  and lenalidomide  in patients 
with high risk SMM.  
 
Pretreatment of MM cells with lenalidomide in -vitro enhances elotuzumab -induced antibody - 
dependent cell -mediated cytotoxicity (ADCC) against MM cells and this has also been 
demonstrated  in in vivo xenograft  MM models6. The mechanism  of synergism  between  these  two 
agents has not been fully explored, however, recent discoveries into the precise mechanism of 
action of lenalidomide in MM has provided some insight9; lenalidomide -enhanced production of 
the cytokine interleukin -2 (IL -2), which spurs T cell production and stimulation of NK cells.  
The importance of the T cell mediated effect of lenalidomide has recently been elegantly 
demonstrated by two studies9,10, uncovering previously unknown mechanisms of action for this 
drug in MM. Lenalidomide induced IL -2 product ion in T cells was found to be due to the 
depletion of two proteins, IKZF1 and IKZF3. These proteins normally function to bind the IL -2 
promoter and repress IL -2 transcription in T cells, treatment with lenalidomide markedly 
depletes IKZF1 and IKZF3 in T c ells inducing IL -2 production and T cell activation. IL -2 is 
known to exert anti -myeloma activity through activation of NK cells. Treatment with 
lenalidomide could therefore prime NK -cells for Elotuzumab -mediated ADCC, which may 
explain the synergistic ant i-myeloma effect of these therapies. Additionally, Elotuzumab itself 
may activate a subset of CD8+ T cells which express EAT -2, and has been shown to bind to 
CD3+CD8+  T cells in blood  and bone  marrow  from  MM patients.  Interestingly,  both EAT -2 and 
CS-1 are  located on chromosome 1q, this region is amplified in 30 -50% of MM patients and is 
associated with poor prognosis and lack of response to lenalidomide plus dexamethasone. 1q 
amplification is known to be an early event in myelomagenesis and has been associ ated with an 
increased risk of conversion from SMM to overt MM.  
 
Our overarching hypothesis is that early therapeutic interventions in patients with 
smoldering MM will prevent/delay progression to overt MM. We will examine the in vivo 
activity and safety o f elotuzumab and lenalidomide in patients with high -risk SMM. We 
will identify  the role of early  intervention  on prevention  of progression  in patients  with high-risk 
SMM who have a 50% rate of progression at 2 years. This will be performed in a phase II st udy 
to determine progression -free survival (PFS) in this patient population. Secondary endpoints 
include response rate, safety of this combination in patients with high -risk SMM.  
 
1.1 Study  Design  
 
This is a phase  II study  using  the combination  of elotuzumab,  lenalidomide  and dexamethasone 
in patients with high -risk smoldering multiple myeloma.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
10  
 1.2 Primary Objectives  
 
• To determine  the proportion  of high risk smoldering  multiple  myeloma  patients  who are 
progression  free at 2 years  after receiving  elotuzumab,  lenalidomide  and dexamethasone 
combination therapy  
 
1.3 Secondary  Objectives  
• To assess the response rate  of the combination in these  patients  
• To assess time to progression  
• To assess duration of response  
• To assess overall  survival  
• To assess  safety  of the combination  
• To examine molecular  evolution of  the tumor  cells obtained  
• To determine  the role of immune  cells in the progression  of smoldering MM 
• To determine minimal  residual  disease (MRD)  
 
2. BACKGROUND  
 
2.1 Multiple Myeloma  
 
Multiple myeloma is a plasma cell neoplasm characterized by multifocal proliferation of clonal, 
long-lived plasma cells associated with an overproduction of monoclonal gammaglobulin 11. In 
2010 the International Myeloma Working Group (IMWG) defined monoclo nal gammopathy of 
undetermined significance (MGUS) by the presence of serum M -protein < 3g/dL, clonal plasma 
cell population in the bone marrow < 10%, and the absence of end -organ damage such as 
hypercalcemia (serum calcium ≥ 11.5 mg/dL), renal insufficien cy (serum creatinine ≥ 2 mg/dL), 
anemia (hemoglobin value below the lower limit of normal by more than 2 g/dL or hemoglobin 
value < 10 g/dL) and lytic bone lesions (CRAB features) that can be attributed to the plasma cell 
proliferative  disorder  12. Smolder ing multiple  myeloma  was defined  by the presence  of serum  M- 
protein ≥ 3 g/dL and/or clonal bone marrow plasma cells ≥ 10% and the absence of CRAB 
features clinically.  
 
In a large  population  based  study  in Olmsted  County,  MN, Kyle  et al. analyzed  serum  samples of 
more than 75% of residents, 50 years or older, within the county 13. They identified MGUS in 
694 of 21,463 patients tested (3.2%). While the overall prevalence was noted to be 3.2% (95 % 
CI, 3.0 to 3.5), there was a significant age dependent increa se in both sexes with the prevalence 
among persons 80 years of age or older 4 times as high as among those 50 -59 years of age. Age - 
adjusted rates were higher in men (4.0 %, 95% C.I., 3.5 to 4.4) than in women (2.7%, 95% C.I., 
2.4 to 3.0). In a subsequent study on a majority of the same patients from Olmsted County, 
Dispenzieri, et al., used the free light chain assay (FREELITE) and showed that 0.8% of people 
older than 50 years had light chain -MGUS. The total MGUS prevalence including the light  
chain -MGUS  cases  was noted  at 4.2%  (95%  C.I., 3.9 to 4.5%)  14. A limitation  of both these 
studies was that 97.3% of the residents of Olmsted County were white.  
 
For SMM  patients  a M-protein  ≥ 3 g/dL,  a FLC ratio outside  the range  of 0.125  to 8, and ≥ 10% 
plasma  cells in  the bone  marrow are  considered as adverse  factors in  this model  15,16. The 5 -year 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
11  
 rate of progression in patients with 1, 2 and 3 risk factors was 25%, 51% and 76% respectively. 
The time to progression with these risk fact ors was 10, 5.1 and 1.9 years respectively. Recently 
Rajkumar  et al. have  proposed  that SMM  with >60%  plasma  cells progress  to multiple  myeloma 
within  2 years in 95% cases and should  be treated at diagnosis even in the absence of symptoms  
17. 
Table  1: Mayo  Clinic  model  for risk factors  and % risk of progression  for smoldering  MM 
 
Model  No. of risk factors  5-year  progression  % Time  to progression 
in years  
Mayo  Clinic  model  1 25 10 Risk factors: M- 
2 51 5.1 protein  ≥ 3.0g/dL,  
≥10% plasma  cells in 
   
the BM, FLC ratio 
outside  the range of  
3  
76  
1.9 
0.125 to 8    
 
2.2 MGUS  and SMM  consistently  precedes  multiple  myeloma  
 
Since  the early  description  of monoclonal  gammopathy  of undermined  significance  it was known 
that some cases of MGUS progressed to symptomatic myeloma, but it was not clear whether all 
cases of myeloma are preceded by MGUS. In a study of more than 77,000 individuals, 55 to 74 
years of a ge, from a cancer screening trial, Landgren et al. found 71 patients who developed 
multiple myeloma18. They performed serum protein electrophoresis, immunofixation and kappa - 
lambda free light chain assay on prediagnostic samples in these patients. The stu dy showed that 
patients who eventually developed multiple myeloma consistently had MGUS in the years 
preceding development of multiple myeloma. Interestingly, in half the patients, there was a 
steady increase in the M -protein before the development of symp tomatic myeloma, while in the 
other half the M -protein stayed fairly stable. A second study by Weiss et al. found a monoclonal 
gammopathy in 27 of 30 patients (90%) in sera 2 or more years before the diagnosis of myeloma  
19. 
 
2.3 Molecular  studies  in MGUS  and SMM  
 
A recent study using SNP -based arrays compared MGUS, SMM and MM samples 20. They 
found  copy  number  abnormalities  in all stages.  The incidence  of genomic  imbalance  did increase 
from a median of 5/case for MGUS to 7.5/case for SMM and 12/case for MM. The study also 
noted certain genomic changes that were exclusive to MM including 11q and 21q gains and 16q 
and 22q deletions. Interestingly, the study found these abnormaliti es in a small subclone in 
MGUS patients indicating that most if not all of the chromosomal changes may be already 
present at the MGUS state.  These findings also support a possible role of ‘clonal tides’ in the 
evolution from precursor state to symptomatic myeloma as explained below.  
Two major pathways have been proposed as the early oncogenic events in the development  of 
the myeloma cell based on chromosomal abnormalities noted in MGUS, SMM and MM - the 
non-hyperdiploid  and the hyperdiploid  pathway.  The main  cytogenetic  changes  that have  been 
observed in MGUS and SMM are indicated in the table below.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
12  
  
Table  2: Cytogenetic  abnormalities  in MGUS,  SMM  and MM 
 
Cytogenetic 
abnormality  Involved  oncogene  MGUS%  SMM%  MM%  
IgH translocations  See below  40-50% 40-50% 50-70% 
t(11;14)(q13;q32)  CCND1 (cyclin D1) 10-25% 10-25% 15% 
t(4;14)(p16;q32)  FGFR3  and 
MMSET  2-9% 3-13% 10-15% 
t(14;16)(q32;q23)  C-MAF  2-5% 2-5% 2-5% 
Other IgH 
translocations - 
t(6;14)(p21;q32),  
t(14;20)(q32;q11) etc. CCND3  (cyclin  D3), 
MAFB, etc.  6-10% 1-10% 10% 
13q deletion  Unknown  25-50% 35-50% 40-50% 
Hyperdiploidy  Unknown  40-50% 40-50% 40-50% 
 
Other  molecular  studies  in MGUS  and SMM  included  microRNA  studies.  MicroRNAs  are single 
stranded RNA molecules that regulate gene expression posttranscriptionally and are being 
implicated in a large number of cancers 21. A study comparing miRNA profiles of normal PC, 
MGUS, SMM and MM found overexpression of mir -21, mir -106~25 and mir18 1a and mir181b 
in MGUS and MM compared to normal PCs 22. The study also found mir -32 and mir17~92 
clusters to be upregulated only in MM and not in any other forms. Mir 17~92 and Mir 106~25 
are known to have a role in B cell development as well as B cell lymphomas targeting PTEN, 
E2F1, Bcl2 and BIM 21,22. The m ir17 cluster has been shown to upregulated by the transcription 
factor c -Myc, which is considered a late event in myeloma progression 23-25. 
 
With  the advances  in deep  sequencing  techniques,  we are now able to study  the whole  genome  of 
myeloma cells and co mpare that to the normal human genome. Several studies employing these 
techniques are beginning to shift our understanding of the pathogenesis of myeloma. These 
studies have revealed that the previously held dogma that cancer progression occurred through a  
linear cumulative acquisition of mutational changes may be too simplistic. A new model of 
clonal heterogeneity is beginning to emerge 26. In fact tumor evolution may indeed proceed like 
Darwinian evolution with tumor progression involving a branching proc ess with coexistent  
clonal heterogeneity. In this model various subclones exist in a dynamic equilibrium, competing 
for limited resources and over time the subclonal populations ebb and flow under environmental 
evolutionary  pressures  with alternating  domin ance of various  subclones  at different  time points27- 
31. Most of these studies were done on patients with symptomatic multiple myeloma and as 
similar studies involving MGUS and SMM emerge, our understanding of the pathogenesis of 
myeloma from these precur sor states will continue to evolve. It is possible that the progression 
from  myeloma  precursor  state to symptomatic  disease  also involves  ‘clonal  tides’  with expansion 
of a subclone leading to progression. Several previous studies have identified clonal 
heterogeneity in a subset of MGUS patients20,32,33 . 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
13  
 2.4 Definition  of SMM  
 
The diagnosis of smoldering (asymptomatic) multiple myeloma (SMM) is based on the 
demonstration  of M-protein  in serum  (>3 gm/dL)  or urine  and/or  the presence  of 10-60% 
clonal bone marrow plasma cells (BMPC). 1-3 The risk of progression of SMM to overt 
MM is approximately 10 percent per year in the first five years after diagnosis , with 
decreasing progression rates in later years.  
 
 
But with  no evidence  of the following  CRAB*  criteria  or other  Myeloma  defining  events 
(MDE):  
 
• Increased  calcium  levels:  Corrected  serum  calcium  >0.25  mmol/L(>1mg/dL)  above  the 
upper limit of normal or >2.75 mmol/L ( >11mg/dL)  
• Renal  insufficiency  (attributable  to myeloma)  
• Anemia  (Hgb  2g/dL  below the  lower  limit of  normal  or <10g/dL)  
• Bone  lesions  (lytic lesions  or generalized  osteoporosis with  compression fractures)  
• Other  (sym ptomatic  hyperviscosity,  amyloidosis,  recurrent  bacterial  infections  (>2 
episodes in 12 months).  
 
*Participants  with CRAB  criteria  that are attributable  to conditions  other  than the disease 
under study may be eligible  
 
New  MDE  criteria that  indicates  overt MM  and not SMM  
 
The following  criteria  are now incorporated  with the CRAB  criteria  to indicate  that patients  meet 
criteria for therapy as symptomatic or overt MM:  
• Bone  marrow clonal plasma  cells >60% on bone marrow examination  
• Serum involved/uninvolved FLC ratio ≥100, provided the level of the involved free light 
chain  is at least 100mg/L  (a patient’s  “involved”  free light chain - either  kappa  or lambda - 
is the one that is above the normal re ference range; the uninvolved light chain is the one 
that typically is in, or below the normal range)*  
• More  than one  focal lesion  on MRI  that is at least  5mm or  greater in size 
*If serum  free light chain  ratio is stable  ( not increasing)  for greater  or equal  to six 
months, the patient may be eligible after discussion with the overall PI  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
14  
 2.5 Definitions  of high -risk SMM  
 
Based  on the new defined high  risk criteria  for smoldering  myeloma2,3 as described below:  
 
Bone  marrow clonal plasma cells  ≥10% and any one  or more of the following:  
Serum  M protein  ≥3.0gm/dL  
IgA SMM  
Immunoparesis  with reduction  of two uninvolved  immunoglobulin  isotypes  
Serum  involved/uninvolved  free light chain ratio  ≥8 (but less than 100) 
Progressive  increase  in M protein  level  (Evolving  type of SMM)† 
Bone  marrow clonal plasma  cells 50 -60% 
Abnormal  plasma  cell immunophenotype  (≥95%  of bone  marrow  plasma  cells 
are clonal) and  reduction of one  or more  uninvolved immunoglobulin isotypes  
t (4;14) or del  17p or 1q gain 
Increased  circulating  plasma  cells 
MRI  with diffuse  abnormalities  or 1 focal  lesion (≥5mm)  
PET-CT with one focal  lesion  (≥5mm)  with increased  uptake  without  underlying 
osteolytic bone destruction  
Monoclonal  light chain  excretion  of 500mg/24  hours  or higher*  
† Increase  in serum  monoclonal  protein  by ≥10%  on two successive  evaluations  within  a 6 
month period  
*Monoclonal  light chain  smoldering  multiple myeloma61 
 
2.6 Treatment  of high  risk SMM  
 
In a randomized open -label phase 3 trial, 119 patients with high -risk smoldering myeloma were 
randomized to treatment or observation. Patients in the treatment group received an induction 
regimen  (lenalidomide  at a dose of 25 mg per day on days 1 to 21, plus dexamethasone  at a dose 
of 20 mg per day on days 1 to 4 and days 12 to 15, at 4-week  intervals  for nine cycles),  followed 
by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of each 28 - 
day cycle for 2 years). The primary  end point was time to progression to symptomatic disease.  
Secondary end points were response rate, overall survival, and safety. After a median follow -up 
of 40 months, the median time to progression was significantly longer in the treatment group  
than in the observation group (median not reached vs. 21 months; hazard ratio for progression, 
0.18; 95% confidence interval [CI], 0.09 to 0.32; P<0.001). The 3 -year survival rate was also 
higher in the treatment group (94% vs. 80%; hazard ratio for death, 0.31; 9 5% CI, 0.10 to 0.91; 
P=0.03).  A partial  response  or better  was achieved  in 79% of patients  in the treatment  group  after 
the induction  phase  and in 90% during  the maintenance  phase.  Toxic  effects  were  mainly  grade  2 
or lower. Early treatment for patients with high -risk smoldering myeloma delays progression to 
active disease and increases overall survival. ([STUDY_ID_REMOVED]).  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
15  
 2.7 Elotuzumab  
 
Elotuzumab (HuLuc63/BMS -901608) is a humanized monoclonal IgG1 antibody  product 
directed  to human  SLAMF7  (CD2  subset -1, also known  as CRACC  ), a cell surface  glycoprotein 
with homology to the CD2 family of cell surface proteins34,35. Originally, SLAMF7 was 
identified as a natural killer cell (NK) marker and was shown to be ex pressed in a subset of 
circulating  leukocytes.10  Blood  analysis  confirmed  expression  of SLAMF7  on the cell surface  of 
NK, NK -like T -cells (NKT), activated monocytes, CD8 positive T cells and on tissue plasma 
cells.11 High SLAMF7 expression was seen in plasma cells obtained from normal healthy 
donors and from patients with MGUS, SMM, and active MM. More than 90% of MM b one 
marrow samples, irrespective of cytogenetic abnormalities, express SLAMF7.. In addition 
SLAMF7 expression is maintained in MM subjects after relapse from therapy. A paired analysis 
of a subset of subjects with MM showed that SLAMF7 gene expression is d etectable in subjects 
both at diagnosis and at relapse.  
 
In agreement with the gene chip data, flow cytometry analysis demonstrated that CD138+ 
plasma cells from MM bone marrow stained strongly positive for elotuzumab binding. In 
addition,  immunohistochemistry  (IHC)  using  anti SLAMF7  antibodies  showed  strong  staining  of 
MM cells in 9/9 plasmacytoma tissue samples and in 20/20 myeloma bone marrow cores 
tested36,37. 
 
The proposed mechanism of action of elotuzumab involves natural killer (NK) cell mediated 
antibody dependent cell -mediated cytotoxicity (ADCC). Elotuz umab monotherapy can kill MM 
cell lines and primary myeloma cells in vitro in the presence of peripheral blood mononuclear 
cells (PBMCs) or purified NK cells. In addition, elotuzumab exhibits significant in vivo 
monotherapy anti -tumor activity against huma n myeloma xenograft models grown in severe 
combined immunodeficient (SCID) mice36-38. This in vivo anti -tumor activity of elotuzumab 
appears  to be largely  dependent  on the presence  of active  NK cells.  Experiments  using  an in vivo 
mouse xenograft model sugg est that maximal antitumor activity is reached at elotuzumab serum 
levels of 70 to 430 mcg/mL.  
 
2.8 Rationale  for Elotuzumab  in SMM  
 
Although several non -clinical models demonstrated elotuzumab monotherapy activity, no 
objective responses were observed in subj ects in Study HuLuc63 -1701 (Study 1701), a Phase 1 
elotuzumab monotherapy trial in humans . This is in contrast to the high response rates observed 
in studies of elotuzumab in combination with lenalidomide/dexamethasone (Study HuLuc -1703 
(Study  1703);  or bortezomib  (Study  HuLuc -1702  (Study  1702).  The best response  in Study  1701 
was stable disease (SD) seen in 27% of all subjects. However, elotuzumab may have slowed 
disease progression in some subjects since SD was also observed in 3 subjects whose best 
response to prior therapy was progressive disease and some of the subjects had prolonged SD 
(median time to progression of 4.2 months in subjects with SD at study Day 52) suggesting 
possible maintenance or disease control.  
 
Study  1701  did not completely  rule out monotherapy  activity  for elotuzumab.  Subjects  in Study 
1701 may have had a lower likelihood of responding to elotuzumab monotherapy due to their 
prior therapies, inadequate elotuzumab dosing, and host immune status. These subjects had  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
16  
 advanced, heavily pretreated myeloma, having received a median of 4.5 prior lines of therapy  
and may have  been  less likely  to respond  to any subsequent  therapy.  In addition,  this was a Phase 
1 multiple ascending dose escalation study, in which subjects were t reated with potentially 
inadequate  doses  of elotuzumab.  Half of the subjects  received  doses  below  the threshold  required 
to consistently saturate bone marrow plasma cell SLAMF7and the percentage of subjects 
achieving SD was higher (35%) at doses adequate to saturate SLAMF7binding sites (10 and 20 
mg/kg).  
 
A primary mechanism of action of elotuzumab is NK  cell mediat ed ADCC.  In vitro, elotuzumab 
has no direct  anti-tumor  effects  and requires  the presence  of active  PBMCs  or NK cells.  In Study 
1701, heavily pretreated subjects with advanced myeloma likely had impaired immune systems, 
which may also have contributed to th e lack of objective responses. Host immune status is a 
function  of both the number  and intrinsic  activity  of specific  immune  cells and advanced  cancers 
and other hematologic diseases have impaired NK cell activity. Reduced NK cell function has 
been  reported  in advanced  myelodysplastic  syndrome.  Subjects  with active  myeloma  have  lower 
levels of a protein (DNAM -1) required for NK -mediated ADCC than control subjects or 
myeloma patients  in complete  response. In Study  1701, the total  lymphocyte  and NK cel l counts 
in all study subjects were below the mean for healthy patients.  
 
Subjects with earlier stages of myeloma have better NK activity and more cytotoxic NK cells. 
Therefore, elotuzumab may demonstrate monotherapy activity in untreated subjects in earli er 
stages of myeloma (e.g., prior to development of symptoms) and who are likely to have a better 
immune function. SMM is an appropriate patient population to test this hypothesis. Limiting 
enrollment  to high risk SMM  narrows  the population  to subjects  in whom  the risk of progression 
to active myeloma is higher (median time to progression of two years) and for whom 
chemoprevention trials are recommended.  
 
2.9 Rationale  for dose  and schedule  of Elotuzumab  
 
In this current  study,  elotuzumab  will be administered  at 10 mg/kg  per cycle.  This dose intensity 
was chosen because it matches the dose intensity in the cohort with the higher response rate in 
the phase 2 portion of study 1703.  
 
2.9.1 Non-clinical  Toxicology  
 
The expression  of the elotuzumab  target,  SLAMF7,  is restricted  to malignant  myeloma  cells and 
subsets of normal leukocytes in humans (NK, NK -like T cells [NKT], activated monocytes, a 
subset of CD8+ T cells, and tissue plasma cells). High SLAMF7 expression was seen in plasma 
cells obtained from nor mal healthy donors and from patients with MGUS, SMM, and active 
MM.11 No significant expression was detected in resting CD4+ T cells, B cells, resting 
monocytes, neutrophils, and granulocytes. Elotuzumab binding was not observed on epithelia, 
vessels, or s mooth muscle cells of any of the organs examined.  
 
Elotuzumab only recognizes human SLAMF7 protein and does not appear to bind SLAMF7 
from other species, including chimpanzee, cynomolgus monkey, dog, mini -pig, mouse, rabbit, 
rat, and rhesus  monkey.  Due to the lack of species -specific  cross -reactivity,  there  are no relevant 
animal species in which to conduct toxicological studies. Therefore, the nonclinical studies  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
17  
 consisted  primarily  of in vitro  safety  assessments  and in vivo biological  activity  assessment  to 
address the selectivity of elotuzumab and potential toxicities.  
 
Elotuzumab  (100 and 200 mcg/mL)  in vitro  had no effect  on lymphocytes,  CD3+,  CD4+,  CD8+, 
and B cell counts in blood samples from healthy donors. NK cell coun ts were decreased on 
average  by 20% at both doses  of elotuzumab.  The observed  decline  was variable  between  donors 
and ranged between 0% and 45%.  
 
Elotuzumab  at concentrations  up to500  mcg/mL  did not adversely  affect  the ability  of bone 
marrow -derived hematopoietic stem cells to differentiate down the erythroid and myeloid 
pathways.  
 
2.9.2 Clinical  Experience  with Elotuzumab  in Multiple  Myeloma  
 
As of March  2011, the elotuzumab clinical development program  has consisted of three  studies 
in active  myeloma:  Study  1701,  a Phase  1 elotuzumab  monotherapy  study;  Study  1702,  a Phase 
1 study of elotuzumab + bortezomib; and Study 1703, a Phase 1/2 study of elotuzumab + 
lenalidomide/low -dose dexamethasone.  
 
2.9.3 HuLuc63 -1701,  a Phase  1 Elotuzumab  Monotherapy  Study  
 
In this Phase 1 study, escalating doses (0.5 - 20 mg/kg) of elotuzumab monotherapy were 
administered  intravenously  (IV) every  2 weeks  for a total of 4 doses  in subjects  with advanced  
MM. Subjects with stable disease or better had the option to receive addi tional doses of 
elotuzumab. As of 03 -Jul-2009, the study is complete. A total of 35 subjects were enrolled: 3 in 
the 0.5 mg/kg cohort, 4 in the 1.0 mg/kg cohort, 6 in the 2.5 mg/kg cohort, 4 in the 5.0 mg/kg 
cohort,  4 in the 10 mg/kg  cohort,  and 14 in the 20 mg/kg  cohort.  One (1) subject  in the 10 mg/kg 
cohort did not receive study drug. The primary objective of this study was to determine the 
MTD.  
 
In the 2.5 mg/kg  cohort,  1 out of the first 3 subjects  dosed  experienced  a dose-limiting  toxicity  of 
(DLT) Grade 3 increase in blood creatinine levels leading to Grade 4 acute renal failure and that 
cohort was then expanded to include another 3 subjects. No further DLTs occurred in the 2.5 
mg/kg cohort and dosing continued up to the 20 mg/kg cohort. In  the 20 -mg/kg cohort, 1 out of 
14 subjects  experienced  a DLT  of Grade  3 hypersensitivity.  Therefore,  the MTD  was not reached 
in this study. A total of 31 SAEs were reported in 15 subjects. Six (6) of the SAEs were assessed 
as related to elotuzumab which in cluded Grade 4 acute renal failure, Grade 2 chills, Grade 2 
pyrexia, Grade 3 hypersensitivity, Grade 2 bradycardia, and Grade 2 chest discomfort. The most 
common treatment emergent AEs (TEAE) overall during the study were chills (13 [38.2%] 
subjects), fati gue (13 [38.2%] subjects), pyrexia (13 [38.2%] subjects), cough (10 [29.4%]  
subjects),  headache  (10 [29.4%]  subjects),  and anemia  (9 [26.5%]  subjects).  The most  common  
treatment -related AEs were chills (11 [32.4% subjects), pyrexia (6 [17.6%] subjects), and 
flushing  (4 [11.8%  subjects).  There  was no apparent  dose response  relationship  with respect  to 
the incidence of AEs overall or treatment related TEAEs. Most TEAEs and  treatment -related 
TEAEs were Grade 1 or Grade 2.  
 
A secondary  objective  of this study  was assessment  for preliminary  activity.  Nine  (9) subjects  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
18  
 had a best response of stable disease. Although no subject had a confirmed response, this study 
was 1) conducted  in heavily  pre-treated  subjects  with likely  compromised  immune  systems  (for 
example compromised NK cell function), and 2) did not include immune activating myeloma 
therapies such as lenalidomide or bortezomib.  
 
2.9.4 HuLuc63 -1702,  a Phase  1 Elotuzumab  + Bortezomib  Study  
 
This is a Phase 1 study of elotuzumab in combination with bortezomib (plus dexamethasone if 
applicable) in subjects with MM who have had 1 to 3 prior therapies. Escalating doses (2.5 - 
20mg/kg) of elotuzumab (dosed Days 1, 11) are administered in combinatio n with 1.3 mg/m2 
bortezomib (dosed Days 1, 4, 8, 11) in a 21 -day cycle. Subjects with disease progression at the 
end of Cycle  2 or 3 also received  an oral dose of 20 mg dexamethasone  on Days  1, 2, 4, 5, 8, 9, 
11, and 12 of each cycle thereafter.  
 
Data are preliminary as of 25 -Mar-2011, 8 subjects with relapsed and relapsed and refractory 
MM have been treated; 3 each at 2.5, 5, and 10 mg/kg and 19 at 20 mg/kg of elotuzumab 
respectively. Twenty -eight (28) subjects  in the  intent -to-treat (ITT) population recei ved at least  1 
dose of elotuzumab and all  28 subjects  (100%) experienced at least 1 AE.  No DLT was  observed 
in the study and MTD was not established up to the planned highest dose of 20 mg/kg. There 
were 23 (82.1%) subjects with an elotuzumab related AE. T he most common AEs (in 45% or 
higher,  regardless  of causality)  include  Grade  1 to 3 fatigue,  diarrhea,  anemia,  thrombocytopenia, 
nausea, hyperglycemia, lymphopenia, leukopenia, neutropenia, constipation, and peripheral 
neuropathy.  
 
Grade 3 or higher AEs occurred in 22 (78.6%) subjects of whom 7 (25%) subjects experienced 
Grade 3 or higher AEs assessed as related to  elotuzumab (lymphopenia, thrombocytopenia, 
gastroenteritis,  chest  pain,  fatigue,  and hypersensitivity).  SAEs  occurred  in 10 (35.7%)  subjects.  
 
Additionally, 6 (21.4%) subjects,  2 in the 5.0 mg/kg and 4 in the 20.0 mg/kg cohorts, withdrew 
from treatment du e to an AE (neuropathy peripheral (2 subjects), acute myocardial infarction, 
gastroenteritis,  sepsis  and pain in extremity).  No deaths  have  been  reported  due to AEs.  Overall 
there does not appear to be a dose relationship with the incidence of AEs.  
 
As of 25-Mar-2011, the best clinical response ( minimal (minor) response (MR)) and the best 
response rate ( partial response (PR)) by the combined European Group for Blood and Marrow 
Transplantation and uniform criteria33 in 27 response evaluable subjects compar e favorably to 
the historical, Phase 3 clinical trial of bortezomib monotherapy (APEX) in a similar 
population.34  The clinical  response  rate was 63% in Study  1702  compared  to 46% in APEX  and 
the objective response rate was 48% in Study 1702 compared to 38% in APEX. Finally, the 
median time to progression (TTP) was 9.5 months compared to 6.2 months in APEX.  
 
2.9.5 HuLuc63 -1703,  a Phase  1/2 Lenalidomide/dexamethasone  + Elotuzumab  (LdE)  Study  
 
2.9.5.1  Phas e 1 
 
This is a Phase  1/2 study  of elotuzumab  with lenalidomide  and low dose dexamethasone  (Ld) in 
subjects with MM who have had 1 or more prior therapies. Data are preliminary as of 25 -Mar- 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
19  
 2011. Escalating doses (5 -20 mg/kg) of elotuzumab (dosed weekly in the first 2 cycles) are 
administered  with 25 mg lenalidomide  (dosed  orally  Days  1 - 21) and 40 mg dexamethasone 
(dosed orally on Days 1, 8, 15, and 22) in a 28 day cycle.  
 
A total of 28 subjects received  elotuzumab.  One (1) subject  was withdrawn  from  the study  prior 
to receiving study drug due to investigator decision. Subjects had a median of 3 prior MM 
treatments. Three (3) subjects each received 5 mg/kg and 10 mg/kg and 22 subjects  receiv ed 20 
mg/kg of elotuzumab.  
 
No DLT was observed during dose -escalation and an MTD was not established. The interim 
safety analysis revealed a key safety signal of elotuzumab -associated infusion reactions. These 
AEs included mostly Grade 1 and 2 nausea, dyspnea, chills, and headache. Two (2) subjects in 
the 20 mg/kg cohort discontinued due to infusion reactions, one Grade 4 SAE of anaphylaxis 
(related to elotuzumab) and one Grade 3 SAE of stridor (related to elotuzumab/dexamethasone). 
Subsequent  to these  events,  a new elotuzumab  premed ication  regimen  for the whole  program  has 
been instituted to minimize infusion reactions.  
 
The final data of this trial was published  in 2012  36. Three  cohorts  were  enrolled  and treated  with 
elotuzumab  (5.0, 10, or 20 mg/kg  intravenously)  on days 1, 8, 15, and 22 of a 28-day cycle  in the 
first two cycles, and days 1 and 15 of each subsequent cycle; lenalidomide 25 mg orally [PO] on 
days 1 to 21; and dexamethasone 40 mg PO weekly. Dose -limiting toxicities (DLTs) were 
assessed during cycle 1 of each cohort , and clinical responses were evaluated during each cycle. 
The first five patients received up to six cycles of therapy; subsequent patients were treated until 
disease progression.  
 
Twenty -nine patients with advanced MM and a median of three prior MM thera pies were 
enrolled; 28 patients were treated, three each in the 5.0 -mg/kg and 10 -mg/kg cohorts and 22 in 
the 20 -mg/kg cohort. No DLTs were observed up to the maximum proposed dose of 20 mg/kg. 
The most frequent grade 3 to 4 toxicities were neutropenia (36% ) and thrombocytopenia (21%). 
Two patients experienced a serious infusion reaction (one grade 4 anaphylactic reaction and one 
grade  3 stridor)  during  the first treatment  cycle.  Objective  responses  were  obtained  in 82% (23 of 
28) of treated patients. After a median of 16.4 months follow -up, the median time to progression 
was not reached for patients in the 20 -mg/kg cohort who were treated until disease progression.  
 
2.9.5.2  Phase  2 
 
Study 1703 is continuing in Phase 2 where subjects  who have not been previously exposed to 
lenalidomide are  randomized to 10 vs 20 mg/kg elotuzumab + Ld. Data  are preliminary as of 25 - 
Mar-2011. A total of 73 subjects with a median age of 63 years were enrolled in the Phase 2 
portion;  36 subjects  received  10 mg/kg  elotuzumab  and 37 received  20 mg/kg.  In all subjects,  the 
median number of cycles of therapy to date is 10. At least 1 AE was experienced by 100% of 
subjects across both dose groups, with largely similar AE rates; there were some exceptions 
based  on preferred terms, but are not considered statistically significant or clinically meaningful.  
 
Grade 3/4 AEs, regardless of causality occurred in 68% of subjects, which were also similar 
between the 2 arms (Table 1.4.2.3 -1), and comparable to historical AE data for LD with 
lymphopenia  (16%),  neutropenia  (14%),  thrombocytopenia  (15%),  and anemia  (10%)  being  most  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
20  
 common  overall.  SAEs  were  reported  in 41% of all subjects  of which  6 (8.2%)  were  assessed  as 
drug related. Related SAEs included 1 subject with Grade 3 febrile neutropenia and Grade 4 
neutropenia; 1 subject with Grade 3 visceral leishmaniasis, Grade 4 leukopenia, and Grade 4 
thrombocytopenia; 1 subject with Grade 3 bronchitis; 1 subject with Gr ade 4 increased C - 
reactive protein and Grade 3 hyperuricemia; 1 subject with Grade 4 H1N1 influenza; and 1 
subject with Grade 3 nausea. A total of 25 subjects have discontinued treatment as of the cutoff 
date:  9 for adverse events, 9 for disease  progress ion, 4 for subject’s decision, 2 for investigators 
decision, and 1 to start a new therapy.  
 
As with prior elotuzumab studies, the interim safety analysis revealed a key safety signal of 
elotuzumab -associated infusion reactions defined for the purposes of t hese studies to include a 
pre-specified  set of AEs that occurred  on the day of, or the day after,  elotuzumab  infusion.  Rates 
of infusion reactions were similar between arms with 56.2% subjects experiencing at least one 
infusion  associated  AE. All subjects  have  received  a premedication  regimen  instituted  at the end 
of Phase 1. Common infusion -associated AEs in Phase 2 included mostly Grade 1 and 2 nausea 
(16.4%), dizziness (11%), headache (12.3%), pyrexia (13.7%), and cough (8.2%). There was 
only Grade 3 infusion associated reaction: rash in a subject at 10 mg/kg . 
 
Of the 73 treated subjects in the Phase 2 portion of this study, as of this data cut, all were 
randomized  12 weeks  months  prior  to the cutoff  date and are considered  evaluable  for response 
assessment by IMWG criteria. The ORR (  PR) in these 73 subjects was 82.2%. This ORR 
compares favorably with other Ld clinical trials in relapsed/refractory myeloma (60% ORR for 
LD in MM -009/010 and previously untreated myeloma (70% ORR for Ld in E4A03).  
 
Although  the study  is not complete,  the interim  data analysis  demonstrates  91.7%  ORR  at 10 
mg/kg arm and 73.0% ORR at 20 mg/kg arm. This ORR is based on a median of 10 cycles.  
 
Responses  were  rapid,  with a median  time to response  of approximately  1 month  in evaluable 
subjects.  
 
2.9.5.3  Infusion Reactions  
 
Treatment with therapeutic monoclonal antibodies is associated with infusion reactions with 
variable time of onset and varying levels of incidence and severity. As of March 2011 the key 
safety signal  with elotuzumab  is infusion  reactions.  As stated  above,  the definition  of an infusion 
reaction for this analysis includes relevant signs and symptoms reported the day of or the day 
after elotuzumab infusion. The most frequent elotuzumab infusion reaction AEs regardless of 
causality across all Phase 1 studies included nausea, vomiting, chills, fever, flushing, dyspnea, 
cough, headache, dizziness, and rash. The majority of infusion reaction AEs were Grade 1 or 2 
and resolved with little or no treatm ent. There was no apparent dose relationship for infusion 
reaction.  
 
To minimize  infusion  reactions,  all ongoing  elotuzumab  studies  were  amended  in 2010,  after the 
Grade 3 infusion AEs in the Phase 1 program (1701, 1702, and 1703Ph1), to ensure that all 
subjects receive premedication with IV corticosteroids, oral or IV diphenhydramine and oral 
acetaminophen prior to each elotuzumab infusion. As of 25 -Mar-2011 all subjects treated in the 
Phase 2 expansion of Study 1703 have received this amended premedicatio n regimen. Of the 73  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
21  
 treated subjects, 56% of subjects experienced at least 1 Grade 1/2 infusion associated AE either 
the day of or the day after elotuzumab infusion. In contrast, 89% of subjects in the Phase 1 of 
Study  1703  (prior  to new pre-medication  regimen)  experienced  at least 1 infusion  associated  AE 
regardless of causality. Most infusion reactions occurred during the first cycle of therapy.  
 
In summary, elotuzumab infusions have been associated with predominantly Grade 1 or 2 
infusi on reactions. All infusion reactions were managed by infusion rate changes and/or 
medications  and almost  all resolved  the same  day or within  24 hours.  In most  cases,  subjects 
have been able to continue on study. Only 1 subject premedicated with diphenhydra mine, 
acetaminophen,  and IV corticosteroids  prior  to all doses  of elotuzumab  developed  a Grade  3 
infusion reaction related to elotuzumab and discontinued.  
 
2.9.5.4  Clinical  Pharmacokinetics  
 
Blood samples were collected for estimation of serum elotuzumab concentrations following 
single and multiple dose administration in Studies 1701, 1702, and 1703. Preliminary 
pharmacokinetic  (PK)  analysis  results  limited  to Cmin and Cmax have  been  reported  for all 3 of 
these studies.  
 
Following  single  dose administration  (Study  1701)  of escalating  doses  of elotuzumab  alone,  Cmax 
increased with increasing dose over the dose range of 0.5 to 20 mg/kg. Following multiple dose 
administration of escalating doses o f elotuzumab on Days 1 and 11 of a 21 -day cycle in 
combination with bortezomib (Study 1702), the observed steady -state C min values consistently 
remained above 70 µg/mL, the minimum maximally efficacious trough concentration, following 
administration of the  10 mg/kg dose (296 to 698 µg/mL) and the 20 mg/kg dose (572 to 1092 
µg/mL).  Following  administration  of elotuzumab  every  7 days for the first 2 cycles,  and every  14 
days for all subsequent cycles in combination with lenalidomide and dexamethasone (Study 
1703),  the steady  state Cmin concentrations  associated  with the 10 mg/kg  dose ranged  from  163 to 
301 µg/mL, which was above the minimum maximally efficacious trough  concentration.  
 
2.9.5.5  Overall  Risk/Benefit  Assessment  
 
Elotuzumab is a humanized monoclonal IgG1 antibody directed to human SLAMF7, a cell 
surface glycoprotein. SLAMF7 is expressed on plasma cells and a subset of circulating 
leukocytes. Since elotuzumab does no t recognize non -human SLAMF7, minimal animal 
toxicology  has been  performed.  Non-clinical  activity  as monotherapy  as well as in combination 
led to human trials. Although as monotherapy in heavily pretreated subject the best responses 
were SD, elotuzumab sho wed high response rates in combination with bortezomib or 
lenalidomide.  
 
Elotuzumab  as monotherapy  or with bortezomib  or lenalidomide  is well tolerated.  As of March 
2011 the key elotuzumab related serious AEs have been infusion -related AEs.  
 
2.10 Trial Rationale  
 
Pretreatment of MM cells with lenalidomide in -vitro enhances elotuzumab induced ADCC 
against  MM cells,  and this has also been  demonstrated  in in vivo xenogr aft MM models,37. The 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
22  
 mechanism of synergism between these two agents has not been fully explored, however, recent 
discoveries into the precise mechanism of action of lenalidomide in MM has provided some 
insight; lenalidomide enhanced product ion of the cytokine interleukin -2 (IL -2), which spurs T 
cell production and stimulation of NK cells.  The importance of the T cell mediated effect of 
lenalidomide  has recently  been  elegantly  demonstrated  by two studies10,39, uncovering  previously 
unknown  mechanisms  of action  for this drug in MM.  Lenalidomide  induced  IL-2 production  in T 
cells was found to be due to the depletion of two proteins, IKZF1 and IKZF3. These proteins 
normally function to bind the IL -2 promotor and repress IL -2 transcription in T cells, treatment 
with lenalidomide markedly depletes IKZF1 and IKZF3 in T cells in ducing IL -2 production and 
T cell activation. IL -2 is known to exert anti -myeloma activity through activation of NK cells.  
Treatment with lenalidomide could therefore prime NK -cells for Elotuzumab -mediated ADCC, 
which may explain the synergistic anti -myelo ma effect of these therapies. The evidence for 
elotuzumab activation of immune system is based on SLAMF7 on NK cells (where EAT -2 is 
expressed). Interestingly, both EAT -2 and SLAMF7 are located on chromosome 1q, this region 
is amplified in 30 -50% of MM pat ients and is associated with poor prognosis and lack of 
response  to lenalidomide  plus dexamethasone.  1q amplification  is known  to be an early  event  in 
myelomagenesis and has been associated with an increased risk of conversion from SMM to 
overt MM.  
 
We wil l be using lenalidomide for only two years and not for longer time periods. In addition, 
patients who develop symptomatic disease will receive induction therapy with standard 
therapeutic options for multiple myeloma including combinations such as those of proteasome 
inhibitors, immunomodulators and steroids or cyclophosphamide, proteasome inhibitors and 
dexamethasone.  If we observe  any problems  with stem  cell collection,  we will follow  the current 
standard guidelines of using cyclophosphamide or plerixafor mobilization. Based on data using 
combination therapies for induction, there has been no major concerns regarding stem cell 
collections after treatment with those agents.  
 
 
2.11 Correlative  Studies  Background  
 
2.11.1  Clonal  evolution in MM 
 
The "clonal evolution" model of cancer emerged amid ongoing advances in technology, 
especially in recent years, during which next generation sequencing has provided ever higher 
resolution pictures of the genetic changes in cancer cells and heterogeneity in  tumors where 
tumor progression proceeds in a branching rather than in a linear manner, leading to substantial 
clonal diversity and coexistence of wide genetic heterogeneity40,41. The genomic complexity in 
MM was recently corroborated by massive parallel -sequencing studies displaying the lack of a 
universal driving mutation26. Recent studies have shown intraclonal heterogeneity that occurs at 
different stages of progression in MM27,28. Most recently, exome sequencing confirmed that the 
heterogeneity observe d in the transformation from MGUS/SMM to MM is likely to be an 
essential  feature  of clonal  evolution  and disease  progression42,43. Point  mutations  such as N-RAS, 
K-RAS, MYC up -regulation44, and gain or loss of chromosome 1q or 1p seem to correlate with 
disease progression from MGUS and SMM25. A progressive increase in the incidence of copy 
number abnormalities from MGUS to SMM and to MM has been recently observed45. 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
23  
  
2.11.2  Immune  cells and MM 
 
An important step in the progression of tumors is evasio n and suppression of the host immune 
system46,47. Several numerical and functional T cell abnormalities have been reported in MM48. 
Studies have shown an increase of functional T -regs in MM patients  and MM mouse models, 
which may lead to suppression of imm une effector cells49,50. It was also reported that T -regs 
increase  during  progression  in MM,  and increased  number  of T-regs are associated  with survival. 
Since, there are some conflicting data8 and lack of good murine myeloma models for analyzing 
immune  cells,  the significance  of T-regs and other  immune  cells in MM pathogenesis  is not fully 
understood.  Myeloid -derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid 
cell population with the ability to suppress immune responses. Recent studies have shown that 
MDSCs induce MM growth while suppressing T -cell-mediated immune responses. SLAMF7 is 
highly expressed on NK cells. Accumulating evidence indicates that EAT -2 mediates its 
activat ing effect on NK cells via tyrosine 127 which is believed to undergo phosphorylation on 
engagement of SLAMF7. Elotuzumab may interfere with the ability of myeloid derived 
suppressor cells (MDSC’s) to suppress anti -myeloma immune responses by T cells or oth er 
immune cells, In mice it has been demonstrated that engagement of SLAMF7 on T helper cells 
inhibited antigen induced T cell proliferation and cytokine production51, indicating that  
SLAMF7 may be inhibitory in T -cells however this would depend on the pre sence or absence of 
EAT2. Therefore the characterization of SLAMF7, EAT2 and elotuzumab treatment on T cell 
subsets remains an unanswered question in MM and may help to unravel the mechanism of 
synergy between elotuzumab and lenalidomide. Based on these st udies and based on the 
SLAMF7 role in these cells, we will focus our studies of immune regulation on 3 types of cells: 
NK cells, T -regs and MDSCS.  
 
3. PARTICIPANT  SELECTION  
 
3.1 Eligibility  Criteria  
 
3.1.1 Age  18 years.  
 
3.1.2 Must  meet  criteria  of high risk smoldering  MM as described  with one of the below 
criteria:  
• Bone  marrow clonal plasma  cells ≥10% and any  one or more of the following:  
o Serum  M protein  ≥3.0 gm/dL  
o IgA SMM  
o Immunoparesis  with reduction  of two uninvolved  immunoglobulin 
isotypes  
o Serum  involved/u ninvolved  free light chain ratio  ≥8 (but less than 100) 
▪ Free  Light  Chain  Smoldering  Myeloma  patients  as defined  in 
section 2.4 are not excluded  
o Progressive  increase  in M protein  level  (Evolving  type of SMM)†  
o Bone  marrow clonal plasma  cells 50 -60% 
o Abnormal  plasma  cell immunophenotype  (≥95%  of bone  marrow 
plasma  cells are clonal)  and reduction  of one or more  uninvolved  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
24  
 immunoglobulin  isotypes  
* All patients should have four or six color flow cytometry performed on the 
baseline bone marrow sample, as feasible. Patients evaluated for eligibility by 
Spanish  Criteria  must  have  their  result  confirmed  by four color  flow cytometry.  If 
four or six color flow cytometry is not available at the site, the baseline bone 
marrow must be sent to Dana -Farber Cancer Institute to confirm eligibility prior 
to enrollment.  
o t (4;14) or del  17p or 1q gain 
o Increased  circulating  plasma cells 
o MRI  with diffuse  abnormalities  or 1 focal  lesion (≥5mm)  
o PET-CT with one focal  lesion  (≥5mm)  with increased  uptake  without 
underlying osteolytic bone destruction  
† Increase  in serum  monoclonal  protein  by ≥10%  on two successive 
evaluations within a 6 month period  
 
3.1.3 No evidence  of CRAB  criteria*  or new criteria  of active  MM which  including  the 
following:  
• Increased calcium levels: Corrected serum calcium >0.25 mmol/L 
(>1mg/dL)  above  the upper  limit  of normal  or >2.75  mmol/L  (>11mg/dL);  
• Renal  insufficiency  (attributable  to myeloma);  
• Anemia  (Hgb  2g/dL  below the  lower  limit of  normal  or <10g/dL);  
• Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with compression 
fractures)  
• No evidence of the following new criteria for active MM including the 
following:  Bone  marrow  plasma  cells >60%,  Serum  involved/uninvolved 
FLC ratio ≥100, and MRI with more than one focal lesion  
* Participants  with CRAB  criteria  that are attributable  to conditions  other  than 
the disease under study may be eligible  
 
3.1.4 ECOG  Performance  Status  (PS) 0, 1, or 2 (Appendix  A) 
 
3.1.5 The following laboratory values  obtained  21 days prior  to registration:  
• ANC   1000/ L 
• PLT  50,000/ L 
• Total  bilirubin  ≤ 2.0 mg/dL  (If total is elevated  check  direct  and if normal 
patient is eligible.)  
• AST   3 x institutional  upper limit  of normal  (ULN)  
• ALT   3 x institutional  upper limit  of normal (ULN)  
• Estimated  creatinine clearance   60mL/min  or a creatinine  2.2 mg/dL  
 
3.1.6 Voluntary  written  informed  consent  before  performance  of any study -related  procedure 
not part of normal  medical  care,  with the understanding  that consent  may be withdrawn 
by the subject at any time without prejudice to future medical care.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
25  
 3.1.7 Females of childbearing potential* must have a negative serum or urine pregnancy test 
with a sensitivity of at least 50 mIU/mL within 10 – 14 days and again within  24 hours 
prior  to prescribing  lenalidomide  for Cycle  1 (prescriptions  must  be filled  within  7 days 
as required by Revlimid REMS®) and must either commit to continued abstinence 
from heterosexual intercourse or begin TWO acceptable methods of birth control , one 
highly effective method and one additional effective method  AT THE  SAME  TIME,  at 
least 28 days before she starts taking lenalidomide.  
 
* A female  of childbearing  potential  is a sexually  mature  female  who:  
• has not undergone  a hysterectomy  (the surgical  removal  of the uterus)  or 
bilateral oophorectomy (the surgical removal of both ovaries) or  
• has not been naturally postmenopausal (amenorrhea following cancer 
therapy  does not rule out childbearing  potential)  for at least  24 consecutive 
months (i.e ., has had menses at any time during the preceding 24 
consecutive months)  
 
3.1.8 All study participants must be registered into the mandatory Revlimid REMS® 
program,  and be willing  and able to comply  with the requirements  of the REMS® 
program.  
 
3.1.9 Females  of reproductive  potential  must  adhere  to the scheduled  pregnancy  testing  as 
required in the Revlimid REMS® program.  
 
3.1.10  Men must  agree  to use a latex  condom  during  sexual  contact  with a female  of 
childbearing potential even if they have had a successful vasectom y. 
 
3.1.11  Ability  to understand  and the willingness  to sign a written  informed  consent.  
 
3.2 Exclusion Criteria  
 
3.2.1 Symptomatic  Multiple  Myeloma  or any evidence  of CRAB  criteria  including  the new 
criteria for overt myeloma. Any prior therapy for active Myeloma should also be 
excluded. Prior therapy for smoldering myeloma is not an exclusion criterion. 
Bisphosphonates are not excluded  
 
3.2.2 Other  concurrent  chemotherapy,  immunotherapy,  radiotherapy,  or any ancillary  therapy 
considered investigational. Prior therapy with bisphosphonate is allowed. Prior 
radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials or therapy 
for smoldering MM or MGUS are allowed but should be discussed  with the Principal 
Investigator.  
 
3.2.3 Serious  medical  or psychiatric  illness  likely  to interfere  with participation  in this 
clinical study.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
26  
 3.2.4 Diagnosed or treated for another malignancy within 2 years of enrollment, with the 
exception  of complete  resection  of basal  cell carcinoma  or squamous  cell carcinoma  of 
the skin, an in situ malignancy, or low -risk prostate cancer after curative therapy.  
 
3.2.5 Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, sym ptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia,  or psychiatric  illness/social  situations  that would  limit  compliance  with 
study requirements.  
 
3.2.6 Pregnant  or nursing  women  will be excluded  from  the study  because  lenalidomide  is an 
agent with the potential for teratogenic or abortifacient effects.  
 
3.2.7 History  of allergic  reactions  attributed  to compounds  of similar  chemical  or biologic 
composition to elotuzumab or lenalidomide.  
 
3.2.8 Known seropositive for or active viral infection with human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).  Patients who are 
seropositive because of hepatitis B virus vaccine are eligible. Patients who are positive 
for hep atitis B core antibody or hepatitis B surface antigen must have a negative 
polymerase  chain  reaction  (PCR)  result  before  enrollment.  Those  who are PCR  positive 
will be excluded.  
 
 
3.3 Inclusion  of Women  and Minorities  
 
3.3.1 Both  men and women  of all  races and  ethni c groups are  eligible for  this trial. 
 
4. REGISTRATION  PROCEDURES  
 
4.1 General  Guidelines  for DF/HCC  and DF/PCC  Institutions  
 
Institutions  will register  eligible  participants  in the Clinical  Trials  Management  System  (CTMS) 
OnCore.  Registrations must occur prior to the initiation of protocol  therapy. Any  participant not 
registered to the protocol before protocol therapy begins will be considered ineligible and 
registration will be denied.  
An investigator  will confirm  eligibility  criteria and a member  of the study  team  will complete  the 
protocol -specific eligibility checklist.  
 
Following registration, participants may begin protocol therapy. Issues that would cause 
treatment  delays  should  be discussed  with the Overall  Principal  Investigator  (PI). If a participant 
does not receive protocol therapy following registration, the participant’s registration on the 
study must be canceled. Registration cancellations must be made in OnCore as soon as possible  
 
 
4.2 Registration  Process  for DF/HCC  and DF/PCC  Institutions  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
27  
 DF/HCC  Standard  Operating  Procedure  for Human  Subject  Research  Titled  Subject  Protocol 
Registration (SOP #: REGIST -101) must be followed.  
 
 
4.3 General  Guidelines  for Other  Investigative  Sites  
 
Eligible  participants  will be entered  on study  centrally  at DFCI  by the Study  Coordinator.  All 
sites should call the Research Project Manager, at the lead site.  
 
Following  registration,  participants  should  begin  protocol  therapy  as soon  as possible.  Issues  that 
would cause treatment delays should be discussed with the Overall PI.  If a participant does not 
receive  protocol  therapy  following  registration,  the participant’s  registration  on the study  must  be 
canceled.  The lead study team should be notified of ca ncellations as soon as possible.  
 
4.4 Registration  Process  for Other  Investigative  Sites  
 
To register  a participant,  the following  documents  should  be completed  by the research  nurse  or 
data manager and e -mailed to the Research Project Manager:  
• Copy  of labs and clinical  information  that satisfy  inclusion  criteria  
• Signed  participant  consent  form  
• HIPAA  authorization  form  
• Registration  Form  
• Completed  eligibility  checklist  
 
The research  nurse  or data manager  at the participating  site will then call or e-mail the Research 
Project  Manager  to verify  eligibility.  To complete  the registration  process,  the Research  Project 
Manager  will follow  DF/HCC  Standard  Operating  Procedure  for Human  Subjec t Research  titled 
Subject Protocol Registration (SOP# REGIST -101) and register the participant on the protocol. 
The lead site will then fax or email the participant study number to confirm registration.  
 
Treatment  may not begin  without  confirmation  from  the Coordinating  Center  that the 
participant has been registered.  
 
NOTE : Registration  and randomization  can only be conducted  during  the business  hours 
of 8:00 AM and 5:00 PM Eastern Time Monday through Friday. Same day treatment 
registra tions will only be accepted with prior notice and discussion with the DF/HCC.  
 
5. TREATMENT PLAN  
 
5.1 Treatment Regimen  
 
All patients  will be treated  with elotuzumab,  lenalidomide  and dexamethasone.  Patients  will also 
by stratified by age>65 years or older and hi gh risk cytogenetics based on t(4:14), t(14:16), 17p 
deletion or p53 mutation, +1q amplification.  
 
A treatment cycle  is defined  as 28 consecutive days.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
28  
  
Elotuzumab  will be administered  Cycles  1 and 2 on days 1, 8, 15, 22 and cycles  3-8 on days 1 
and 15.  Lenalidomide will be administered days 1 -21 every 28 days. Dexamethasone will be 
administered on days 1, 8, 15 and 22 on cycles 1 -2 then on days 1, 8 and 15 on cycles 3 -8. 
Patients  on maintenance  treatment  will be administered  elotuzumab  on day 1, and lenalidomide 
on days 1 -21. For treatment cycles 1 and 2, a  +/- 3 day window is allowed.  
 
For treatment  cycle  3-24, a +/-7 day window  is allowed. Treatment  will be administered  on an 
outpatient  basis.  
 
Reported adverse events and potential risks are described in Section 7.  Appropriate dose 
modifications  are described  in Section  6. No investigational  or commercial  agents  or therapies 
other than those described below may be administered with the intent to treat the participant's 
malignancy.  
 
The participant will be requested to maintain a medication diary of each dose of lenalidomide 
and dexamethasone.  The medication  diary  should  be returned  to clinic  staff at the end of each 
cycle.  
 
 
Elotuzumab  and Lenalidomide  Dexamethasone  Combination  (Cycles  1-2) 
Agent  Premedication  and 
Precautions  Schedule  Dose  Route  Cycle  Length  
 
Elotuzumab  Premedications  are 
described below  Days  1, 8, 
15, 22  
10 mg/kg  Intravenous -See 
appendix B for 
more details   
 
 
28 days 
(4 weeks)   
Lenalidomide   
None  Days  1-21 
of each 
cycle   
25 mg  
Oral 
 
Dexamethasone  Take with food; 
recommended  to be 
taken in the 
morning  Days  1, 8, 
15, 22 8 mg IV 
32 mg Oral 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
29  
  
 
Elotuzumab  and Lenalidomide  Dexamethasone  Combination  (Cycles  3-8) 
Agent  Premedication  and 
Precautions  Schedule  Dose  Route  Cycle  Length  
 
Elotuzumab  Premedications  are 
described below  Days  1 and 
15  
10 mg/kg  Intravenous - See 
appendix B for 
more details   
 
 
28 days 
(4 weeks)   
Lenalidomide   
None  Days  1-21 
of each 
cycle   
25 mg  
Oral 
 
 
Dexamethasone   
Take with food; 
recommended  to be 
taken in the 
morning   
Days  1, 15 8 mg IV 
32 mg Oral 
Day 8 40mg  Oral 
 
 
Elotuzumab  and Lenalidomide Maintenance Therapy (Cycles 9 -24) 
Agent  Premedication  and 
Precautions  Schedule  Dose  Route  Cycle  Length  
 
Elotuzumab  Premedications  are 
described below  Days 1 of 
each  cycle  20 mg/kg  Intravenous -See 
appendix B for 
more details   
 
 
28 days 
(4 weeks)   
Lenalidomide   
None  Days  1-21 
of each 
cycle  15 mg Oral 
 
 
Dexamethasone*  Take with food; 
recommended  to be 
taken in the 
morning   
Day 1  of 
each  cycle  8 mg IV 
 
28 mg  
Oral 
* After discussion with the overall PI, high -dose dexamethasone may be re -added during 
maintenance  due to biochemical  progression  (progressive  increase  in SPEP  [25%  and an absolute 
increase of 0.5g/d] or UPEP [25% and an absolute increase of 200mg/24hours] on 2 successive 
evaluations as determined by the IMWG response criteria or documented progression by the 
FreeLiteTM progressive disease criteria in the absence of serum or  urine involvement).  
Dexamethasone  should  be given  as follows  after overall  PI approval:  
 
Day Dose  Route  
1 8 mg IV 
32 mg Oral 
8 40 mg Oral 
15 40 mg Oral 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
30  
 5.2 Pre-Treatment  Criteria  
 
There  are no pretreatment  criteria  for elotuzumab  dosing.  Refer  to section  6.2 for Lenalidomide 
pretreatment criteria and 6.3 for Dexamethasone pre treatment criteria.  
 
5.2.1 Premedication  Regimen  in Subjects  without  a Prior  Infusion  Reaction  
 
• Premedication  is required  prior  to all Elotuzumab  infusions.  Refer  to table  3 for the 
guidelines for premedication.  
 
5.2.2 Premedication  Regimen  in Subjects  With  a Prior  Infusion  Reaction  
 
To be re-treated  with elotuzumab,  subjects  with a prior  infusion  reaction  must  receive  
H1, H2 blockers  and acetaminophen  at maximum  doses  specified  (e.g.,  50 mg diphenhydramine, 
50 mg ranitidine [or equivalent], and 1000 mg acetaminophen) 90 -45 minutes before initiating 
the elotuzumab.  
 
Doses  of intravenous  dexamethasone  above  10 mg require  a decrease  in the oral dexamethasone. 
Recommended dexamethasone dosing is summarized below and in Table 3.  
 
For subjects with prior Grade 2 infusion reaction, administer 10 mg IV dexamethasone (instead 
of 8 mg IV) as the premedication  steroid  90-45 minutes  before  elotuzumab.  Subjects  should  take 
30 mg oral dexamethasone 24 -3 hou rs before elotuzumab administration.  
 
For subjects with Grade 3 or recurrent Grade 2 elotuzumab infusion reactions, consultation with 
the Principal Investigator is recommended. Administer 18 mg IV dexamethasone as the 
premedication  steroid  at least 45 minu tes before  elotuzumab.  These  patients  should  receive  8mg 
of oral dexamethasone  24-12 hours  the day prior  to elotuzumab  administration.  Then,  administer 
14 mg oral dexamethasone at most 3 hours prior to elotuzumab administration.  
 
If a subject  with a prior  Grade  2 (recurrent)  or 3 infusion  reaction  also requires  dose reduction  of 
oral dexamethasone, the dexamethasone dose on the days of elotuzum ab infusion should be no 
less than 18 mg IV  (on the day of elotuzumab infusion at least 45 minutes before elotuzumab).  
 
Subjects  with a Grade  4 infusion  reaction  are not eligible  to receive  additional  elotuzumab. 
These subjects may continue to receive lena lidomide and dexamethasone. Subjects who 
experience an infusion reaction of any grade should be administered the recommended 
premedication for that reaction severity for the duration of the trial.  
 
Subjects  with prior  infusion  reactions  may receive  more  aggressive  pre-medications  after 
discussion with the Overall Principal Investigator  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
31  
 Table  3: Recommended  Corticosteroid  Premedication  
 
None  or 24-3 hours prior to 32 mg PO  Dexamethasone  
Grade 1 Elotuzumab  Infusion   
Prior  90-45 min prior  to 8mg IV Dexamethasone  
Infusion  Elotuzumab  Infusion  Diphenhydramine  25-50 mg IV or PO or equivalent  
Reaction   H1 blocker  
  Ranitidine  50mg IV  or equivalent  H2 blocker  
  Acetaminophen  650-1000mg  PO 
 
Prior  24-3 hours prior to 30mg  PO Dexamethasone  
Grade 2 Elotuzumab  Infusion   
Infusion  90-45 min prior  to 10mg IV Dexamethasone  
Reaction  Elotuzumab  Diphenhydramine  50 mg IV or PO or equivalent  H1 
  blocker  
  Ranitidine  50mg IV  or equivalent  H2 blocker  
  Acetaminophen  1000mg  PO 
 
Prior 
Grade 3 
Infusion 
Reaction  or 
recurrent 
Grade 2  24-12 hours prior to 
Elotuzumab  Infusion  8mg PO Dexamethasone  
No more  than 3 hours  prior 
to Elotuzumab Infusion  14mg  PO Dexamethasone  
90-45min  prior  to 
Elotuzumab  18mg IV Dexamethasone  
Diphenhydramine  50 mg IV or PO or equivalent  H1 
blocker  
Ranitidine  50mg  IV or equivalent  H2 blocker 
Acetaminophen 1000mg PO  
5.3 Agent  Administration  
 
The order in  which elotuzumab  and lenalidomide  are administered  does not matter.  
 
5.3.1 Elotuzumab  
 
Elotuzumab  will be administered  intravenously  at a dose of 10 mg/kg  on Days  1, 8, 15 and 22 for 
the first 2 cycles (a cycle =28 days). During cycles 3 through 8, elotuzumab will be given on  
days 1 and 15. Elotuzumab will be administered intrave nously at a dose of 20 mg/kg only on  
Day 1 for cycles 9 -24. The patient should be observed for 60 minutes after the infusion is 
complete for cycle 1 and should be observed for 30 minutes after the infusion for subsequent 
cycles.  All patients  should  have  their vital signs  checked  before  and after elotuzumab  infusion  or 
per institutional  standard.  If an infusion  reaction  occurs,  reference  section  6.4.2  for guidelines  on 
additional vital monitoring.  
 
Cycle  1 and Cycle  2 treatment  may be administered  +/- 3 days.  For subsequent  cycles  +/- 7 days 
is allowed.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
32  
 5.3.1.1  Guidelines  for Elotuzumab  infusion  in subjects  with infusion  reactions 
Please refer to section 6.4 of the protocol.  
5.3.1.2  Dose Delay or Interruption 
Please  refer  to section  6.4.3  of the protocol.  
5.3.2 Lenalidomide  
 
Lenalidomide will be given as a single daily oral dose of 25 mg per day on days 1 -21 followed 
by a 7 -day rest period for cycles 1 -8 and 15 mg per day on days 1 -21 for cycles 9 -24. Cycle 1 
and Cycle 2 treatment may be administered +/ - 3 days.  For subsequent  cycles +/ - 7 days is 
allowed.  Dose  modification  guidelines  are described  in Section  6.2 (Dose  Modifications/Delays).  
 
Lenalidomide capsules should be swallowed whole, and should not be broken, chewed or 
opened. Administration of lenalidomide should be at approximately the same time each day. 
Drug may be taken with or without food. If a dose is missed and less than 12 hours has elapsed 
since the missed dose, the patient can take the dose for that day. If more than 12 hours has 
elapsed  since  missing  a dose at the normal  time,  the patient  should  not take the dose,  but take the 
next dose at  the normal time on the  following day. If a dose is missed,  it should  be taken as soon 
as possible on the same day. If a dose is vomited, the dose should not be made up and the 
participant should continue with the regular schedule of the drug at the next dose. A drug diary 
will be provided to participants to record oral admi nistration of doses.  
 
Participants  who take more  than the prescribed  dose of lenalidomide  should  be instructed  to seek 
emergency  medical  care if needed  and contact  study  staff immediately.  Participants  experiencing 
adverse events may need study treatment m odifications (see Section 6.2).  
 
Lenalidomide  related  resources  will be provided  to all patients  prior  to receiving  lenalidomide 
therapy as part of the Revlimid REMS program. For more information regarding program 
registration and drug ordering, refer to s ection 8.2.  
 
5.3.2.1  Dose  Delay  or Interruption  
 
Dose  modification  and delay  guidelines  are described  in Section  6.2 (Dose 
Modifications/Delays)  
 
5.3.3 Dexamethasone  
 
Dexamethasone will be obtained by commercial supply in this study. This may lead to added 
costs  for the participant  or the participant’s  insurance  company.  It will be given  as an oral dose. 
Dexamethasone should be taken at approximately the same time each day. Doses of oral 
dexamethasone  should  be taken  with food and administered  per the recommended  guidelines  in 
Table 3. It is recommended that dexamethasone be taken in the morning to reduce insomnia. A 
drug diary will be provided to participants to record oral administration of doses.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
33  
 Please  refer  to Section  5.1 for instructions  on dexamethasone  dosing.  
 
5.3.3.1  Dose  Delay  or Interruption  
 
Dose  modification  and delay  guidelines  are described  in Section  6.3 (Dose 
Modifications/Delays).  
 
5.4 General  Concomitant  Medication  and Supportive  Care  Guidelines  
 
5.4.1 Medications  permitted  at Investigator’s  Discretion  
 
• Steroids, diphenhydramine, or hydroxyzine, acetaminophen/ paracetamol, H2 
inhibitors  (e.g.,  cimetidine),  leukotriene  inhibitors  (montelukast  sodium)  for the 
management of elotuzumab infusion reactions. Additional  supportive measures 
should be provided as indicated including oxygen inhalation, epinephrine, and 
bronchodilators.  
 
• At the discretion  of the treating  investigator,  patients  will receive  Pneumocystis 
jiroveci pneumonia (PJP) prophylaxis during treatment (Bactrim or acceptable 
alternative).  This may be discontinued  at the start of maintenance  therapy,  or at 
the investigator’s discretion.  
 
• Stem  cell mobilization  will be allowed  at the time of best response  or at the end 
of 8 cycles for patients who are eligible for stem cell transplant. Stem cell 
collection may be done sooner after discussion with overall PI. Standard 
mobilization treatment (with GCSF or with cyclophosphamide or plerixa for, 
etc) will be used based  on Institutional  guidelines.  Patients  may delay  treatment 
for up to 3 weeks after stem cell collection is complete.  
 
• Use of white cell growth factors [G -CSF (Filgrastim or acceptable equivalent)] 
is allowed for management of tr eatment induced neutropenia at physician 
discretion.  Daily  use of Filgrastim  is not allowed,  and participants  may receive  a 
maximum of 3 doses per week. Filgrastim should be given according to the 
ASCO guidelines. Pegfilgrastim is not to be used in replace  of filgrastim.  
 
• Patients  will receive  bisphosphonates  per recommendations  of myeloma 
therapy. A note should be placed about patients who are not receiving 
bisphosphonates for clinical reasons such as osteonecrosis of the jaw.  
 
• Nausea/Vomiting: If nausea and/or vomiting is noted at any point in time, 
premedication  with prochlorperaz ine or other  antiemetics  may be used before 
future doses.  If nausea persists in spite of the use of standard antiemetics 
additional symptom management should be as per standard antiemetic 
guidelines.  
 
• Thromboprophylaxis  is required for  all participants. Pa rticipants  may receive  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
34  
 daily aspirin administration (81 or 325 mg), daily enoxaparin (40 mgs), or low 
molecular weight heparin (type Innohep® 4500 UI anti -Xa as needed) or 
equivalent to decrease the risk of thromboembolic complications. Aspir in 
prophylaxis will be the preferred first choice unless contraindicated. It is 
recommended that if the platelet count falls below 50,000/mm3, 
thromboprophylaxis  be held to minimize  the risk of bleeding  and then resumed 
when platelet counts are equal to or  above this level.  
 
o For patients  at high  risk for thromboembolic  events,  full 
anticoagulation is recommended . 
 
5.5 Criteria  for Taking  a Participant  Off Protocol  Therapy  
 
In the absence of  treatment delays due to  adverse event(s), treatment may  continue for 24 cycles  
or until one  of the following criteria applies:  
 
• Disease  progression  
o Participants  who have  developed  symptoms  similar  to CRAB  criteria  
or MDE (see section 2.4), but are not attributable to active, 
symptomatic  myeloma  may remain  on study  after  discussion  with the 
Overall PI.  
 
• Intercurrent  illness that  prevents  further administration of treatment  
 
• Unacceptable  adverse  event(s)  
 
• Participant  demonstrates  an inability  or unwillingness  to comply  with the oral 
medication regimen and/or documentation requirements  
 
• Participant  decides  to withdraw  from  the protocol  therapy  
 
• General  or specific  changes  in the participant's  condition  render  the participant 
unacceptable for further treatment in the judgment of the treating investigator  
 
Participants will be removed from the protocol therapy when any of these criteria apply.  The 
reason for removal from protocol therapy, and the date the participant  was removed, must be 
documented  in the case report  form  (CRF).  Alternative  care options  will be discussed  with the 
participant.  
 
A QACT  Treatment  Ended/Off  Study  Form  will be filled  out when  a participant  is removed  from 
protocol therapy. This form can be found on the QACT website or obtained from the QACT 
registration staff. External sites should submit the form to the Research Project Manager.  
 
In the event  of unusual  or life-threatening  complications,  treating  investigators  must  immediately 
notify the Overall PI, Irene Ghobrial at telephone # 617 -632-4198.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
35  
  
5.6 Duration  of Follow  Up 
 
Participants will be followed for up to 3 years after removal from protocol therapy or until 
progression  to active  symptomat ic MM,  whichever  occurs  first. Assessments  will be performed 
every 3 to 6 months ( +/ - 28 days ) for up to 3 years. Patients who have undergone stem cell 
mobilization will also be followed for 3 years after removal from protocol therapy or until 
progressio n to active  symptomatic  myeloma,  whichever  occurs  first. Participants  removed  from 
protocol therapy for unacceptable adverse event(s) will be followed until resolution or 
stabilization of the adverse event.  
 
 
Participants unable to participate in follow up every 3 months may follow up every 6 months at 
PI discretion in accordance wi th standard of care follow -up frequency and COVID precautions. 
Physical exams and correlative blood draws that are not done due to virtual visits will not be 
considered violations.  Local myeloma labs must be provided to the participating site for data 
entry purposes. Bone marrow biopsy and scans are strongly recommended yearly after EOT, but 
not require however, scans and bone marrow biopsy and research samples are required at time of 
suspected disease progression  
 
The following  is required  during  the Active  Follow  Up period  (for up to  3 years):  
1. Physical  exams  are voluntary  during  this period  
a. Virtual  visits/telehealth  visits  are acceptable  
2. SPEP  and Immunofixation  
3. Serum  Free Light  Chains  (SFLC)  
4. UPEP  and Immunofixation  only for those  where  disease  is tracked  by 
the urine  
5. Serum  Immunoglobulin  test 
6. PET/CT  assessments  are strongly  recommended  yearly  and is required 
at the time of suspected progression  
a. The same  assessment  modality  should  be used consistently 
across the duration of the trial  
7. Bone  marrow  biopsies  are and strongly  recommended  yearly  after 
EOT and is required at the time of suspected progression  
8. Research  bone  marrow  samples  will be collected  at the time of any 
bone marrow biopsy/aspirate procedure  
9. Research  blood  will be collected  whenever  an in person  visit to the site 
occurs. Research blood samples that are not collected at time points in 
the collection calendar due to COVID precautions or q6 month follow 
up will not be considered violations unless it is missed at the time of 
suspected progression.  
10. Response  
11. CRAB/MDE Assessment  
12. Bone  marrow  biopsy/aspirate results  and cytogenetics/FISH  if ordered  
13. Scan  results  and modality  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
36  
 Participants who come off active follow up when they pursue other SMM or MM 
directed therapy will be followed for survival indefinitely which will capture survival 
stats, and subsequent therapy information.  
 
5.7 Criteria  for Taking  a Participant  Off Study  
 
Participants  will be removed  from  study  when  any of the following  criteria  apply:  
 
• Lost to follow -up 
• Completion  of 3 years of follow up 
• Withdrawal  of consent  for data  submission  
• Death  
 
The reason  for taking  a participant  off study,  and the date the participant  was removed,  must  be 
documented in the case report form (CRF).  
 
 
6. DOSING  DELAYS/DOSE  MODIFICATIONS  
 
6.1 Elotuzumab  
 
No dose reductions for elotuzumab are allowed. If Elotuzumab is held on Day 1 of a new cycle, 
treatment  with Lenalidomide/Dexamethasone  will also be delayed.  If Elotuzumab  is held during 
any cycle on days 8, 15, or 22, the treating investigator will decide  if Lenalidomide will be held 
using recommended guidance for retreatment below. Dexamethasone should always be given 
with Elotuzumab. The dose of dexamethasone may be modified per guidance below. Treatment 
may be delayed for a maximum of 21 days. If a pati ent must discontinue treatment with 
lenalidomide,  they may continue  to receive  elotuzumab  on study  after discussion  with the overall 
principal investigator.  
 
If a patient  must  discontinue  elotuzumab  for unacceptable  toxicity,  they may continue  to receive 
lenalidomide and dexamethasone on study after discussion and approval of the overall principal 
investigator.  
 
6.2 Lenalidomide  
 
Patients may hold treatment of lenalidomide for up to 21 if the toxicity is considered either 
possibly, probably or definite ly related to the drug. Patients may hold lenalidomide for greater 
than 21 days only after discussion  and subsequent  approval  of the overall  principal  investigator.  
 
Hematologic  Toxicities:  For adverse  hematologic  events  that are considered  possibly,  proba bly 
or definitely related to Lenalidomide, the following criteria for retreatment and dose 
modification should be followed. Treatment may be held for a maximum of 21 days. Refer to 
Table 4 for dose reduction levels for Lenalidomide.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
37  
 Non Hemat ologic Toxicity: For adverse non hematologic events that are considered to be 
possibly, probably or definitely related to Lenalidomide, the following criteria for retreatment 
and dose modification should be followed.  The treating investigator should determ ine the 
clinical significance of laboratory values or radiographic findings and attribution to study 
medications  before  a treatment  decision  is made.  Treatment  may be held for a maximum  of 21 
days. Refer to Table 4 for dose reduction levels for Lenalidomide.  
 
Dose delays and modifications will be made as indicated in the following table(s). The 
descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse  Events  (CTCAE)  version  4.0 will be utilized  for dose delays  and dose modifications.  A 
copy of the CTCAE version 4.0 can be downloaded from the CTEP website 
http:// ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
 
Hematologic  Toxicities  
 
CTCAE  4.0 Category  CTCAE  
Grade  Lenalidomide  Dose  Modification  
 
 
 
Absolute  Neutrophil  Count 
(ANC)1 Grade  1 
or 
Grade  2  
Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE 
therapy  
 
 
Grade 3 Hold  dose 
Administer  Filgrastim  
Resume  at same  dose when  ANC  is ≥ 1000  if neutropenia  is 
the only hematologic toxicity  
If other  hematologic  toxicity  ≥Grade  2 is present,  reduce 
dose one level when ANC≥1000  
 
Grade 4 Hold  dose 
Administer  Filgrastim  
Resume  therapy  at one dose  level  lower when  ANC  is ≥ 
1000  
Neutropenia  with  Fever  
 
ANC  <1000  and temperature  
≥38.5o C or 101ºF   
Grade  3 
or 
Grade  4  
Hold  dose 
Administer  Filgrastim  
Reduce  dose one level  when  ANC≥1000  
 
 
 
Thrombocytopenia  
 
 
Aspirin  prophylaxis  should  be 
held if platelets are ≤50,000  Grade  1 
or 
Grade  2 Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE 
therapy  
 
 
 
Grade  3 
or 
Grade  4 Provide  platelet  transfusion  support 
Redraw platelets  
 
If redrawn  platelet  value  ≥ 50,000  -> Do NOT  OMIT  and 
DO NOT REDUCE therapy  
 
If redrawn  platelet  value  <50,000  continue  to transfuse  at 
the discretion of the investigator and hold therapy until 
platelets are  ≥ 50,000 on Day 1 or  ≥ 30,000 intracycle  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
38  
  
   
Resume  therapy  at one dose level  lower  when  the patient’s 
platelets are ≥ 50,000 on Day 1 or ≥ 30,000 intracycle  
 
 
Anemia  Grade 1 
Grade 2 
Grade 3 Continue  to treat- Do NOT  OMIT  and DO NOT  REDUCE 
therapy  
Transfuse  at the discretion  of treating investigator  
 
Grade 4 Hold  treatment 
Transfuse  
Resume  treatment  when  hemoglobin  ≥ 8.0 g/dL 
DO NOT REDUCE therapy  
1 ANC can be calculated two ways: From the percentage of neutrophils: White Blood Count (WBC) x total 
neutrophils  (polys%  + bands%)  x 10. From  the absolute  number  of cells:  (Absolute  polys  + Absolute  bands)  x 10. 
 
 
Non Hematologic  Toxicities  
 
CTCAE  4.0 
Category  CTCAE  
Grade  Lenalidomide  Dose  Modification  
 
 
Infection  or Viral 
Ilness  with  ANC1 
≥1000  
 
Including herpes 
zoster  reactivation   
 
 
 
N/A Day 1 of Cycle: Delay cycle until infection/viral 
illness  has resolved.  Resume  treatment  at the same 
dose level. Do not dose reduce.  
 
Intracycle: Hold lenalidomide for a maximum of 21 
days to allow  for recovery.  Resume  treatment  at same 
dose level.  
 
If patient  has delay  of greater  than 21 days,  the patient 
must come off -study  
 
 
 
 
Infection  or Viral 
Illness  with  ANC1 
< 1000   
 
 
 
 
 
N/A Day 1 of Cycle:  Delay  cycle  until infection/viral 
illness has resolved. Administer filgrastim or 
equivalent as indicated.  
 
Reduce  one dose level  when  infection/virus  has 
resolved, and ANC ≥1000  
 
Intracycle: Hold lenalidomide for a maximum of 21 
days.  Reduce  one dose level  when  infection/vi rus has 
resolved and ANC ≥ 500  
 
If patient  has a delay  of less than or equal  to 21 days, 
dose reduce  to next dose level.  If patient  has delay  of 
greater  than 21 days,  the patient  must  come  off-study  
Allergic  reaction  or 
hypersensitivity to  Grade 1 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
39  
  
Lenalidomide  
 
Including  Rash 
related to 
Lenalidomide  Grade 2 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
Grade  3 
or 
Grade  4 Hold lenalidomide 
Follow  at least weekly.  
 
If toxicity  resolves  to ≤ grade  2, restart  at next lower 
dose level  
 
 
 
 
Renal/Metabolic  
 
 
For all grades, 
provide  hydration  and 
other supportive care 
as needed at the 
discretion of the 
treating investigator   
Grade 1  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade 2 Hold  Lenalidomide  until < grade  2 and resume 
treatment  at the same dose level  
 
If toxicity  recurs,  dose reduce  one dose level  at the 
treating investigator’s discretion  
 
 
Grade  3 
or 
Grade  4 Hold  Lenalidomide  until < grade  2 and resume 
treatment  with one dose level reduction  
 
If the toxicity  remains  ≥ grade  3, omit dose and restart 
at subsequent scheduled visit with one dose level 
reduction  
 
If treatment -related  toxicity  occurs  on day one of the 
cycle, the cycle will be delayed.  
 
 
 
 
 
Diarrhea, 
Constipation, 
Nausea,  or Vomiting   
Grade 1 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade 2 Treat  at the discretion  of the investigator 
Provide aggressive supportive care  
DO NOT  REDUCE  therapy  
 
Grade 3 Hold  Lenalidomide  until toxicity resolves  to < grade 2 
 
If the patient  has received  maximum  supportive  care, 
resume therapy with one dose level reduction  
 
 
Grade 4 Hold  Lenalidomide  until toxicity resolves  to < grade 2 
 
Resume  therapy  with one dose level reduction  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
40  
  
   
 
 
 
 
 
 
 
 
 
 
All other related 
toxicities  not listed 
previously in this 
table   
Grade 1  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
 
Grade 2 Continue to treat - Do NOT OMIT and DO NOT 
REDUCE  therapy  unless  considered  to be a clinically 
significant finding  
 
Provide  supportive  care as needed  
 
Grade 3 Hold  Lenalidomide  until toxicity resolves  to < grade 2 
 
Resume  therapy  with one dose level  reduction  at the 
discretion of the treating investigator  
 
 
 
 
 
Grade 4  
Hold  Lenalidomide  until toxicity  resolves  to < grade  2 
Resume therapy with one dose level reduction  
If treatment -related  toxicity  occurs  on day one of the 
cycle, the cycle will be delayed.  
 
If patient  has a delay  of less than or equal  to 21 days, 
dose reduce  to next dose level.  If patient  has delay  of 
greater  than 21 days,  the patient  must  come  off-study  
1 ANC can be calculated two ways: From the percentage of neutrophils: White Blood Count (WBC) x total 
neutrophils  (polys%  + bands%)  x 10. From  the absolute  number  of cells:  (Absolute  polys  + Absolute  bands)  x 10 
 
 
Table  4 Lenalidomide  Dose  Reduction  
 
Dose  Level  Lenalidomide Dose  
Starting  Dose  Level  25 mg 
First Dose  Reduction  20 mg 
Second  Dose  Reduction  15 mg 
Third  Dose  Reduction  10 mg 
Fourth  Dose  Reduction  5 mg 
 
6.3 Dexamethasone 
Dexamethasone  Dose  Modifications  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
41  
 Premedication with dexamethasone is required prior to all elotuzumab infusions. If there are 
clinically significant, intolerable ≥Grade 3 adverse events attributed to dexamethasone (given as 
a premedication) treatment may be delayed until recovery to ≤ Gra de 2 at the discretion of 
treating  investigator.  For adverse  events  that are considered  to be possibly,  probably  or definitely 
related to dexamethasone, the following criteria for retreatment and dose modification should be 
followed. The treating investiga tor should determine the clinical significance and attribution of 
the toxicity to dexamethasone.  If toxicity is unlikely or not related to dexamethasone, do not 
omit or reduce therapy. Patients may continue on study if oral dexamethasone has been 
permanent ly discontinued  
 
Patients who have not experienced an infusion reaction related to elotuzmab and have 
experienced an adverse event attributable to dexamethasone may have their premedication of 
dexamethasone  decreased  after completion  of cycle  1 at the discretion  of the treating  investigator 
and after discussion with the overall PI.  
 
 
CTCAE  4.0 
Category  CTCAE  Grade  Dexamethasone  Dose  Modification  
 Grade 1 Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
 
Hyperglycemia   
Grade 2 Hold  dexamethasone  until < Grade  2 and resume  at 
same dose level at the discretion of the treating 
investigator  
Treat  with oral 
medication or 
insulin at 
discretion of 
treating 
investigator    
 
Grade 3 Hold  dexamethasone  until < Grade  2 
 
Resume  therapy  with one dose level  reduction  at the 
discretion of the treating investigator  
  Hold  dexamethasone  until < Grade  2 
 Grade 4  
  Resume  therapy  with one dose level reduction  
Symptomatic 
pancreatitis  Any Grade  Discontinue  dexamethasone  permanently  
 
 
 
OTHER   
Grade 1 or 2  
Continue  to treat- Do NOT  OMIT  and DO NOT 
REDUCE therapy  
Grade 3 Hold  dexamethasone  until ≤ Grade 2 
Resume  therapy  with one dose level reduction  
Grade 4 Hold  dexamethasone  ≤ Grade  2 
Resume  therapy  with one dose level reduction  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
42  
  
 
 
 
 
Table  5 Dexamethasone  dose  reduction  
 
Total  Dexamethasone  Dose  Administration  for Patients  with  none  or Prior  Grade  1 
Infusion Reaction  
Dose  Levels  Week  with  Elotuzumab  Week Without Elotuzumab*  
PO IV PO IV 
Starting  Dose  Level  32 8 40 0 
First Dose  Reduction  28 8 20 0 
Second  Dose  Reduction  28 8 10 0 
* During  Maintenance,  patients  only receive  dexamethasone  on Day 1 
 
Total  Dexamethasone  Dose  Administration  for Patients  with  Prior  Grade  2 
Infusion Reaction  
Dose  Levels  Week  with  Elotuzumab  Week Without Elotuzumab*  
PO IV PO IV 
Starting  Dose  Level  30 10 40 0 
First Dose  Reduction  28 10 20 0 
Second  Dose  Reduction  28 10 10 0 
* During  Maintenance,  patients  only receive  dexamethasone  on Day 1 
 
 
Total  Dexamethasone  Dose  Administration  for Patients  Prior  Grade  3 or recurrent  Grade 
2 Infusion Reaction  
Dose  Levels  Week  with  Elotuzumab  Week Without Elotuzumab*  
PO IV PO IV 
Starting  Dose  Level  22 18 40 0 
First Dose  Reduction  16 18 20 0 
Second  Dose  Reduction  16 18 10 0 
* During  Maintenance,  patients  only receive  dexamethasone  on Day 1 
 
** If patient  is intolerant  of dexamethasone,  after discussion  with overall  PI, oral 
dexamethasone may be omitted at any dose level.  
 
6.4 Guidelines  for Elotuzumab  Infusion  in Subjects  with  Infusion  Reactions  
 
6.4.1 Grade  1 Infusion  Reaction  
 
Grade  1 elotuzumab  infusion -related  reactions  by definition  do not require  intervention; 
however, increased monitoring is recommended.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
43  
 6.4.2 Grade  2 Infusion  Reaction  
 
Infusion  reactions  during  the elotuzumab  infusion:  For a Grade   2 elotuzumab  infusion - related 
reaction, the infusion must be interrupted. The subject should be treated as clinically indicated 
with one or more of the following medications or interventions: antiemetics, antihistamines, 
analgesics, corticosteroids, leukotriene inhibitors, oxyg en inhalation, epinephrine, 
bronchodilators, or other supportive measures as indicated.  
 
Subjects  with a Grade  3 infusion  reaction  may be discontinued  from  study  drug at the discretion 
of the investigator, but must be discontinued if the Grade 3 infusion r eaction recurs. Subjects 
with any Grade 4 infusion reaction are not eligible to receive additional elotuzumab.  
 
If a patient’s elotuzumab regimen is discontinued before the completion of cycle 2, he or she 
must  come  off protocol  therapy.  If elotuzumab  is discontinued  after completion  of cycle  2, he or 
she can remain on protocol therapy.  
 
Once the elotuzumab infusion -related reaction has resolved to  Grade 1, the infusion can be 
restarted at 0.5 mL/minute. If symptoms do not recur after 30 minutes, the infu sion rate may be 
increased  in a stepwise  fashion  (0.5 mL/minute  every  30 minutes)  to a maximum  of 2 mL/minute 
or the rate at which the infusion reaction occurred, whichever is lower. Subjects who experience 
an infusion  reaction  require  vital signs  to be monitored  approximately  every  30 minutes  for up to 
2 hours after the end of the elotuzumab infusion. I f the elotuzumab infusion reaction recurs, the 
infusion must be stopped and not restarted on that day. Appropriate therapy should be 
administered  to address  the subject’s  signs  and symptoms.  The infusion  can be reattempted  at the 
next protocol defined infu sion time point at the investigator’s discretion with additional 
premedication as described previously.  
 
Infusion reactions after the completion of elotuzumab infusion: Should a Grade 2 infusion 
reaction  occur  following  completion  of an elotuzumab  infusion,  the subject  should  be treated  as 
clinically indicated with 1 or more of the following medications or interventions: 
diphenhydramine, acetaminophen, hydrocortisone, H2 inhibitor, leukotriene inhibitor, oxygen 
inhalation, epinephrine, br onchodilators, or other supportive measures as indicated.  
 
Elotuzumab infusions on subsequent weeks after a prior Grade 2 infusion reaction: Subjects 
with prior Grade 2 or higher infusion reactions should have future infusions started at 0.5 
mL/min  and then escalated  in a stepwise  fashion  (0.5 mL/minute  every  30 minutes).  If no Grade  
 2 infusion  reaction  recurs,  the escalation  regimen  may be resumed  and the next infusion  may 
be initiated as planned per the regimen.  
 
If a patient experiences an infusion re action of less than or equal to Grade 2, and the infusion 
reaction  does not recur,  the patient  can resume  elotuzumab  administration  at the rate at which  the 
reaction occurred at the start of the next cycle at the investigator’s discretion  
 
6.4.3 Dose  Delay  or Interruption  
 
If a patient’s elotuzumab administration is delayed on day 1 of a cycle, both lenalidomide and 
dexamethasone  will also be delayed  until the elotuzumab  is resumed,  which  would  then become  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
44  
 the new day 1 of that cycle.  
 
If a patient’s elotuzumab  is held in the middle of a cycle, lenalidomide dosing will continue as 
scheduled. If the patient’s elotuzumab is delayed during the cycle and is resumed within the 
designated window, (+/ -3 days Cycles 1 and 2; +/ -7 days Cycles 3 and beyond) the patient ma y 
receive that scheduled dose.  If the elotuzumab is not resumed within the given window (+/ -3 
days Cycles  1 and 2; +/-7 days Cycles  3 and beyond),  the patient  is to omit that dose,  and resume 
dosing at the next dosing time point. Dexamethasone should be held and resumed when 
Elotuzumab is held and subsequently resumed.  
 
Patients  may delay  treatment  for up to 3 weeks  for elective  surgeries  and other  non toxicity 
related events.  
 
 
Table  6: Dose  Delay  Instructions  
 
 To be resumed 
within  window?  Lenalidomide  Dexamethasone  Elotuzumab  
Elotuzumab 
delayed  on Day 
1 of Cycle   
N/A To be delayed 
until Elotuzumab 
is resumed  To be delayed 
until Elotuzumab 
is resumed  Resume 
dosing= new 
Day 1 of Cycle  
Elotuzumab 
held on Day 
8,15,or  22 of 
Cycle   
 
Yes  
Dosing  to continue 
as scheduled   
To be delayed 
until Elotuzumab 
is resumed  Resume dose 
any day within 
window; dose 
time point not 
skipped  
Elotuzumab 
held on Day 
8,15,  or 22 of 
Cycle   
No  
Dosing  to continue 
as scheduled  To be delayed 
until Elotuzumab 
is resumed  Resume  dosing 
at next dosing 
time point 
(skip dose)  
 
7. ADVERSE  EVENTS:  LIST  AND  REPORTING  REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of reported and/or potential AEs (Section 7.1) and the characteristics of an 
observed  AE (Section  7.2) will determine  whether  the event  requires  exped ited reporting  in 
addition to routine reporting.  
 
7.1 Expected Toxicities  
 
7.1.1 Adverse  Events  List(s)  
 
7.1.1.1  Adverse  Event  List of Elotuzumab  
 
Treatment with therapeutic monoclonal antibodies is associated with infusion reactions with 
variable  time of onset  and varying  levels  of incidence  and severity.  The key safety  signal  with 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
45  
 elotuzumab  is infusion  reactions.  As stated  above,  the definition  of an infusion  reaction  for this 
analysis includes relevant signs and symptoms reported the day of or the day after elotuzumab 
infusion.  The most  frequent  elotuzumab  infusion  reaction  AEs regardless  of causality  across  all 
Phase 1 studies included nausea, vomiting, chills, fever, flushing, dyspnea, cough, headache, 
dizziness,  and rash.  The majority  of infusion  reaction  AEs were  Grade  1 or 2 and resolved  with 
little or no treatment. There was no apparent dose relationship  for infusion reaction.  
 
7.1.1.2  Adverse  Event  List for Lenalidomide  
 
Events  that have  occurred  in >10%  of individuals  treated  with lenalidomide  include  neutropenia, 
anemia,  thrombocytopenia,  fatigue,  rash,  diarrhea,  constipation,  nausea,  loss of appetite,  itching, 
dry skin, muscle cramps, lack or loss of strength, dizziness, insomnia, swelling of the 
extremities, headache, back and joint pain, fever, cough, upper respiratory infection, and 
dyspnea.  
 
Events  that have  occurred  in >1%  of individuals  treated  with lenalidomide  include  risk of DVT, 
PE, and blood clots that could lead to stroke, heart attack, or organ failure, febrile neutropenia, 
atrial fibrillation, pneumonia or lung infections, sepsis, dehydration and renal failure.  
 
Events that have o ccurred in <1% of individuals treated with lenalidomide include rare 
treatment -emergent adverse events of angioedema, serious skin reactions including Stevens - 
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) or an allergic skin reaction 
similar  to that seen with thalidomide,  tumor  lysis syndrome  (TLS),  tumor  flare reaction  (TFR),  
and rhabdomyolysis.  In addition,  lenalidomide  has been  shown  to increase  the level  of digoxin  in 
the blood in some patients. Patients will be instructed to inform their doctor if taking digoxin.  
 
There  may be an increased  risk of second  cancers  in patients  who are on lenalidomide 
maintenance therapy after a bone marrow transplant.  
 
7.1.1.3  Adverse  events  list of Dexamethasone  
 
Events that have occurred in 10 -15% of individuals treated with dexamethasone include 
increased appetite, weight gain, sleep disturbance, hypertension, fluid retention, ankle swelling, 
bruising, infection, mood changes, slow wound hea ling, depression, and hyperglycemia, which 
may lead to fatigue, weight loss, excessive thirst and frequent urination. Events that have 
occurred in 1 -9% of individuals treated with dexamethasone include loss of appetite, muscle 
twitching,  increased  thirst,  frequent  urination,  increased  perspiration,  diarrhea,  nausea,  headache, 
bone thinning, spinal fracture or fracture of bones, tachycardia, fungal infections. Events that 
have occurred in <1% of individuals treated with dexamethasone include blurred vision,  
personality changes, stomach ulcers with bleeding that may cause hematemesis, blood in the 
stool and abdominal pain. Other, less frequent, events may include bowel perforation, irritation 
and bleeding of the esophagus, heart failure, allergic reaction tha t may lead to facial redness, 
shortness of breath, abdominal cramps and hypotension, convulsions, brain swelling, dizziness, 
cataracts,  glaucoma  and increased  blood  pressure  in the eye, development  of diabetes, pancreatic 
inflammation, abdominal swelling, hypokalemia, DVT or PE, malaise, swelling and/or redness 
of skin, allergic skin reactions, itching, hirsutism, muscle weakness or loss of muscle mass, 
rupture of tendons, menstrual cycle disturbances, facial puffiness, leading to the appearance of a  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
46  
 “moon  face”  hormonal disturbances,  and hiccups.  
 
7.2 Adverse  Event  Characteristics  
 
• CTCAE term (AE description) and grade:  The descriptions and grading 
scales found in the revised NCI Common Terminology Criteria for Adverse 
Events  (CTCAE)  version  4.0 will be utilized  for AE reporting.  All appropriate 
treatment areas should have access to a copy of the CTCAE version 4.0.  A 
copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
• For expedite d reporting  purposes  only:  
o AEs for the agent(s)  that are listed  above  should  be reported  only if the 
adverse event varies in nature, intensity or frequency from the 
expected toxicity information which is provided.  
o Other  AEs for the protocol  that do not require  expedited  reporting  are 
outlined in the next section (Expedited Adverse Event Reporting) 
under the sub -heading of Protocol -Specific Expedited Adverse  Event 
Reporting Exclusions.  
 
• Attribution  of the AE: 
o Definite  – The AE is clearly  related  to the study  treatment.  
o Probable  – The AE is likely  related  to the study  treatment.  
o Possible  – The AE may be related  to the study  treatment.  
o Unlikely  – The AE is doubtfully  related  to the study  treatment.  
o Unrelated  – The AE is clearly  NOT  related  to the study  treatment.  
 
7.3 Expedited  Adverse  Event  Reporting  
 
Investigators  must  report  to the Overall  PI any serious  adverse  event  (SAE)  that occurs  after the 
initial dose of study treatment, during treatment, or within 30 days of the last dose of treatment 
on the local institutional SAE form.  
 
For multi -institution studies where a DF/HCC investigator is serving as the Overall Principal 
Investigator, each pa rticipating institution must abide by the reporting requirements set by the 
DF/HCC. This applies to any medical event equivalent to an unexpected grade 2 or 3 with a 
possible,  probable  or definite  attribution,  all grade  4 toxicities,  and grade  5 (death)  regardless  of 
study phase or attribution.  
 
7.4 DF/HCC  Expedited  Reporting  Guidelines  
 
Investigative  sites within  DF/HCC  and DF/PCC  will report  SAEs  directly  to the DFCI  Office  for 
Human Research Studies (OHRS) per the DFCI IRB reporting policy.  
 
Other investigative sites will report SAEs to their respective IRB according to the local IRB’s 
policies  and procedures  in reporting  adverse  events.  A copy  of the submitted  institutional  SAE  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
47  
 form  should  be forwarded  to the Overall  PI within  the timeframes  detailed  in the table  below.  
 
DF/HCC  Reportable  AEs 
 
Attribution  Gr. 2 & 3 
AE 
Expected  Gr. 2 & 3 AE 
Unexpected  Gr. 4 AE 
Expected  Gr. 4 AE 
Unexpected  Gr. 5 AE 
Expected  or 
Unexpected  
Unrelated 
Unlikely  Not required  Not required  5 calendar 
days# 5 calendar 
days 24 hours*  
Possible 
Probable 
Definite   
Not required  5 calendar 
days 5 calendar 
days# 5 calendar 
days  
24 hours*  
# If listed  in protocol  as expected  and not requiring  expedited  reporting,  event  does not need  to 
be reported.  
* For participants enrolled and actively participating in the study or for AEs occurring within 
30 days of the last intervention,  the AE should  be reported  within  1 business  day of learning  of 
the event.  
 
The Overall  PI will submit  SAE  reports  from  outside  institutions  to the DFCI  OHRS  according 
to DFCI IRB policies and procedures in reporting adverse events.  
 
If, following initiation of the investigational product, it is subsequently discovered that a study 
subject is pregnant or may have been pregnant at the time of investigational pro duct exposure, 
including  during  at least 6 half lives  after product  administration,  the investigational  product  will 
be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for 
subject safety).  
 
Protocol -required  procedures  for study  discontinuation  and follow -up must  be performed  on the 
subject unless contraindicated by pregnancy (e.g., x -ray studies). Other appropriate pregnancy 
follow -up procedures should be considered if indicated. The investigator must immediately 
notify  the BMS,  Celgene  (or designee)  Medical  Monitor  of this event  and complete  and forward 
an SAE Form to BMS and Celgene (or designee) within 24 hours and in accordance with SAE 
reporting procedures described in this section.  
 
Pregnancy  
 
Any pregnancy that occurs in a female partner of a male study participant should b e reported to 
the Overall PI. Information on this pregnancy will be collected on the BMS Pregnancy 
Surveillance Form. Follow -up information regarding the course of the pregnancy, including 
perinatal  and neonatal  outcome  and, where  applicable,  offspring  information  must  be reported  on 
the Pregnancy Surveillance Form. Please contact the Research Project Manager if you do not 
have this form in your regulatory files.  
 
 
Pregnancies  and suspected  pregnancies  (including  a positive  pregnancy  test regardless  of age or 
disease state) of a female subject occurring while the subject is on lenalidomide, or within  28 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
48  
 days of the subject’s  last dose of lenalidomide,  are considered  immediately  reportable  events. 
Lenalidomide is to be discontinued immediately. The pregnancy, suspected pregnancy, or 
positive  pregnancy  test must  be reported  to Celgene  Drug  Safety  immediately  by facsimile  or 
email using the Pregnancy Initial Report Form. The female subject sho uld be referred to an 
obstetrician -gynecologist, preferably one experienced in reproductive toxicity for further 
evaluation and counseling.  
 
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Saf ety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form.  If the outcome of the 
pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the Investigator should 
report the a bnormal outcome as an AE. If the abnormal outcome meets any of the serious  
criteria,  it must  be reported  as an SAE  to Celgene  Drug  Safety  immediately  by facsimile,  or other 
appropriate method, within 24 hours of the Investigator’s knowledge of the event using the SAE 
Report Form.  
 
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality,  as SAEs.  In addition,  any infant  death after 28 days that the Investigator  suspects  is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form.  
 
Male  Subjects  
If a female  partner  of a male  subject  taking  investigational  product  becomes  pregnant,  the male 
subject taking lenalidomide should notify the Investigator, and the pregnant female partner 
should be advised to call their healthcare provider immediately.  
 
Celgene  Drug  Safety  Contact  Information:  
 
Celgene  Corporation  
Global  Drug  Safety  and Risk Management 
Connell Corporate Park  
300 Connell Dr.  Suite 6000 
Berkeley  Heights,  NJ 07922 
Fax: (908) 673 -9115  
E-mail:  drugsafety@celgene.com  
 
Overdose  
 
Include  any product -specific  definition  of overdose  in addition  to the following  mandatory 
statement as the last sentence.  
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered  both excessive  and medically  important.  All occurrences  of overdose  must  be 
reported as SAEs.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
49  
 Overdose of Lenalidomide  
 
Overdose,  as defined  for this protocol,  refers  to Revlimid  dosing only.  
 
On a per dose basis,  an overdose  is defined  as the following  amount  over the protocol -specified 
dose of Revlimid assigned to a given patient, regardless of any associate d adverse events or 
sequelae.  
• PO any amount over  the protocol -specified dose 
On a schedule  or frequency  basis,  an overdose  is defined  as anything  more  frequent  than the 
protocol required schedule or frequency.  
 
Complete  data about  drug administration,  including  any overdose,  regardless  of whether  the 
overdose was accidental or intentional, should be reported in the case report form.  
 
 
7.4.1 Protocol -Specific  Expedited  Adverse  Event  Reporting  Exclusions 
There are no protocol specific exclusions . 
7.5 Expedited  Reporting  to the Food  and Drug  Administration  (FDA)  
 
The Overall  PI, as study  sponsor,  will be responsible  for all communications  with the FDA.  The 
Overall  PI will report  to the FDA,  regardless  of the site of occurrence,  any serious  adverse  event 
that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by the FDA.  
 
7.6 Expedited  Reporting  to Bristol -Myers  Squibb  (BMS)  
 
The Overall  PI, as study  sponsor,  will be responsible  for all communications  with the BMS.  With 
the exception of any serious adverse event that meets the FDA’s criteria for expedited reporting 
following the reporting requirements and timelines set by the FDA. All SAEs and SUSARs 
should simultaneously be faxed or e -mailed to BMS by each participating site at:  
 
Global  Pharmacovigilance  & Epidemiology 
Bristol -Myers Squibb Company  
Fax Number:  609-818-3804  
Email:  Worldwide.safety@bms.com  
 
The written  report  must  be complet ed and supplied  to BMS  by facsimile  or e-mail within  3 
business  days..  The report  should  also include  the BMS  trial number, which  is CA204 -119. 
 
7.7 Expedited  Reporting  to Celgene  
 
Serious adverse events (SAE) are defined above.  The investigator must inform Celgene in 
writing  using  a Celgene  SAE  form  or MEDWATCH  3500A  form  of any SAE  within  24 hours  of 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
50  
 being aware of the event . The written report must be completed and s upplied to Celgene by 
facsimile within 24 hours . The initial report must be as complete as possible, including an 
assessment of the causal relationship between the event and the investigational product(s). 
Information not available at the time of the initi al report (e.g., an end date for the adverse event 
or laboratory values received after the report) must be documented on a follow -up report.  A 
final report to document resolution of the SAE is required.  The Celgene tracking number (RV - 
CL-MM-PI-004473)  and the institutional  protocol  number  should  be included  on SAE  reports  (or 
on the fax cover letter) sent to Celgene . A copy of the fax transmissi on confirmation of the SAE 
report to Celgene should be attached to the SAE and retained with the patient records.  
 
7.8 Expedited  Reporting  to Hospital  Risk  Management  
 
Participating  investigators  will report  to their local  Risk Management  office  any participant 
safety reports or sentinel events that require reporting according to institutional policy.  
 
7.9 Routine  Adverse  Event  Reporting  
 
All Adverse  Events  must  be reported  in routine  study  data submissions  to the Overall  PI on the 
toxicity case report forms. AEs reported through expedited processes (e.g., reported to the 
IRB, FDA, etc.) must also be reported in routine study data submissions.  
8. PHARMACEUTICAL  INFORMATION  
 
A list of the adverse  events  and potential  risks  associated  with the Elotuzumab  and lenalidomide 
administered in this study can be found in Section 7.  
 
8.1 Elotuzumab  
 
8.1.1 Description  
 
Elotuzumab (BMS - 901608; formerly known as HuLuc63) is a humanized recombinant 
monoclonal  IgG1  antibody  product  directed  to human  SLAMF7  (CD2 -subset -1, also known  as 
CRACC), a cell surface glycoprotein that is highly expressed in MM cells.  
 
8.1.2 Form  
 
Elotuzuma b for injection has been developed to be used as an intravenous (IV) infusion for the 
clinical  studies.  Drug  product  is a non-pyrogenic  lyophilized  powder  which  is white  to off-white 
contained in 20 -cc Type I glass vials, closed with 20 -mm stoppers and sea led with aluminum 
seals. Each vial of drug product contains the labeled amount of BMS -901608 drug substance, 
sucrose, sodium citrate dihydrate, citric acid, and polysorbate 80. A 10% overfill is included in 
each vial to account for vial, needle, syringe (V NS) holdup. The drug product will be 
reconstituted prior to administration.  
 
Table 7 
 
Product  Potency  Primary  Secondary  Appearance  Storage  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
51  
  
Description  and 
Dosage Form   Packaging 
(Volume)/ 
Label  Type  Packaging 
(Qty)  /Label 
Type   Conditions 
(per  label)  
 
Elotuzumab 
Powder for 
Solution  for 
Infusion   
 
400mg/vial   
 
20 ml vial/ 
open  Label   
10 vials  per 
kit/open 
Label  Sterile,  white 
to off -white, 
preservative - 
free, 
lyophilized  
cake   
Store  at 2°C - 
8°C 
 
8.1.3 Storage  and Stability  
 
The product  storage  manager  should  ensure  that the study  drug is stored  in accordance  with the 
environmental conditions (temperature, light, and humidity) as determined by the sponsor. If 
concerns regarding the quality or appearance of the study drug arise, do  not dispense the study 
drug and contact the sponsor immediately.  
 
The lyophilized elotuzumab drug product should be stored at 2° to 8° C. Prior to administration 
the drug product must be reconstituted with Sterile Water for Injection, USP, and then furthe r 
diluted  in 0.9%  sodium  chloride  normal  saline,  USP,  as per the instructions  in Appendix  B. After 
the dose is diluted in normal saline, it must be administered within 8 hours if stored at room 
temperature. If a delay is anticipated, the prepared dose may be refrigerated at 2° to 8° C for up 
to 24 hours. If stored under refrigerated conditions, th e prepared study drug solution should be 
equilibrated to room temperature (process takes 2 - 2.5 hours) and the container must be gently 
inverted to mix well before administration. Do not use the accelerated warming method. If 
administration is delayed bey ond the specified time, the prepared dose solution must be 
discarded, and the reason documented by the pharmacist in study drug accountability records.  
The dose of elotuzumab to be administered to a subject will be calculated by multiplying the 
subject’s w eight (kg) by 10 mg/kg. The subject’s predose weight on Day 1 of each cycle or 
predose  weight  at each visit,  whichever  is institutional  policy,  will be used to calculate  the dose 
for each cycle. Each dose should be infused as per instructions in Appendix B . 
 
8.1.4 Handling  
 
The lyophilized  elotuzumab  drug product  should  be stored  at 2° to 8°C. Prior  to administration 
the drug product must be reconstituted with Sterile Water for Injection, USP, and then further 
diluted in 0.9% sodium chloride normal saline, USP, as per the instructions in Appendix B.  
 
Qualified  personnel,  familiar  with procedures  that minimize  undue  exposure  to themselves  and 
the environment, should undertake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self -contained and protective environment.  
 
8.1.5 Availability  
 
Bristol -Myers  Squibb  will supply  elotuzumab.  Elotuzumab  is an investigational  agent  and will 
be supplied free -of- charge. Drug will be shipped to the pharmacy at the study site.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
52  
 8.1.6 Preparation  
 
The product  storage  manager  should  ensure  that the study  drug is stored  in accordance  with the 
environmental conditions (temperature, light, and humidity) as determined by the sponsor. If 
concerns regarding the quality or appearance of the study drug arise, do not dispense the study 
drug and contact the sponsor immediately.  
 
After the dose is diluted in normal saline, it must be administered within 8 hours if stored at  
room  temperature.  If a delay  is anticipated,  the prepared  dose may be refrigerated  at 2° to 8°C for 
up to 24 hours. If stored under refrigerated conditions, the prepared study drug solution should  
be equilibrated to room temperature (process takes 2 - 2.5 hours) and the container must be 
gently  inverted  to mix well before  administration.  Do not use the accelerated  warming  method.  If 
administration is delayed beyond the specified time, the prepared dose solution must be 
discarded, and the reason documented by the pharmacist in study drug accountability records.  
 
8.1.7 Administration  
 
Elotuzumab  will be given  cycle  1 & 2 at 10 mg/kg  IV once  a week  (days,  1, 8, 15, and 22). 
Elotuzumab will be given cycle 3 to 8 at 10mg/kg IV days 1 and 15 every cycle.  
Maintenance  elotuzumab  will be given  at 20 mg/kg  IV day 1 every  cycle  up to cycle  24 (total  of 
2 years).  
 
8.1.8 Ordering  
 
The investigator or designee will order drug from Bristol -Myers Squibb, according to the 
ordering  instructions  provided  by company.  A study  specific  order  form  will be provided  by the 
lead site.  
 
8.1.9 Accountability  
 
The investigator, or designee, is responsible for taking an inventory of each shipment of 
elotuzumab received, and comparing it with the accompanying accountability form. The 
Investigator, or designee, will verify the accuracy of the information on the for m, sign and date 
it, retain  a copy  in the study  fill. Accurate  records  will be kept in the source  documentation  of all 
drug administration (including dispensing and dosing).  
 
8.1.10  Destruction  and Return  
 
If study drugs (those supplied by the sponsor or sourced by the investigator) are to be destroyed 
on site, it is the investigator’s responsibility to ensure that arrangements have been made for the 
disposal, procedures for proper disposal have been established according to applicable 
regulations,  guidelines  and institutional  procedures,  and appropriate  records  of the disposal  have 
been documented.  
 
8.2 Lenalidomide  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
53  
 8.2.1 Description  
 
Lenalidomide (REVLIMID®), a thalidomide analogue, is an immunomodulatory agent with 
antiangiogenic  properties.  The chemical  name  is 3-(4-amino -1-oxo 1,3-dihydro  -2H- isoindol -2- 
yl) piperidine -2,6-dione and it has the following chemical structure:  
 
3-(4-amino -1-oxo 1,3-dihydro -2H-isoindol -2-yl) piperidine -2,6-dione . The empirical  formula  for 
lenalidomide is C13H13N3O3,  and the gram molecular weight is 259.3.  
 
8.2.2 Form  
 
Lenalidomide is off -white to pale -yellow solid powder. It is soluble in organic solvent/water 
mixtures,  and buffered  aqueous  solvents.  Lenalidomide  is more  soluble  in organic  solvents  and 
low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about  
0.4 to 0.5 mg/ml. Lenalidomide has an asymmetric carbon atom and can exist as the optically 
active  forms  S(-) and R(+),  and is produced  as a racemic  mixture  with a net optical  rotation  of 
zero.  
 
Lenalidomide is available for this study as 5 and 25 mg capsules for oral administration. Each 
capsule contains lenalidomide as the active ingredient and the following inactive ingredients: 
lactose  anhydrous,  microcrystalline  cellulose,  croscarmellose  sodium,  and magnesium  stearate.  
 
8.2.3 Storage  and Stability  
 
At the study  site, all investigational  study  drugs  will be stored  in a locked,  safe area to prevent 
unauthorized access. Lenalidomide should be stored at room  temperature away from direct 
sunlight and protected from excessive heat and cold.  
 
8.2.4 Handling  
 
Females  of childbearing  potential  should  not handle  or administer  lenalidomide  unless  they are 
wearing gloves.  
 
Qualified  personnel,  familiar  with procedures  that minimize  undue  exposure  to themselves  and 
the environment, should undertake the preparation, handling, and safe disposal of the 
chemotherapeutic agent in a self -contained and protective environment.  
 
8.2.5 Availability  
 
Celgene  Corporation  will supply  Revlimid®  (lenalidomide)  to study  participants  at no charge 
through Celgene’s Revlimid Risk Evaluation and Mitigation Strategy™ (REMS) (formerly 
known as RevAssist® Program, Research). Each patient’s individual drug supply will be 
delivered  to the site by the drug courier  Biologics  and be distributed  to the patient  through  the 
research side of the pharmacy of that site.  
 
8.2.6 Preparation  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
54  
 Lenalidomide  is an oral drug, and  does not require  specific preparation details.  
 
8.2.7 Administration  
 
Lenalidomide  will be given  daily  at 25 mg days 1-21 on a 28 day cycle,  cycles  1-8. Maintenance 
therapy can be given until cycle 24 (total of 2 years).  During  maintenance, lenalidomide will  be 
given 15 mg daily days 1 -21 every cycle.  
 
At all times  when  dispensing  lenalidomide  protocol  therapy,  study  site personnel  will review  the 
instructions, printed on the packaging, with participants.  
 
8.2.8 Ordering  
 
Lenalidomide (Revlimid®) will be provided to research subjects for the duration of their 
participation  in this trial at no charge  to them  or their insurance  providers.  Lenalidomide  will be 
provided in accordance with the Celgene Corporation’s Revlimid REMS® program.  Per 
standard Revlimid REMS® program requirements,  all physicians who prescribe le nalidomide 
for research  subjects  enrolled  into this trial, and all research  subjects  enrolled  into this trial, must 
be registered in, and must comply with, all requirements of the Revlimid REMS® program.  
Drug  will be shipped  on a per patient  basis  by the contract  pharmacy  to the clinic  site. Only 
enough  lenalidomide  for one cycle  of therapy  will be supplied  to the patient  each  cycle . 
 
Lenalidomide  will be shipped  directly  to the clinic  site. Bottles  will contain  a sufficient  number 
of capsules for one cycle of dosing . A study specific order form will be provided by the lead 
site. 
 
8.2.9 Accountability  
 
The Investigator  or designee  is responsible  for taking  an inventory  of each shipment  of study 
drug received, and comparing it with the accompanying study drug accountability form.  
 
8.2.10  Destruction  and Return  
 
If study drugs (those supplied by the sponsor or sourced by the investigator) are to be destroyed 
on site, it is the investigator’s respons ibility to ensure that arrangements have been made for the 
disposal, procedures for proper disposal have been established according to applicable 
regulations, guidelines and institutional procedures, and appropriate records of the disposal have 
been  docume nted.  The unused  study  drugs  should  be destroyed  per institutional  policies  after the 
drug returns  have been  reconciled by  the monitor,  or when  the lead site  instructs the  site to  do so. 
 
If any study drug is lost or damaged, its disposition should be documented in the source 
documents.  Patients  will be instructed  to return  empty  bottles  or unused  capsules  to the clinic 
site. 
 
8.3 Dexamethasone  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
55  
 8.3.1 Description  
 
Dexamethasone is a synt hetic adrenocortical steroid. Corticosteroids are naturally occurring 
chemicals  produced  by the adrenal  glands  located  above  the kidneys.  Corticosteroids  affect  the 
function of many cells within the body and suppress the immune system. Corticosteroids also 
block inflammation and are used in a wide variety of inflammatory diseases affecting many 
organs.  
 
The molecular weight for dexamethasone is 392.47. It is desig nated chemically as 9 - fluoro - 
11β,17,21 -trihydroxy -16α-methylpregna -1,4-diene -3,20-dione.  Dexamethasone  is stable  in air 
and almost insoluble in water.  
 
8.3.2 Form  
 
Dexamethasone  is a white  to practically  white,  odorless,  crystalline  powder.  It is available  in 2 or 
4 mg tablets (commercially) for oral administration. Each tablet contains dexamethasone as the 
active ingredient, and the following inactive  ingredients: calcium phosphate, lactose, magnesium 
stearate, and starch. The tablet shell may con tain the following: D&C Yellow 10, FD&C Yellow 
6, and/or FD&C Blue 1.  
 
8.3.3 Storage  and Stability  
 
At the study site, all investigational study drugs will be stored in a locked, safe area to prevent 
unauthorized  access.  Dexamethasone  should  be stored  at controlled  room  temperature,  68-77◦F 
(20-25◦C) and not frozen, and according to label requirements.  
 
8.3.4 Handling  
 
Dexamethasone  should  be handled  by trained  pharmacy  staff.  The use of gloves  and other 
appropriate protective clothing is recommended as necessar y. 
 
8.3.5 Availability  
 
Dexamethasone  supply  will be obtained  through  commercial  supply.  
 
8.3.6 Preparation  
 
Dexamethasone  is an oral drug,  and does not require  specific  preparation  details.  
 
8.3.7 Administration  
 
, Participants  will receive  dexamethasone  Days  1, 8 15 and 22 during  cycles  1-2 and then days 
1, 8, 15 on cycles 3 -8 and on day 1 of cycles 9 -24 of maintenance .  
 
8.3.8 Ordering  
 
The investigator  or designee  will order  drug supply  from  commercial  supply.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
56  
  
8.3.9 Accountability  
 
As drug is from  commercial  supp ly, sites should  keep  records  per their institutional  policies.  
 
8.3.10  Destruction  and Return  
 
At the end of the study,  unused  supplies  of dexamethasone  should  be destroyed  and documented 
according to institutional policies.  
 
9. BIOMARKER,  CORRELATIVE,  AND  SPECIAL  STUDIES  
 
This trial will provide samples high -risk SMM patients treated with elotuzumab and 
lenalidomide  to comprehensively  characterize  the MM genome  and immune  cells function  and 
define molecular events driving development and progression of MM.  
 
We will attempt  to obtain  samples  on all patients  at the following  time points:  before  therapy,  at 
the end of cycle  8, at the time of response  determination  (CR)  , at disease  relapse,  and at several 
more time points over the course of the study. It is anticipated that approximately 90% of 
samples collected will be adequate for sequencing studies proposed.  
 
The tumor  cells will be collected  as described  below.  From  these  samples,  high quality  DNA  (for 
tumor cells) and RNA (for tumor cells and immune cells) for both exome sequencing and RNA 
sequencing will be obtained. Germline DNA will be also obtained from a buccal swab from all 
patients at any time point of the study.  
 
Peripheral blood and bone marrow derived mononuclear cells will undergo immunologic 
assessments to assess the impact of therapy on general measures of cellular immunity, MM 
reactive  T cells,  and antigen  specific  immunity.  The percentage  of circulating  and bone  marrow 
derived regulatory T cells, NK cells and MDSCs will be determined.  The percent of PD -1 and 
other  checkpoint  regulators  on immune  cells will also be measured.  Levels  of naïve,  effector  and 
central memory cells will  be quantified.  T cell prolife rative response to tetanus toxoid and PHA 
mitogen will be determined.  NK cell mediated cytotoxicity will be measured.  
 
We will also determine  the level  of SLAMF7  on these  cells.  
 
In addition,  we will examine  the level  of soluble  SLAMF7  pre-treatment  and monthly  on Day 1 
of each cycle.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
57  
 Peripheral blood and bone marrow samples will be collected at the screening time and for 
analysis in order to confirm response as well as at C9D1. The collection kits and shipping 
supplies wil l be provided to the sites by Sequenta. These samples will be packaged whole, and 
shipped to Sequenta, Inc. in South San Francisco, CA same day priority overnight..  Using 
Sequenta’s LymphoSIGHT platform, rearranged immunoreceptor loci from genomic DNA will  
be extracted,  amplified,  and sequenced  using  V and J segment  primers  for each immunoreceptor 
gene.  Tumor -specific clonotypes will be identified for each patient based on their high 
prevalence in peripheral blood.  Sequences will be analyzed using standardi zed algorithms for 
clonotype determination.  Sequenta MRD levels will be quantified using spiked -in reference 
sequences . 
 
9.1 Bone  Marrow  Aspirate  Samples  
 
Collection  of bone  marrow  aspirate  specimens  for exploratory  analysis  will be requested  for this 
trial. Collections  that are requested  will be obtained  at screening,  C9D1,  confirmation  of CR and 
at end of study treatment. At any time a bone marrow aspirate procedure is performed, an 
additional sample for exploratory analysis is requested. This wi ll not require extra access for 
participants. Specimens will be shipped (via traceable carrier) to and subsequently processed, 
analyzed, and stored at Dana -Farber Cancer Institute.  
 
Specimens  Requested:  2 Purple  Top Tubes  (K2EDTA),  10mL  each.  Specimens  must be 
collected on Mondays to Thursdays for same -day shipment.  
 
Processing  Information:  There  is no required  processing  for bone  marrow  samples  at each 
participating site prior to shipment.  
 
Shipping Information for Bone Marrow Aspirate Specimens: Label all specimens with the 
following: Subject  Initials,  Subject  study  number  (will  include  protocol  number),  Visit  at which 
sample was drawn (screening, response or relapse/progression), Date sampl e drawn 
(mm/dd/yyyy), Time sample drawn (24 hour clock)  
 
9.1.1 Shipping  Instructions:  
 
Shipments  must  be sent on the day of collection  and cannot  be batched.  
 
1. An inventory sheet including a complete list of samples shipped (patient number, 
timepoint,  study  #) must  accompany  each shipment.  Please  sign and date the requisition 
form.  
 
2. An electronic copy (Word or Excel) of the sample list must also be sent via email. The 
listing  must  also include  a contact  name,  address  and phone  number  of the person  who is 
respons ible for the shipment.  
 
3. Please  email  the lead site contact  to notify  of an incoming  shipment.  
 
4. Please  ship ONLY  Monday  to Thursday  as shipments  cannot  be received  on weekends 
and/or on holidays.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
58  
  
5. Once  drawn,  samples  may be shipped  via overnight  air to: 
 
Dana  Farber  Cancer  Institute 
Ghobrial Lab  
360 Longwood  Avenue  LC8116 
Boston, MA 02215  
Email:  GhobrialLab@dfci.harvard.edu  
 
Please  retain  a copy  for site record  maintenance.  Please  see Appendix  C and D for 
Collection Schedule and Requisition Form  
 
9.2 Peripheral  Blood Samples  
 
Collection  of peripheral  blood  specimens  (including  serum  and plasma)  for exploratory  analysis 
are requested  for this trial. Purple  top tube collections  should  be obtained  at the same  timepoints 
as bone marrow samples for correlative studies (see Section 10 for list of required timepoints, 
and Appendix C for specific instructions). These collections will be taken at the time of routine 
blood collection timepoints required for this study. Specimens will be processed on site 
according to instructions below and shipped (via traceable carrier) to Dana -Farber Cancer 
Institute. Once the shipment is received, samples will be subsequently processed , analyzed, and 
stored at Dana -Farber.  
 
9.2.1 Specimens  Required:  2 x 10ml  Purple  Top Tubes  (K2EDTA),  and 1x 6ml Red Top (no 
additive) tube, must be collected Mondays to Thursdays for same -day shipment.  
 
9.2.2 Shipping  Information:  Label  all specimens  with the followi ng: 
 
• Subject  Initials  
• Subject  study  number  (will  include  protocol  number)  
• Visit  at which  sample  was drawn  (screening,  response  or relapse/progression)  
• Date  sample  drawn  (mm/dd/yyyy)  
• Time  sample  drawn  (24 hour clock)  
9.2.3 Processing  Information : Once  collected,  the vacutainers  will be refrigerated  and stored 
according  to instructions  below.  There  is no required  processing  for purple  top tubes  at 
each participating site prior to shipment.  
 
9.2.4 Shipping  Instructions:  Shipments  must  be sent on the day of collection  and cannot  be 
batched.  
 
Processing  Information:  
 
Invert each tube 5 times at blood collection to ensure adequate mixing of anticoagulant with 
blood immediately after the blood collection. Package tubes at room temperature and wrap in a 
liberal a mount of paper towel around the tubes to ensure adequate insulation of the specimen(s) 
and absorption  in the event  of a breakage.  Place  wrapped  specimen  in a biohazard  labeled  Ziploc  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
59  
 bag with a fridge  pack  and zip close.  Wrap  bubble  wrap  around  the bag and place  in a cardboard 
box. If space remains in the box, stuff with extra paper towel to reduce shifting of samples.  
Complete  the shipping  requisition  form  using  the address  listed  below.  Prepare  the package  for 
shipping, applying packing tape as needed. Ship the package using FedEx or UPS next day or 
overnight  delivery  the same  day the sample  was collected.  Please  only ship Monday -Thursday, 
as the lab is only able to accept Saturday shipments with 1 week advance notice. With each 
shipment,  please include the following:  
 
1. An inventory sheet including a complete list of samples shipped (patient number, 
timepoint,  study  #) must  accompany  each shipment.  Please  sign and date the form,  and 
retain a copy for site record maintenance. See Appendix D for Sample Requisition 
Form  
 
2. An electronic copy (Word or Excel) of the sample list must also be sent via email and 
include  the tracking  number  of the package.  The listing  must  also include  a contact name, 
address and phone number of the person who is responsible for the shipment.  
 
3. Please  email  the Dana -Farber/lead  site contact  to notify  of an incoming  shipment.  
 
4. Please  ship Monday  to Thursday  as shipments  cannot  be received  on weekends  and/or  on 
holidays.  
 
5. Once  drawn,  samples  may be shipped  via overnight  air to: 
 
Dana  Farber  Cancer  Institute 
Ghobrial Lab  
360 Longwood  Avenue  LC8116 
Boston, MA 02215  
 
Email:  GhobrialLab@dfci.harvard.edu  
 
For Sequenta  samples,  use the packing  supplies  provided  in each individual  kit and follow  the 
directions below:  
 
1. Label  each tube with date of collection,  patient’s  study  specific  number,  initials,  and date 
of birth  
 
2. Store  collected  tubes  at room  temperature  until same  day shipment.  
 
3. On the ClonoSEQtest  requisition  form,  fill out requisition  with patient  first and last name, 
date of birth, and gender. Ordering physician should be listed as Irene Ghobrial, MD. 
Please ensure that the sample tubes are labeled, and reference patient specific study 
number, the treating site, and the treating physician name at the top of the r equisition 
form.  
 
4. Under  ICD-10, Other:  Multiple  Myeloma  C90.00  should  be entered  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
60  
 5. Under  specimen  information,  enter  collection  date under  fresh  specimens,  and mark 
which samples have been provide ( blood and bone marrow )  
 
6. For baseline  samples,  ClonoSIGHT  ID Test should  be checked.  For confirmation  of 
response time point, ClonoSIGHT MRD Test should be checked.  
 
7. Under  billing,  please  provide  insurance  information  for the patient  
 
8. Complete  pathology,  physician  signature,  and billing  information  sections  
 
9.  Please  make  a copy  of the requisition  to retain  for your records  along  with the Fed-Ex 
tracking number in the event that the package is lost.  
 
10. Follow  the sample  packing  instructions  included  in the kit, and send out same  day. 
Shipping on Friday is ok for Saturday processing for these samples.  
 
11. An electronic  notification  must  be sent via email  and include  the tracking  number  of the 
package, and all relevant sample information and patient identifiers to the study team 
The li sting must also include a contact name, address and phone number of the person 
who is responsible for the shipment.  
 
a) Please  email  the lead site contact  to notify  of an incoming  shipment.  
Protocol  #: 14 -338 
Version  Date:  02.04.15  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
61  
 10. STUDY  CALENDAR  
Screening evaluations are to be conducted within 28 days prior to initiation of registration. 
Protocol  therapy  should  start as soon  after registration  as feasible.  Baseline  assessments  are to be 
conducted on C1D1 of initial therapy and should be considered  separate from screening 
evaluations. Evaluations need not be repeated for C1D1 if screening evaluations are performed 
within 7 days of registration. Scans and bone marrow assessments do not need to be repeated if 
performed within 6 weeks of registration. All assessments must be performed prior to 
administration of any study  medication.. See  below for detailed scheduled  of assessments. Study 
medications will be administered according to the schedule and guidelines outlined in Section 5.  
 Pre-registration  Cycles 1-24 (28 days)  3   Follow Up11 
 
 
Tests and procedures   
≤ 28 days 
prior to 
registration   
≤ 21 days 
prior to 
registration   
Day 1 
of all 
cycles1 Days  8, 15 
and 22 of 
cycles  1 & 2  
Cycle 9 
Day 1/ Or 
to confirm 
CR9  
 
End of 
Tx  
Every 3 or 
6 Months  
(+/- 28 
days)  Days  1 &15 
from cycle 
3-8 
History and exam, height, 
weight.  Performance  Status  X  
X   
X (X) 
Toxicity  Notation    X   X  
Hematology  group  (WBC 
w/ diff, PLT, Hgb, ANC)   X X X  X X 
Chemistry4  X X X  X X 
Direct  & total bilirubin2  X X   X  
Free light chain  assay   X X   X X 
Serum and Urine 
Immunofixation  (SPEP  and 
UPEP) with quantitative 
immunoglobulins10   
X  
X    
X  
X 
2M, CRP, LDH   X    X  
Metastatic  Bone  Survey/ 
Spine  MRI  or PET/CT12 X     X (X) 
EKG   X    X  
Serum  pregnancy  test  X      
Unilateral  bone  marrow 
aspirate and biopsy5 X    X X (X) 
Research  bone  marrow 
aspirate6 X5    X6 X6 (X) 
Research Blood7 X8  X  X X (X) 
1- Cycle  1, Day 1 laboratory values  need  to meet  eligibility criteria  
2- Direct  bilirubin  to be obtained  if total bilirubin  is abnormal.  
3- Scheduling  allows  for +/- 3 days cycles 1 -2 and +/- 7 days for cycle  3 and beyond.  
4- Chemistry  includes  sodium,  potassium,  chloride,  bicarbonate,  bun, creatinine,  calcium,  glucose,  albumin,  ALT  (SGPT),  total protein,  AST  (SGOT), 
total bilirubin, magnesium, and phosphorus.  
5- These  procedures  should  also be  done  at any  time during  the course  of the study  to confirm CR. 
6- Research  bone  marrow  aspirate and  biopsy at the  same  time of clinically  indicated bone  marrow  biopsy and  to confirm response . 
7- Peripheral  blood  samples  for correlative  studies  including  serum  SLAMF7  levels.  
8- Oragene  kit for germline  DNA  will be acquired  once at  any time point  from  patients  enrolled  on this study.  
9- If C9D1  or confirmation  of response  BM biopsy  was performed  within  3 weeks  of subsequent  time point  listed;  do not need  to repeat  BM biopsy.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
62  
 10- Patients  who are not followed  for disease  response  in their urine  per IMWG  criteria  need  only bring  urine  every  third  cycle  and at end of 
treatment after baseline  
11- Follow up will occur approximately every 3 to 6 months (+/ - 28days) for up to 3 years after discontinuation of therapy (EOT). Participants unable to 
participate in follow up every 3 months may follow up every 6 months at PI discretion in accordance with st andard of care follow -up frequency and 
COVID precautions. Physical exams and correlative blood draws that are not done due to virtual visits will not be considered violations.  Local myeloma 
labs must  be provided  to the participating  site for data entry  purposes.  Bone  marrow  biopsy  and scans  are strongly  recommended  yearly  after EOT  but are 
required when there is suspicion of clinical progression. These assessments can be waived due to extenuating circumstances or  for insurance coverage 
reasons.  Scans  and bone marrow  biopsy  and research  samples  are required  at time of suspected  disease  progression  if one is performed  as part of standard 
of care procedures.  
12- A CD of scans  at screening  and end of treatment  is requested  to be sent to the lead site for central  review.  Screening  scans  should  be sent with the 
eligibility packet to the lead site  
 
(X)- Indicates  this assessment  may not be required  
Note : Research  blood  and bone  marrow  studies  are voluntary  and do not exclude  patients  from participating  
 
11. MEASUREMENT OF EFFECT  
 
11.1 Development  of symptomatic  disease  
 
In this study,  the final endpoint  is development  of symptomatic  MM that requires therapy.  
This is defined  as one  of the  following criteria  (CRAB* and  Myeloma defining  events< MDE):  
 
• Increased  calcium  levels  (corrected  serum  calcium  >0.25  mmol/dL  above  the 
upper limit of normal or >.275 mmol/dL);  
• Renal  insufficiency  (attributable  to myeloma);  
• Anemia  (Hgb  2g/dL  below the  lower  limit of  normal  or <10g/dL);  
• Bone  lesions  (lytic  lesions  or generalized  osteoporosis  with compression 
fractures)  
• Or any MYELOMA  DEFINING  EVENTS  (MDE)  as follows:  
o Clonal  bone  marrow plasma  cell percentage*> 60%2 
o An abnormal  FLC-ratio ≥100  (involved  kappa)  or ≤0.01  (involved 
lambda)52 
o 2 or more  focal  lesions  on MRI  or PET-CT studies53,54 
 
* Participants  with CRAB  criteria  that are attributable  to conditions  other  than the disease 
under study may be eligible  
 
For measurement of response:  
 
In this study,  patients  must  have  measurable  disease.  The disease  response  will be assessed  using 
criteria  based  on the International  Working  Group Uniform Response Criteria  in Section  11.2.4. 
If the only measurable parameter is serum immunoglobulins  free light chain (FLC), the 
participant  will be followed  by FreeLite™  Disease  Response  Criteria  provided  in Section  11.2.5.  
 
Disease  response  by the Modified  EBMT  Response  Criteria  in Section  11.2.6.2  will also be 
collected on participants as a secondary measure.  
 
The same  method  of assessment  and technique  should  be used  for disease  measurement  at 
baseline  and during  follow -up. Disease  response  should  be confirmed  by two consecutive  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
63  
 assessments.  
 
 
 
 
 
 
 
 
11.2 Antitumor  Effect  
 
11.2.1  Disease  Parameters  
 
Measurable  disease : Measurable  disease  is disease  that can be measured  either  by serum  or 
urinary evaluation of the monoclonal component or by serum assay of  
FLC and is defined  by at  least one of the following  three  measurements:  
 
• Serum  M-protein  > 0.5 g/dl 
 
• Urine  M-protein  > 200 mg/24  h 
 
• Serum  FLC assay:  Involved  FLC level  > 10 mg/dl  (> 100 mg/l)  provided 
serum FLC ratio is abnormal.  
 
If a patient  has measurable  disease,  but not by IMWG  standards  listed  above,  the patient  may 
be eligible after discussion with the Overall Principal Investigator.  
 
11.2.2  Methods  for Evaluation  of Measurable  Disease  
 
All baseline  evaluations  should  be performed  on Cycle  1, Day 1 of initial  therapy.  Response  will 
be assessed by M -protein quantification,  protein electrophoresis  and immunofixation  from 
serum  and a 24 -hour urine  collection.  A serum  sample  for FreeLiteTM testing  will be obtained. 
In addition,  bone  marrow aspiration  and biopsy,  as well  as skeletal  survey will  be performed  to 
determine overall response or confirm response.  
The same  method  of assessment  and technique  should  be used  for disease 
measurement at baseline and during follow -up. 
 
11.2.3  Response  Criteria  
 
A confirmation  measurement  for disease  response  assessments  is required  in this 
protocol.  
 
11.2.4  International  Myeloma  Working  Group  Response  Criteria  
 
Response  criteria  for all categories  and subcategories  of response  except  CR are applicable  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
64  
 only to patients who have ‘measurable’  disease, as defined in Section 11.2 All response 
categories require two consecutive  assessments made at any time before the institution  of 
any new therapy;  all categories  also require  no known  evidence  of progressive  or new bone 
lesions if radiographic  studies were performed. Radiographic studies are not required to 
satisfy these response requirements.  
 
Stringent  CR: CR as defined  below  plus normal  free light chain  ratio and absence  of 
clonal cells in bone marrow* by immunohistochemistry  or immunofluorescence.** 
*Confirmation  with repeat  bone  marrow  biopsy  is not needed.  
**Presence/absence  of clonal  cells is based  upon  the k/λ ratio.  An abnormal  k/ λ ratio by 
immunohistochemistry and/ or immunofluorescence requires a minimum of 100 plasma 
cells for analysis.  An abnormal  ratio reflecting  presence  of an abnormal  clone  is k/λ of > 
4:1 or < 1:2.  
 
CR: Negative  immunofixation  on the serum  and urine  and disappearance  of any soft 
tissue plasmacytomas and <5% plasma cells in bone marrow.  
*Confirmation  with repeat  bone  marrow  biopsy  is not needed.  
 
VGPR : Serum and urine M -protein detectable by immunofixation  but not on 
electrophoresis  or 90% or greater  reduction  in serum  M-prote in plus urine  M-protein 
level <100mg per 24 hours.  
 
PR: > 50% reduction  of serum  M-protein and reduction  in 24 -h urinary M -protein  by > 90% or 
to < 200mg  per 24 hours.  If the  serum  and urine  M-protein  are unmeasurable,  a > 50% decrease 
in the difference  between  involved  and uninvolved  free light chain levels is required in place of 
the M-protein  criteria  (definition  of measurable  disease  in Section  10.2.3).  If serum  and urine  M- 
protein are unmeasurable,  and serum free light  assay is also unmeasurable,  > 
50% reduction in plasma cells is required in place of M -protein, provided baseline bone 
marrow  plasma  cell percentage  was > 30%.  In addition  to the above  listed  criteria,  if present  at 
baseline, a > 50% reduction  in the size of soft tissue plasmacytomas  is also required.  
 
SD: Not meeting  criteria  for CR, VGPR, PR or progressive  disease.  This is not 
recommended  as an indicator  of response;  stability  of disease  is best described  by 
providing the time to progression estimates.  
 
PD: > 25% increase  of serum  M-protein  (which  must also be an absolute  increase  of > 0.5 g/dL) 
and/or  urine  M-protein  (which  must  also be an absolute  increase  of > 200 mg/24hr).  If serum  and 
urine M -protein  are unmeasurable,  there must be an absolute increase of > 10 mg/dL between 
involved and uninvolved  FLC levels.  PD is also measured by an absolute increase in bone 
marrow plasma cells > 10%.  In addition to the above listed criteria, prog ression may also be 
measured  by a definite  development  of new bone  lesions  or soft tissue  plasmacytomas  or definite 
increase in the size of existing bone lesions or soft tissue plasmacytomas  or development  of 
hypercalcemia  (corrected serum calcium  > 11.5 m g/dL or 2.65 mmol/L) that can be attributed 
solely to the plasma cell proliferative disorder.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
65  
 11.2.5  FreeLite™  Disease  Response  Criteria  
 
Complete  Response : For those  patients  being  followed  by serum  free light chain  (and NO 
measurable  serum or urine M -spike), which were immunofixation negative at enrollment, 
normalization of serum free light chain ratio.  
 
- Normalization  is defined  as the serum  free light chain  ratio being  within  the normal  range. 
If the serum  free light chain  ratio is not within  the normal  range,  but the individual  kappa  and 
lambda light chain values are within normal range, this may be considered CR.  
 
 
Partial  Response : If only measurable  parameter  is serum  immunoglobulins  free light chain 
(FLC), EITHER of the following changes qualify as partial response:  
 
- A 50% decrease  in the difference  between  involved  and uninvolved  FLC levels; OR 
 
- A 50% decrease  in the level  of involved  FLC AND  a 50% decrease  (or 
normalization) in the ratio of in volved/uninvolved  FLC 
 
Progressive  Disease : If only measurable  parameter  is serum  immunoglobulins  free light 
(FLC), either of the following qualify as progression:  
 
- 50% increase  in the difference  between  involved  and uninvolved  FLC levels  from  the lowest 
response level, which must also be an absolute increase of at least  
10 mg/dL;  OR 
 
- 50% increase  in the level  of involved  FLC AND  a 50% increase  in the ratio of 
involved/uninvolved  FLC from the lowest response level.  
 
11.2.6  Criteria  for Molecular  CR and Minimal  Residual  Disease  (MRD)  measurement  
We will measure  MRD  in patients  who achieve  CR to determine  the number  of patients  who are 
MRD negative vs MRD positive.  
 
11.2.6.1  MRD  by LymphoSIGHT  
MRD  will be carried  out according  to the LymphoSIGHTTM method  (Sequenta,  Inc., San 
Francisco, CA)55. Prior studies have compared this technique to the traditional MRD 
immunofluorescence technique, as previously reported 60 and showed that MRD by 
LymphoSigh t is a sensitive method that can be used in future clinical practice.  
For MM diagnostic  samples,  genomic  DNA  will be amplified  using  locus -specific  primer  sets for 
the immunoglobulin heavy -chain locus (IGH ) complete (IGH -VDJH), IGH incomplete (IGH - 
DJH), a nd immunoglobulin κ locus (IGK ). The amplified product will be subjected to  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
66  
 sequencing, and the sequences and frequencies of the different clonotypes in the sample will be 
obtained. Myeloma gene rearrangements will be identified. Patients in whom a high -frequency 
myeloma clone (>5%) is not identified will be excluded from the MRD analysis. MRD will be 
assessed in patients with a high -frequency myeloma clone using the IGH -VDJH and IGK or 
IGH-VDJH, IGH -DJH, and IGK assays. Once the absolute amount of total cancer -derived 
molecules  present  in a sample  will be determined,  a final MRD  measurement  will be calculated, 
providing the number of cancer -derived molecules per 1 million cell equivalents. In cases in 
which 2 or more tumor clones existed, the clone with the highest MRD value will be reported. 
Molecular  CR will be defined  according  to the International  Myeloma  Working  Group  (IMWG) 
consensus recommendations.56 
11.2.6.2  Modified  EBMT  Response  Criteria  
 
Response  Criteria  for Responsea 
 
 
 
 
 
Complete  response 
(CR)  Requires all of  the following:  
Disappearance  of the original  monoclonal  protein  from  the blood  and 
urine on at least two determinations for a minimum of six weeks by 
immunofixation studies.  
<5%  plasma  cells in the bone  marrow  on at least two 
determinations for a minimum of six weeks. b 
No increase in the size or number of lytic bone lesions 
(development  of a compression  fracture  does not exclude 
response).c 
Disappearance  of soft tissue  plasmacytomas  for at least six weeks.  
Near  Complete 
Response 
(nCR)  Requires the  following:  
Same  as CR, but immunofixation  studies  continue  to show  presence 
of the monoclonal protein  
Very  Good  Partial 
Response  
(VGPR)  Requires the  following:  
> 90% reduction  in serum  M-protein  plus urine  M-protein  level  <100mg 
per 24 hours  on at least two  determinations for  a minimum  of six weeks.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
67  
  
 
 
 
 
 
 
Partial  response 
(PR) PR includes participants in whom some, but not all, criteria for CR are 
fulfilled  providing  the remaining  criteria  satisfy  the requirements  for PR. 
Required all of the following:  
50% reduction  in the level  of serum  monoclonal  protein  for at 
least two determinations six weeks apart.  
If present,  reduction  in 24-hour urinary  light chain  excretion  by either  
90% or to 
<200  mg for at least two determinations  six weeks  apart.  
50% reduction  in the size of soft tissue  plasmacytomas  (by 
clinical or radiographic examination) for at least six weeks.  
No increase  in size or number  of lytic bone  lesions  (development  of 
compression fracture does not exclude response).c 
 
 
 
 
 
 
Minimal  response 
(MR)  MR included  participants  in whom  some,  but not all, criteria  for PR 
were fulfilled, providing the remaining criteria satisfied the 
requirements for MR. Required all of the following:  
25% to  49% reduction  in the level  of serum  monoclonal  protein  for 
at least two determinations six weeks apart.  
If present, a 50 to 89% reduction in 24 -hour light chain excretion, 
which  still exceeds  200 mg/24  h, for at least two determinations  six 
weeks apart.  
25-49% reduction  in the size of plasmacytomas  (by clinica l or 
radiographic examination) for at least six weeks.  
No increase  in size or number  of lytic bone  lesions  (development  of 
compression fracture does not exclude response).c 
No change  (NC)  Not meeting  the criteria for  MR or PD. 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
68  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response  Criteria  for Responsea 
  
Requires  one or more  of the following:  
 >25%  increased in the  level  of serum  monoclonal  paraprotein,  which 
must  also be an absolute  increase  of at least 5 g/L and confirmed  on a 
repeat investigation.  
 
 
Progressive 
disease  (PD)  (for 
participants not 
in CR)  >25% increased in 24 -hour urinary light chain excretion, which must 
also be an absolute  increase  of at least 200 mg/24  h and confirmed  on a 
repeat investigation.  
>25%  increased in plasma  cells in a bone  marrow  aspirate  or on trephine 
biopsy, which must also be an absolute increase of at least 10%.  
 Definite  increase  in the size of existing  lytic bone  lesions  or soft 
tissue plasmacytomas.  
 Development  of new bone  lesions  or soft tissue  plasmacytomas  (not 
including compression fracture).  
 Development  of hypercalcemia  (corrected  serum  calcium  >11.5  mg/dL 
or 2.8 mmol/L not attributable to any other cause).  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
69  
  
 
 
 
 
 
 
Relapse  from  CR Required  at least one of the following:  
Reappearance  of serum  or urinary  paraprotein  on immunofixation  or 
routine electrophoresis confirmed by at least one follow -up and 
excluding oligoclonal immune reconstitution.  
5% plasma  cells in the  bone  marrow  aspirate  or biopsy.  
Development  of new lytic bone  lesions  or soft tissue  plasmacytomas  or 
definite increase in the size of residual bone lesions (not including 
compression fracture).  
Development  of hypercalcemia  (corrected  serum  calcium  >11.5  mg/dL 
or 2.8 mmol/L not attributable to any other cause).e 
a Based  on the criteria reported by  Blade  et al., 1998.  
b Per Blade et al., 1998, if absence of the monoclonal protein is sustained for 6 weeks it is not necessary to 
repeat  the bone  marrow  except  in participants  with nonsecretory  myeloma  where  the marrow  examination 
must be repeated after an interval of at least 6 weeks to confirm CR.  
c Per Blade  et al., 1998,  skeletal  X-Rays  are not required  for the definition  of response,  but if performed  there 
must be no evidence of progression of bone disease (no increase in size or number of lytic bone lesions).  
d It is suggested that the reference point for calculating any increase should be the lowest value of the 
preceding  confirmed  response  (MR,  PR or CR) or the baseline  value  if there  is no previous  confirmed 
response.  
e Other  clinical  data may  be requested  by the IRC,  as necessary,  to assess  the cause  of the hypercalcemia.  
 
 
11.2.7  Duration  of Response  and Endpoint  Definitions  
 
Duration  of overall  response : The duration  of overall  response  is measured  as the time from 
initiation  of first response  to first documentation  of disease  progression  or death.  Patients 
who have not progressed or died are censored at the date last known progression -free. 
 
Duration of overall complete response:  The duration  of overall CR is progression 
or death. Patients who have not progressed or died are censored at the date last 
known progression -free. 
Time to progression: Time to progression is defined as the time of ran domization until 
progression.  Patients  who have  died without  evidence  of progression  are censored  in the TTP 
analysis  at the time of death  and patients  who are alive  without  progression  are censored  at the 
last disease assessment.  
Overall  survival  (OS) : OS is defined  as the time from  randomization  to death.  Alive  patients 
are censored at the date last known alive.  
11.2.8  Progression -Free Survival  
Progression -Free Survival  (PFS) : the primary  endpoint  in this study.  PFS is defined  as the time 
from  randomization  to the disease  progression  or death  from  any cause.  Patients  who have not 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
70  
 progressed  or died are censored  at the date last known  progression -free. 
11.2.9  Response  Review  
Central  review  of disease  response  assessments  is not planned.  
 
12. DATA  REPORTING  / REGULATORY  REQUIREMENTS  
 
Adverse  event  lists, guidelines,  and instructions  for AE reporting  can be found  in Section  7.0 
(Adverse Events: List and Reporting Requirements).  
 
12.1 Data  Reporting  
 
12.1.1  Method  
 
The QACT  will collect,  manage,  and perform  quality  checks on  the data for this study.  
 
12.1.2  Responsibility  for Data  Submission  
 
Investigative sites within DF/HCC or DF/PCC are responsible for submitting data and/or data 
forms to the QACT according to the schedule set by the QACT. Data should be entered within 
14 business  days of the corresponding  visit and within  14 business  days of the end of a cycle  for 
any forms to be completed per cycle.  
 
12.2 Data  Safety  Monitoring  
 
The DF/HCC  Data  and Safety  Monitoring  Committee  (DSMC)  will review  and monitor  toxicity 
and accrual data from this study. The committee is composed of clinical specialis ts with 
experience in oncology and who have no direct relationship with the study. Information that 
raises any questions about participant safety will be addressed with the Overall PI and study 
team.  
 
The DSMC will review each protocol up to four times a y ear or more often if required to review 
toxicity and accrual data. Information to be provided to the committee may include: up -to-date 
participant accrual; current dose level information; DLT information; all grade 2 or higher 
unexpected adverse events tha t have been reported; summary of all deaths occurring with 30  
days of intervention  for Phase  I or II protocols;  for gene  therapy  protocols,  summary  of all deaths 
while being treated and during active follow -up; any response information; audit results, and a 
summary provided by the study team. Other information (e.g. scans, laboratory values) will be 
provided upon request.  
 
13. STATISTICAL  CONSIDERATIONS  
 
13.1 Study  Design/Endpoints  
 
The primary  endpoint of  this phase  II study  is to determine  the proportion of  high risk 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
71  
 smoldering  multiple  myeloma  (SMM)  patients  who are progressive  free at 2 years  after receiving 
treatment (Elotuzum ab + lenalidomide+ Dexamethasone). The secondary objectives include 
toxicities,  objective  response  rate, time to progression,  duration  of response,  and overall  survival. 
In addition, we will examine the molecular evolution of the tumor cells, the role of circulating 
tumor cells and immune cells, and the role of NK cells and other immune cells present in the 
bone marrow in the progression of smoldering MM.  
 
The pr oportion of patients who achieve progression free at 2 years will be compared to the rate 
published for the high risk SMM. By the Mayo Clinic model for risk factors, the median time to 
progression for patients with high risk SMM was only 1.9 years. Therefo re, we assume that for 
this study, a 2 -years progression -free rate of 50% will not be considered promising and a true 
progression free rate of 70% or higher will be considered promising. A single -stage design will 
be employed with 39 eligible patients ente red. If 24 or more of the 39 eligible patients are 
progression free at 2 years (observed rate of 62%), we will conclude that this treatment warrants 
further study. The probability of concluding that the treatment is effective if the true rate is 50% 
is 0.10 and is >0.9 if the true rate is 70%.  Assuming  an ineligibility  rate of 5%, we will accrue  41 
patients/per Arm to the trial in order to have 39 eligible patients. A total of 55 patients will be 
enrolled.  
 
 
13.1.1  Analysis  of Primary  Endpoint  
 
Time to progression  (TTP) is defined as the time from protocol therapy initiation until 
documented progression, censored at date last known progression -free for those who have not 
progressed. At time of final analysis, the 2 -year progression -free rate will be estimated using  the 
Kaplan -Meier method with 90% confidence interval per Arm. All patients who have received 
one dose of study  treatment  will be included  for the TTP analysis,  including  those  who die or are 
lost to follow -up within 2 years.  
 
The percent  of patients  who undergo  stem  cell mobilization  and the modality  of mobilization  will 
be noted in the study. These patients will not be censored.  
 
13.1.2  Analysis  of Secondary  Endpoints  
 
The objective  response  rate (partial  response  or better  according  to the modified  IMWG  criteria) 
and the proportion of patients with a MRD, CR, PR or MR will be reported by Arm with 90% 
exact binominal confidence interval (CI). The exact 90% CI around response rate will be no 
wider than 28% with 39 eligible patients.  
 
To estimate the duratio n of response (time from objective response to disease progression or 
death, or date last known progression -free and alive for those who have not progressed or died), 
progression -free survival (time from protocol therapy initiation to the disease progressi on or 
death from any cause, censored at date last known progression free for those who have not 
progressed or died), and overall survival (time from protocol therapy initiation to death or date 
last known  alive),  the Kaplan -Meier  method  will be used.  The results  will be reported  separately 
for each Arm.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
72  
  
Safety  analysis  will be conducted  using  the Safety  Population  defined  as any patient  receiving 
one dose of study treatment. For toxicity reporting, all adverse events and laboratory 
abnormalit ies will be graded and analyzed using CTCAE version 4 as appropriate.  
 
13.2 Sample  Size,  Accrual  Rate  and Study  Duration  
 
A total of 55 patients  will be enrolled.  We expect  3.5 years  of active  accrual  (approximately  2 
patients per month) and 3 years of follow -up of patients.  
 
The final analyses  of progression -based  endpoints,  such as estimating  the 2-year progression -free 
rate and estimating the TTP distribution, will be conducted at the end of the study, which will 
occur after either all subjects have progressed or died or 2 -years after the initiation of therapy of 
the last subject enrolled, whichever occurs first.  
 
13.3 Stratification  Factors  
 
The patients  will be stratified  based  on age and cytogenetics.  
• Age 65 years  or older  
• High  risk cytogenetics based  on t(4:14),  t(14:16), 17p  deletion or  p53 mutation,  
+1q amplification (3 groups:  high risk, low  risk or Fish failure)  
 
13.4 Interim  Monitoring  Plan  
 
The study will be monitored by the DFCI Data Safety Monitoring Committee (DSMC). The 
DSMC  will meet  at least four times  a year and more  often  if needed  (e.g.,  for safety  review).  For 
each meeting, the study will be reviewed for safety and progress toward c ompletion. When 
appropriate, the DSMC will also review interim analyses of the outcome data. Copies of the 
toxicity  reports  prepared  by the DSMC  meetings  will be distributed  to the Principal  Investigator. 
The Principal Investigator will then distribute to sub -investigators. Any DSMC 
recommendations for changes to the study will be distributed to the Principal Investigator and 
then circulated to sub - investigators by the Principal Investigator.  
 
13.5 Stopping  Rule  for Safety  
 
All participants will be evaluable for treatment -related toxicity from the time of therapy 
initiation. The severe adverse event (SAE) is defined as any grade 3 adverse events that affect 
organ function (cardiac, hepatic, thrombo embolic) or grade 4/5 non hematologic AEs.  We 
anticipate that the rate of SAE is low in this study population. However, if 2 or more SAEs are 
observed  at any time in the first 20 treated  patients  in any study  cohort,  further  patient  enrollment 
will be paus ed for that cohort.  
 
The following table provides the probabilities of observing 2 or more SAEs with 20 treated 
participants in each cohort. For example, with 20 participants, there is 0.82 probability of 
observing  2 or more  SAEs  if a true rate is 15% and the probability  is 0.12 if a true rate is 3%. 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
73  
  
True  SAE  Rate 1% 3% 5% 10% 15% 20% 30% 
Probability  (≥2 SAEs)  0.017  0.120  0.264  0.608  0.824  0.931  0.992  
 
 
 
14. PUBLICATION  PLAN  
 
The results  should  be made  public  within  24 months  of reaching  the end of the study.  The end of 
the study is the time point at which the last data items are to be reported, or after the outcome 
data are sufficiently mature for analysis, as defined in the section on Sample Size, Accrual Rate 
and Study Duration . If a report is planned to be published in a peer -reviewed journal, then that 
initial release may be an abstract that meets the requirements of the International Committee of 
Medical  Journal Editors. A  full report  of the outcomes  should be made public no later than three  
(3) years  after the end of the study.  Data  sets from  other  relevant  studies  such as 17-212, 16-313, 
or data sets from other collaborators may be used and/or analyzed for the purposes of the 
publication.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
74  
 15. REFERENCES  
 
1. Ghobrial  IM, Landgren  O. How  I treat smoldering  multiple  myeloma.  
Blood.  2014 Nov  27;124(23):3380 -8. doi:  10.1182/blood -2014 -08-551549. Epub 2014  
Oct 8. 
2. Rajkumar  SV, Dimopoulos  MA, Palumbo  A, et.al.  International  
Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 
Lancet  Oncol.  2014  Nov;15(12):e538 -48. doi: 10.1016/S1470 -2045(14)70442 -5. Epub 
2014 Oct 26. Review. PubMed PMID: 25439696.  
3. Rajkumar  SV, Landgren  O, Mateos  MV. Smoldering  Multipl e Myeloma.  Blood.  2015 
Apr 2. pii: blood -2014 -09-568899  
4. Mateos,  M.V. , et al. Lenalidomide  plus dexamethasone  for high-risk smoldering  multiple 
myeloma. The New England journal of medicine 369, 438 -447 (2013).  
5. Lonial, S., Kaufman, J., Laubach, J. & Richardson, P. Elotuzumab: a novel anti -CS1 
monoclonal  antibody  for the treatment  of multiple  myeloma.  Expert  Opin  Biol Ther  13, 
1731 -1740 (2013).  
6. Collins,  S.M. , et al. Elotuzumab  directly  enhances  NK cell cytotoxicit y against  myeloma 
via CS1 ligation: evidence for augmented NK cell function complementing ADCC. 
Cancer immunology, immunotherapy : CII 62, 1841 -1849 (2013).  
7. Kuroda, J., Nagoshi, H., Shimura, Y. & Taniwaki, M. Elotuzumab and daratumumab: 
emerging  new monoclonal  antibodies  for multiple  myeloma.  Expert  Rev Anticancer  Ther 
13, 1081 -1088 (2013).  
8. Lonial, S. , et al. Elotuzumab in combination with lenalidomide and low -dose 
dexamethasone  in relapsed  or refractory  multiple  myeloma.  Journal  of clinical  oncology  : 
official journal of the American Society of Clinical Oncology 30, 1953 -1959 (2012).  
9. Kronke,  J., et al. Lenalidomide  causes  selective  degradation  of IKZF1  and IKZF3  in 
multiple myeloma cells. Science 343, 301 -305 (2014).  
10. Lu, G., et al. The myeloma  drug lenalidomide  promotes  the cereblon -dependent 
destruction of Ikaros proteins. Science 343, 305 -309 (2014).  
11. Anderson,  K.C.  & Carrasco,  R.D.  Pathogenesis  of myeloma.  Annu  Rev Pathol  6, 249-274 
(2011).  
12. Kyle,  R.A. , et al. Monoclonal  gammopathy  of undetermined  significance  (MGUS)  and 
smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk 
factors for progression and guidelines for monitoring and management. Leukemia 24, 
1121 -1127 (2010).  
13. Kyle,  R.A. , et al. Prevalence  of monoclonal  gammopathy  of undetermined significance.  
N Engl J Med 354, 1362 -1369 (2006).  
14. Dispenzieri, A. , et al. Prevalence and risk of progression of light -chain monoclonal 
gammopathy  of undetermined  significance:  a retrospective  population -based  cohort 
study. Lancet 375, 1721 -1728 (2010).  
15. Kyle,  R.A. , et al. Clinical  course  and prognosis  of smoldering  (asymptomatic)  multiple 
myeloma. The New England journal of medicine 356, 2582 -2590 (2007).  
16. Dispenzieri,  A., et al. Immunoglobulin  free light chain  ratio is an independent  risk factor 
for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785 -789 
(2008).  
17. Rajkumar,  S.V.,  Larson,  D. & Kyle, R.A.  Diagnosis  of smoldering  multiple  myeloma. N 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
75  
 Engl  J Med 365, 474 -475 (2011).  
18. Landgren,  O., et al. Monoclonal  gammopathy  of undetermined  significance  (MGUS) 
consistently precedes multiple myeloma: a prospective study. Blood 113, 5412 -5417 
(2009).  
19. Weiss, B.M., Abadie, J., Verma, P., Howard, R.S. & Kuehl, W.M. A monoclonal 
gammopathy  precedes  multiple  myeloma  in most  patients.  Blood  113, 5418 -5422  (2009).  
20. Lopez -Corral,  L., et al. SNP-based  mapping  arrays  reveal  high genomic  complexity  in 
monoclonal g ammopathies, from MGUS to myeloma status. Leukemia (2012).  
21. Visone,  R. & Croce,  C.M.  MiRNAs  and cancer.  Am J Pathol  174, 1131 -1138 (2009).  
22. Pichiorri,  F., et al. MicroRNAs  regulate  critical  genes  associated  with multiple  myeloma 
pathogenesis. Proc Natl Acad Sci U S A 105, 12885 -12890 (2008).  
23. O'Donnell,  K.A.,  Wentzel,  E.A.,  Zeller,  K.I., Dang,  C.V.  & Mendell,  J.T. c-Myc- 
regulated microRNAs modulate E2F1 expression. Nature 435, 839 -843 (2005).  
24. Chesi, M. , et al. AID-dependen t activation of a MYC transgene induces multiple 
myeloma  in a conditional  mouse  model  of post-germinal  center  malignancies.  Cancer 
Cell 13, 167 -180 (2008).  
25. Chiecchio, L. , et al. Loss of 1p and rearrangement of MYC are associated with 
progression  of smouldering  myeloma  to myeloma:  sequential  analysis  of a single  case. 
Haematologica 94, 1024 -1028 (2009).  
26. Chapman,  M.A. , et al. Initial  genome  sequencing  and analysis  of multiple myelom a. 
Nature 471, 467 -472 (2011).  
27. Egan, J.B. , et al. Whole -genome sequencing of multiple myeloma from diagnosis to 
plasma  cell leukemia  reveals  genomic  initiating  events,  evolution,  and clonal  tides.  Blood 
120, 1060 -1066 (2012).  
28. Keats,  J.J., et al. Clonal  competition  with alternating  dominance  in multiple  myeloma.  
Blood 120, 1067 -1076 (2012).  
29. Walker, B.A. , et al. Intraclonal heterogeneity and distinct molecular mechanisms 
characterize  the development  of t(4;14)  and t(11;14)  myeloma.  Blood  120, 1077 -1086 
(2012).  
30. Bahlis,  N.J. Darwinian  evolution  and tiding  clones  in multiple  myeloma.  Blood  120, 927- 
928 (2012).  
31. Greaves,  M. & Maley,  C.C. Clonal  evolution  in cancer.  Nature  481, 306-313 (2012).  
32. Rasillo,  A., et al. Fluorescence  in situ hybridization  analysis  of aneuploidization  patterns 
in monoclonal gammopathy of undetermined significance versus multiple myeloma and 
plasma cell leukemia. Cancer 97, 601 -609 (2003).  
33. Bergsagel,  P.L. & Kuehl,  W.M.  Molecular  pathogenesis  and a consequent  classification 
of multiple myeloma. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 23, 6333 -6338 (2005).  
34. Tassi, I. & Colonna, M. The cytotoxicity receptor CRACC (CS -1) recruits EAT -2 and 
activates  the PI3K  and phospholipase  Cgamma  signaling  pathways  in human  NK cells.  J 
Immunol 175, 7996 -8002 (2005).  
35. Boles,  K.S. & Mathew,  P.A. Molecular  cloning  of CS1,  a novel  human  natural  killer  cell 
receptor belonging to the CD2 subset of the immunoglobulin superfa mily. 
Immunogenetics 52, 302 -307 (2001).  
36. Tai, Y.T., et al. CS1 promotes  multiple  myeloma  cell adhesion,  clonogenic  growth,  and 
tumorigenicity via c -maf-mediated interactions with bone marrow stromal cells. Blood  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
76  
 113, 4309 -4318 (2009).  
37. Hsi, E.D., et al. CS1,  a potential  new therapeutic  antibody  target  for the treatment  of 
multiple myeloma. Clinical cancer research  : an official journal of the American 
Association for Cancer Research 14, 2775 -2784 (2008).  
38. Tai, Y.T., et al. Anti-CS1 humanized  monoclonal  antibody  HuLuc63  inhibits  myeloma 
cell adhesion  and induces  antibody -dependent  cellular  cytotoxicity  in the bone  marrow 
milieu. Blood 112, 1329 -1337 (2008).  
39. Ebert,  B.L., et al. An erythroid  differentiation  signature  predicts  response  to lenalidomide 
in myelodysplastic syndrome. PLoS Med 5, e35 (2008).  
40. Anderson,  K., et al. Genetic  variegation  of clonal  architectu re and propagating  cells in 
leukaemia. Nature 469, 356 -361 (2011).  
41. Barrett,  M.T. , et al. Evolution  of neoplastic  cell lineages  in Barrett  oesophagus.  Nat 
Genet 22, 106 -109 (1999).  
42. Morgan,  G.J., Walker,  B.A.  & Davies,  F.E. The genetic  architecture  of multiple 
myeloma. Nat Rev Cancer 12, 335 -348 (2012).  
43. Walker,  B.A. , et al. Intraclonal  heterogeneity  is a critical  early  event  in the development 
of myeloma and precedes the development of clinical symptoms. Leukemia (2013).  
44. Chng, W.J. , et al. Clinical and biological implications of MYC activation: a common 
difference  between  MGUS  and newly  diagnosed  multiple  myeloma.  Leukemia  25, 1026 - 
1035 (2011).  
45. Lopez -Corral,  L., et al. SNP-based  mapping  arrays  reveal  high genomic  complexity  in 
monoclonal gammopathies, from MGUS to myeloma status. Leukemia 26, 2521 -2529 
(2012).  
46. Quail,  D.F. & Joyce,  J.A. Microenvironmental  regulation  of tumor  progressi on and 
metastasis. Nature medicine 19, 1423 -1437 (2013).  
47. Swann,  J.B. & Smyth,  M.J. Immune  surveillance  of tumors.  J Clin Invest  117, 1137 -1146 
(2007).  
48. Dhodapkar,  M.V.  Immune  response  to premalignancy:  insights  from  patients  with 
monoclonal gammopathy. Ann N Y Acad Sci 1062 , 22-28 (2005).  
49. Beyer,  M. & Schultze,  J.L. Regulatory  T cells  in cancer.  Blood  108, 804-811 (2006).  
50. Feyler, S. , et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst 
CD3(+)CD4( -)CD8( -)alphabetaTCR(+) Double Negative T cells are decreased in the 
peripheral  blood  of patients  with multiple  myeloma  which  correlates  with disease  burden. 
British journal of haemato logy 144, 686 -695 (2009).  
51. Cruz -Munoz, M.E., Dong, Z., Shi, X., Zhang, S. & Veillette, A. Influence of CRACC, a 
SLAM  family  receptor  coupled  to the adaptor  EAT -2, on natural  killer  cell function.  Nat 
Immunol 10, 297 -305 (2009).  
52. Larsen,  J.T., et al. Serum  free light chain  ratio as a biomarker  for high-risk smoldering 
multiple myeloma. Leukemia 27, 941 -946 (2013).  
53. Hillengass, J. , et al. Prognostic significance of focal lesions in whole -body magnetic 
resonance  imaging  in patients  with asymptomatic  multiple  myeloma.  J Clin Oncol  28, 
1606 -1610 (2010).  
54. Hillengass,  J. & Landgren,  O. Challenges  and opportunities  of novel  imaging  techniques 
in monoclonal  plasma  cell disorders:  imaging  "early  myeloma".  Leuk  Lymphoma  (2013).  
55. Martinez -Lopez,  J., et al. Prognostic  value  of deep  sequencing  method  for minimal 
residual disease detection in multiple myeloma. Blood 123, 3073 -3079 (2014).  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
77  
 56. Rajkumar,  S.V., et al. Consensus  recommendations  for the uniform  reporting  of clinical 
trials: report of the International Myeloma Workshop Consensus Panel 1 . Blood 117, 
4691 -4695 (2011).  
57. Durie,  B.G. , et al. International  uniform  response  criteria  for multiple myeloma.  
Leukemia  20, 1467 -1473  (2006).  
58. Cavo, M. , et al. International Myeloma Working Group consensus approach to the 
treatment  of multiple  myeloma  patients  who are candidates  for autologous  stem  cell 
transplantation. Blood 117, 6063 -6073 (2011).  
59. Ludwig,  H., et al. International  Myeloma  Working  Group  recommenda tions  for global 
myeloma care. Leukemia 28, 981 -992 (2014).  
60. Paiva, B. , et al. High -risk cytogenetics and persistent minimal residual disease by 
multiparameter  flow cytometry  predict  unsustained  complete  response  after autologous 
stem cell transplantation in multiple myeloma. Blood 119, 687 -691 (2012).  
61. Rajkumar,  S.V.,  et, al. Clinical  course  of light chain  smouldering  multiple  myeloma 
(idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet 1, 28-36 
(2014). 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
78  
 APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  
 
ECOG  Performance  Status  Scale  Karnofsky Performance  Scale  
Grade  Descriptions  Percent  Description  
 
0 Normal  activity.  Fully  active,  able 
to carry on all pre -disease 
performance without restriction.  100 Normal,  no complaints,  no evidence 
of disease.  
90 Able to carry on normal activity; 
minor  signs  or symptoms  of disease.  
 
 
1 Symptoms, but ambulatory. 
Restricted  in physically  strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work).   
80 Normal  activity  with effort;  some 
signs or symptoms of disease.  
 
70 Cares for self, unable to carry on 
normal  activity  or to do active  work.  
 
 
2 In bed <50% of the time. 
Ambulatory and capable of all 
self-care, but unable to carry out 
any work  activities.  Up and about 
more than 50% of waking hours.   
60 Requires  occasional  assistance,  but 
is able to care for most of his/her 
needs.  
50 Requires  considerable  assistance  and 
frequent medical care.  
 
3 In bed >50%  of the time.  Capable 
of only limited  self-care,  confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled,  requires  special  care and 
assistance.  
30 Severely  disabled,  hospitalization 
indicated.  Death not imminent.  
 
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally  confined  to bed 
or chair.  20 Very  sick, hospitalization  indicated. 
Death not imminent.  
10 Moribund,  fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
79  
 APPENDIX  B: PREPARATION  AND  ADMINISTRATION  OF ELOTUZUMAB  
 
Dose  Preparation  Instructions  
 
After dilution in normal saline, elotuzumab must be administered within 8 hours if kept at room 
temperature (25°C). If a delay is anticipated after the dose has been diluted in normal saline, the  
prepared  dose (properly  identified)  may be refrigerated  at 2°C to 8°C for up to 24 hours.  If stored 
under  refrigerated  conditions,  the study  drug solution  should  be equilibrated  to room  temperature 
(takes about 2 to 2.5 hours), and the container must be gently inverted to thoroughly mix the 
contents before administration. If the storage time limit is exceeded, the prepared dose solution 
must be discarded and the reason documented by the p harmacist in the study drug accountability 
records.  
 
Elotuzumab will be administered to each subject as an IV infusion, using an automated infusion 
pump  set at the appropriate  rate according  to the dose administration  section  (see Administration 
Instructio n section  below)  discussed  below.  The dose of elotuzumab  will be calculated  using  the 
subject’s predose weight on Day 1 of each cycle or predose weight at each visit, whichever 
institutional policy is, and then added to 0.9% saline for infusion. Do not round up or down.  
 
Reconstitute  elotuzumab  lyophilized  study  drug,  as described  in Steps 1 to 5. Each  400 mg vial 
contains 10% overfill for a total of 440 mg of study drug but is intended to deliver 400 mg of 
elotuzumab. Standard aseptic technique should be utilized.  
 
Step 1: Remove  the flip-top from  elotuzumab  and Sterile  Water  for Injection  (SWFI)  vials.  
 
Step 2: Withdraw 17 mL of SWFI using an 18 -gauge or smaller needle. Place the elotuzumab 
vial upright  on a flat surface  and insert  the syringe  needle  into the vial through  the center  of the 
rubber stopper. Slowly inject the SWFI along the side of the vial to help prevent bubbling or 
foaming. Slowly remove the syringe needle out of the vial.  
 
Step 3: DO NOT SHAKE. Avoid prolonged or vigorous agitation. Hold the vial upright and 
gently  swirl the solution  by rotating  the vial to dissolve  the lyophilized  cake.  Then  gently  invert 
the vial a few times  in order  to dissolve  any powder  that may be present  on top of the vial or the 
stopper. Finally, hold the vial upright again and gently swirl the s olution a few more times to 
dissolve any remaining particles.  
 
Step 4: After  the remaining  solids  are completely  dissolved,  allow  the reconstituted  solution  to 
stand  for 5 to 10 minutes.  The final volume  of the reconstituted  solution  is approximately  17.6 
mL, for an approximate concentration of 25 mg/mL.  
 
It is acceptable  to have  small  bubbles  and/or  foam  around  the edge  of the vial. The reconstituted 
preparation results in a colorless to slightly yellow, clear to slightly opalescent solu tion. 
 
Step 5: Once the reconstitution is completed and prior to IV administration, the reconstituted 
solution is further diluted with 230 -340 ml of 0.9% sodium chloride injection (NS), USP, 
resulting  in elotuzumab  concentrations  between  2 mg/mL  and 6.6 mg/mL.  The infusion  is to be 
administered through a sterile, non -pyrogenic, low protein binding in -line filter. Additionally,  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
80  
 care must be taken to ensure the sterility of the prepared solution, as the drug product does not 
contain  anti-micro bial preservatives  or bacteriostatic  agents.  A sufficient  excess  of drug product 
is included in each vial to account for withdrawal losses.  
 
The first dose of elotuzumab will be administered following pre -medications to each subject as 
an IV infusion,  using an automated  infusion  pump  set at an initial  rate of 0.5 mL per minute  (30 
mL/hour). If the subject does not have an infusion reaction within 30 minutes, escalate the 
infusion rate  by 0.5 mL per minute. If the subject  still does not have  an infusion reaction within 
30 minutes, escalate the infusion rate to a maximum of 2 mL per minute (120 mL/hour). If a 
subject experiences a Grade 2 infusion reaction, the infusion must be interrupted.  
 
The second dose of elotuzumab should be initiated at an infusion rate of 3 mL per minute if no 
infusion reactions were reported with the first elotuzumab infusion. If the subject does not 
experience an infusion reaction during the first 30 minutes of the second dose of elotuzumab, 
escalate  the infusion  rate by 1.0 mL per minute  to a maximum  infusion  rate of 4 mL per minute.  
 
If no infusion  reactions  were  observed  during  the first two doses  cycle  of elotuzumab,  the third 
dose can commence at a rate of 5 mL per minute.  
 
If a patient experiences an infusion reaction of less than or equal to Grade 2, and the infusion 
reaction  does not recur,  the patient  can resume  elotuzumab  administration  at the rate at which  the 
reaction occurred at the start of the next cycle at the investigator’s discretion.  
 
If a subject experiences a Grade 2 infusion reaction, the infusion must be interrupted. Please 
refer  to Section  6.4.2  for detailed  information  on the management  of infusion reaction  and re- 
initiation  of infusion.  If a subject  experiences  a Grade  3 elotuzumab  infusion  reaction  that has 
resolved  to Grade  1, subsequent  infusion  rate of elotuzumab  should  be escalated  in a stepwise 
fashion (0.5 mL every 30 minutes).  
 
1) Administer  through  a low-protein -binding  0.22-micrometer  in-line filter  (placed  as 
proximal to the subject as is practical). Prime the infusion line with study drug before 
starting the infusion.  
 
2) Set the IV pump  to deliver  the infusion  at the rate of 0.5mL  per minute  (including  the 
drug in the line). The total time of infusion will vary depending upon the maximum 
tolerated mL/min infusion rate as discussed above.  
 
3) Record  every  time the infusion  is started  and stopped  and the reason  why the start and 
stop occurred.  
 
4) Monitor  the IV setup  and the subject’s  IV site frequently  during  infusion,  checking  for 
the correct infusion rate and IV site infiltration.  
 
5) Ensure  that the full volume  of elotuzumab is infused.  
 
After  elotuzumab  has been  infused  from  the line, discontinue  the infusion,  disconnect  the IV 
tubing,  and dispose  of materials  appropriately  according  to the facility’s  standard procedure.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
81  
 Note:  Subjects  must  be premedicated  as described  previously  prior  to elotuzumab  infusion.  
 
 
The elotuzumab infusion rate will be increased gradually to a maximum of 5 mL/min as 
presented  in the table  below.  The schedule  below  will be permitted  only if no infusion  reactions 
are e ncountered. For guidance related to elotuzumab infusion reactions, refer to section 6.4.  
 
 
 
Cycle/Day   
Infusion  Rate  Duration  of 
Infusion  Approximate 
Total  Infusion 
Time  
 
Cycle  1 Day 1 
(10mg/kg)  0.5 mL/min  30 minutes   
 
2 hours  and 50 
minutes  1 mL/min  30 minutes  
2mL/min  110 minutes  
 
Cycle  1 Day 8 
(10mg/kg)   
3 mL/min   
30 minutes   
1 hour and 13 
minutes   
4 mL/min   
43 minutes  
 
 
Cycle  1 Day 15 and 22 
And 
Cycle  2-8 
(10mg/kg)   
 
 
5mL/min   
 
 
53 minutes   
 
 
53 minutes  
 
Cycle  9-24 
(20mg/kg)   
5mL/min   
81 minutes   
81 minutes  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
82  
 APPENDIX  C: 14-338 SPECIMEN  COLLECTION  SCHEDULE  
 
Sample  Time  Point  Recipient  Sample  Type  Shipping  Method  Container1,2 
 
 
 
 
Baseline   
 
DFCI   
Peripheral  Blood   
 
Fridge  pack  same  day 3x 10mL  Purple  Top 
1x6ml Red Top  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
Buccal  Swab2 Ambient  same  day 1x Buccal  Swab  Kit 
 
Sequenta   
Bone  Marrow  Aspirate  Same  day – Use kit 
provided   
1x3ml Purple  
Cycle1  Day 1 
(Pre Dose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL  Purple  Top 
1x6ml Red Top  
Cycle  2-8 Day 1 
(Predose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL  Purple  Top3 
1x6ml Red Top  
 
End of Cycle 8 
(Cycle  9 Day 1)  
DFCI  Peripheral  Blood   
Fridge  pack  same  day 2x 10mL  Purple  Top3 
1x6ml Red Top  
Bone  Marrow  Aspirate  2x10mL  Purple  Top3 
Cycle  10-24 Day 1 
(Predose)  DFCI  Peripheral  Blood  Fridge  pack  same  day 2x10mL  Purple  Top 
1x6ml Red Top  
 
 
 
Confirm  Complete 
Response 4  
DFCI  Peripheral  Blood   
Fridge  pack  same  day 2x 10mL  Purple  Top 
1x6ml Red Top  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
 
Sequenta   
Bone  Marrow  Aspirate   
Same  day – Use kit 
provided   
1x3ml  Purple  Top 
End of Treatment 
and/or Disease 
Progression   
DFCI  Peripheral  Blood   
Fridge  pack  same  day 2x 10mL  Purple  Top 
1x6ml Red Top  
Bone  Marrow  Aspirate  2x10mL  Purple  Top 
Clinically Indicated/ 
and/or  Yearly  Bone 
Marrow 
Biopsy/Aspirate   
DFCI  Bone  Marrow  Aspirate   
Fridge  pack  same  day  
2x10mL  Purple  Top3 
Peripheral  Blood  
1 Purple  Top=  K2EDTA  Tube;  Red Top=  No Additive;  Sequenta  Tubes=  Provided  by Sequenta/Lead  Site 
2 Buccal  Swabs  will be provided  by the lead site, and can be sent at any  time point  during  the trial 
3 Samples  at these time  points are  voluntary, and  do not  exclude  patients  from treatment  
4 For definition  of Complete Response,  please  refer  to section 11.2.3.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
83  
  
 
 Protocol  #: 14 -338 
Version  Date:  4.9.2021  
 
APPENDIX  D: 14-338 SPECIMEN  REQUISITION  
Complete  this form  and include  with the specimen  shipment.  Label  all materials  with DFCI  participant  study  ID, collection  time point  and collection 
date and time. Email GhobrialLab@dfci.harvard.edu  to alert study team of shipment and include tracking number.  
 
Ship specimen(s)  to:  
Dana  Farber  Cancer  Institute 
Ghobrial Lab  
360 Longwood  Avenue  LC8116 
Boston, MA 02215  
 
Specimen  Information  
DFCI  Participant  Study  ID Number:    
Date specimen(s) shipped:   
 
Correlative  Sample  Time  Points  
(indicate  inclusion  in shipment  by checking box) Sample  Type  Quantity  of Tubes 
(6ml or 10ml)  Collection  Date  Collection  Time  
Pre-treatment/Baseline  Blood 
Swabs  Aspirate   Red Top 
Purple  Top   
Cycle  1-24 Day 1 Specify  Cycle   Blood   Red Top 
Purple  Top   
Confirm Response  Blood  Aspirate   Red Top 
Purple  Top   
Cycle  9 Day 1 (end  of Cycle 8) Blood  Aspirate   Red Top 
Purple  Top   
End of Treatment  Disease  Progression  Blood  Aspirate   Red Top 
Purple  Top   
Clinical  Necessity/  Standard  of Care Aspirate   Purple  Top   
 
Responsible Contact:    
Site:   Email:    
Phone number:   
Note:  All samples  are to be shipped  with a fridge  pack  Fed-Ex priority  overnight - Please  retain  a copy  of the waybill,  and reference  the tracking 
number in the email and paper correspondence. Ship only Monday - Thursday , as shipments cannot be received over the weekend  
 
 
 
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
84 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
85  
 DFCI  IRB Protocol  #: 14-338 
 
 
 
 
APPENDIX  E: DF/HCC  MULTI -CENTER  DATA  AND  SAFETY  MONITORING  PLAN  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
86  
 TABLE  OF CONTENTS  
SCHEMA  ................................ ................................ ................................ ................................ .........  2 
SYNOPSIS  ................................ ................................ ................................ ................................ ....... 6 
1. OBJECTIVES  ................................ ................................ ................................ ......................  9 
1.1 Study  Design  ................................ ................................ ................................ ............  9 
1.2 Primary  Objectives  ................................ ................................ ................................ . 10 
1.3 Secondary  Objectives  ................................ ................................ .............................  10 
2. BACKGROUND  ................................ ................................ ................................ ................  10 
2.1 Multiple  Myeloma  ................................ ................................ ................................ .. 10 
2.2 MGUS  and SMM  consistently  precedes  multiple  myeloma  ................................ .. 11 
2.3 Molecular  studies  in MGUS  and SMM  ................................ ................................ .. 11 
2.4 Definition  of SMM  ................................ ................................ ................................ . 13 
2.5 Definitions  of high-risk SMM  ................................ ................................ ................  14 
2.6 Treatment  of high risk SMM  ................................ ................................ ..................  14 
2.7 Elotuzumab  ................................ ................................ ................................ .............  15 
2.8 Rationale  for Elotuzumab  in SMM  ................................ ................................ ........  15 
2.9 Rationale  for dose and schedule  of Elotuzumab  ................................ ....................  16 
2.10 Trial  Rationale  ................................ ................................ ................................ ........  21 
2.11 Correlative  Studies  Background  ................................ ................................ .............  22 
3. PARTICIPANT  SELECTION  ................................ ................................ ...........................  23 
3.1 Eligibility  Criteria  ................................ ................................ ................................ .. 23 
3.2 Exclusion Criteria  ................................ ................................ ................................ ... 25 
3.3 Inclusion  of Women and Minorities  ................................ ................................ ....... 26 
4. REGISTRATION PROCEDURES  ................................ ................................ ....................  26 
4.1 General  Guidelines  for DF/HCC  and DF/PCC  Institutions  ................................ .... 26 
4.2 Registration  Process  for DF/HCC  and DF/PCC  Institutions  ................................ .. 26 
4.3 General  Guidelines  for Other  Investigative  Sites  ................................ ...................  27 
4.4 Registration  Process  for Other  Investigative  Sites  ................................ .................  27 
5. TREATMENT PLAN  ................................ ................................ ................................ ........  27 
5.1 Treatment  Regimen  ................................ ................................ ................................  27 
5.2 Pre-Treatment  Criteria  ................................ ................................ ............................  30 
5.3 Agent  Administration  ................................ ................................ .............................  31 
5.4 General  Concomitant  Medication  and Supportive  Care  Guidelines  ......................  33 
5.5 Criteria  for Taking  a Participant  Off Protocol  Therapy  ................................ .........  34 
5.6 Duration  of Follow  Up ................................ ................................ ...........................  35 
5.7 Criteria  for Taking  a Participant  Off Study  ................................ ............................  36 
6. DOSING  DELAYS/DOSE  MODIFICATIONS  ................................ ................................  36 
6.1 Elotuzumab  ................................ ................................ ................................ .............  36 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
87  
 6.2 Lenalidomide  ................................ ................................ ................................ ..........  36 
6.3 Dexamethasone  ................................ ................................ ................................ ...... 40 
6.4 Guidelines  for Elotuzumab  Infusion  in Subjects  with Infusion  Reactions  .............  42 
7. ADVERSE  EVE NTS:  LIST  AND  REPORTING  REQUIREMENTS  .............................  44 
7.1 Expected  Toxicities  ................................ ................................ ................................  44 
7.2 Adverse  Event  Characteristics  ................................ ................................ ................  46 
7.3 Expedited  Adverse  Event  Reporting  ................................ ................................ ...... 46 
7.4 DF/HCC  Expedited  Reporting  Guidelines  ................................ .............................  46 
Overdose  of Lenalidomide  ................................ ................................ ................................ . 49 
7.5 Expedited  Reporting  to the Food  and Drug  Administration  (FDA)  .......................  49 
7.6 Expedited  Reporting  to Bristol -Myers  Squibb  (BMS)  ................................ ...........  49 
7.7 Expedited  Reporting  to Celgene  ................................ ................................ ............  49 
7.8 Expedited  Reporting  to Hospital  Risk Management  ................................ ..............  50 
7.9 Routine  Adverse  Event  Reporting  ................................ ................................ ..........  50 
8. PHARMACEUTICAL  INFORMATION  ................................ ................................ ..........  50 
8.1 Elotuzumab  ................................ ................................ ................................ .............  50 
8.2 Lenalidomide  ................................ ................................ ................................ ..........  52 
8.3 Dexameth asone  ................................ ................................ ................................ ...... 54 
9. BIOMARKER,  CORRELATIVE,  AND  SPECIAL  STUDIES  ................................ .........  56 
9.1 Bone  Marrow  Aspirate  Samples  ................................ ................................ .............  57 
9.2 Peripheral  Blood  Samples  ................................ ................................ ......................  58 
10. STUDY  CALENDAR  ................................ ................................ ................................ ........  61 
11. MEASUREMENT  OF EFFECT  ................................ ................................ .........................  62 
11.1 Development  of symptomatic  disease  ................................ ................................ .... 62 
11.2 Antitumor  Effect  ................................ ................................ ................................ .... 63 
12. DATA REPORTING  / REGULATORY  REQUIREMENTS  ................................ ...........  70 
12.1 Data  Reporting  ................................ ................................ ................................ ....... 70 
12.2 Data  Safety  Monitoring  ................................ ................................ ...........................  70 
13. STATISTICAL  CONSIDERATIONS.  ................................ ................................ ..............  70 
13.1 Study  Design/Endpoints  ................................ ................................ .........................  70 
13.2 Sample  Size,  Accrual  Rate and Study  Duration  ................................ .....................  72 
13.3 Stratification  Factors  ................................ ................................ ..............................  72 
13.4 Interim  Monitoring  Plan ................................ ................................ .........................  72 
13.5 Stopping  Rule  for Safety  ................................ ................................ ........................  72 
14. PUBLICATION  PLAN  ................................ ................................ ................................ ...... 73 
15. REFERENCES  ................................ ................................ ................................ ...................  74 
APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  ................................ .............................  78 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
88  
 APPENDIX  B: PREPARATION  AND  ADMINISTRATION  OF ELOTUZUMAB  ...................  79 
APPENDIX  C: 14-338 SPECIMEN  COLLECTION  SCHEDULE  ................................ ..............  82 
APPENDIX  D: 14-338 SPECIMEN  REQUISITION  ................................ ................................ .... 84 
APPENDIX  E: DF/HCC  MULTI -CENTER  DATA  AND  SAFETY  MONITORING  PLAN  ...... 85 
1. INTRODUCTION  ................................ ................................ ................................ ..............  89 
1.1 Purpose  ................................ ................................ ................................ ...................  89 
1.2 Multi -Center  Data  and Safety  Monitoring  Plan Definitions  ................................ ... 89 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  ................................ ................................  90 
2.1 DF/HCC  Sponsor  ................................ ................................ ................................ ... 90 
2.2 Coordinating  Center  ................................ ................................ ...............................  91 
2.3 Participating  Institution  ................................ ................................ ..........................  91 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  ..............................  92 
3.1 Protocol  Distribution  ................................ ................................ ..............................  92 
3.2 Protocol  Revisions  and Closures  ................................ ................................ ............  92 
3.3 Informed Consent Requirements  ................................ ................................ ............  93 
3.4 IRB Documentation  ................................ ................................ ................................  93 
3.5 IRB Re -Approval  ................................ ................................ ................................ ... 93 
3.6 Participant  Confidentiality  and Authorization  Statement  ................................ ....... 94 
3.7 DF/HCC  Multi -Center  Protocol  Registration  Policy ................................ ..............  94 
3.8 DF/HCC  Protocol  Case  Number  ................................ ................................ ............  95 
3.9 Safety  Assessments  and Toxicity  Monitoring  ................................ ........................  96 
3.10 Data  Management ................................ ................................ ................................ ... 97 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  ................................ ..........................  97 
5. MONITORING:  QUALITY  CONTROL  ................................ ................................ ..........  98 
5.1 Ongoing  Monitoring  of Protocol  Compliance  ................................ ........................  98 
5.2 Monitoring  Reports  ................................ ................................ ................................  99 
5.3 Accrual  Monitoring  ................................ ................................ ................................  99 
6. AUDITING:  QUALITY  ASSURANCE  ................................ ................................ ............  99 
6.1 Audit  Plan:  DF/HCC  Sponsored  Trials  ................................ ................................ .. 99 
6.2 Audit  Notification  ................................ ................................ ................................ ... 99 
6.3 Audit  Reports  ................................ ................................ ................................ ........  100 
6.4 Participating  Institution  Performance  ................................ ................................ ... 100 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
89  
 1. INTRODUCTION  
 
The Dana -Farber/Harvard Cancer Center Multi -Center Data and Safety Monitoring Plan 
(DF/HCC DSMP) outlines the procedures for conducting a DF/HCC Multi -Center research 
protocol.  The DF/HCC  DSMP  should  serve  as a reference  for any sites external  to DF/HCC 
that will be participating in the research protocol.  
 
1.1 Purpose  
 
To establish standards that will ensure that a Dana -Farber/Harvard Cancer Center Multi - 
Center protocol will comply with Federal Regulations, Health Insurance Portability and 
Accountability Act ( HIPAA) requirements and applicable DF/HCC Standard Operating 
Procedures.  
 
1.2 Multi -Center  Data  and Safety  Monitoring  Plan  Definitions  
 
DF/HCC Multi -Center Protocol : A research protocol in which one  or more outside 
institutions are collaborating with Dana -Farber/Harvard Cancer Center where  a DF/HCC 
investigator  is the sponsor.  DF/HCC  includes  Dana -Farber/Partners  Cancer  Care  (DF/PCC) 
Network Clinical Trial Affiliates.  
 
Lead Institution:  One of the Dan a-Farber/Harvard Cancer Center consortium members 
(Dana -Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH), Beth 
Israel Deaconess Medical Center (BIDMC), Boston Children’s Hospital (BCH), Brigham 
and Women’s Hospital (BWH)) responsible fo r the coordination, development, 
submission, and approval of a protocol as well as its subsequent amendments per the  
DFCI IRB and applicable regulatory guidelines (CTEP, Food and Drug Administration 
(FDA), Office of Biotechnology Activities (OBA) etc.).  The Lead Institution is typically 
the home of the DF/HCC Sponsor. The Lead Institution also typically serves as the 
Coordinating Center for the DF/HCC Multi -Center Protocol.  
 
DF/HCC Sponsor:  The person sponsoring the submitted Multi -Center protocol.  Within 
DF/HCC, this person is the Overall Principal Investigator who takes responsibility for 
initiation, management and conduct of the protocol at all research locations. In applicable 
protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory 
agencies.  The DF/HCC  Sponsor  has ultimate  authority  over the protocol  and is responsible 
for the conduct  of the study  at DF/HCC  and all Participating  Institutions.  In most  cases  the 
DF/HCC Sponsor is the same person as the DF/HCC Overall Principal Investigator; 
however, both roles can be filled by two different people.  
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC 
consortium that is collaborating  with DF/HCC on a protocol where the sponsor is a 
DF/HCC Investigator.  The Participating Institution acknowledges the DF/HCC Sponsor  
as having the ultimate authority and responsibility for the overall conduct of the study.  
Coordinating Center: The entity ( i.e. Lead Institution, Medical Monitor, Contract 
Research  Organization  (CRO),  etc) that provides  administrative  support  to the DF/HCC  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
90  
 Sponsor in order that he/she may fulfill the responsibilities outlined in the protocol 
document and DSMP, an d as specified in applicable regulatory guidelines (i.e. CTEP 
Multi -Center Guidelines). In general, the Lead Institution is the Coordinating Center for 
the DF/HCC Multi -Center Protocol. Should the DF/HCC Sponsor decide to use a CRO, 
the CRO will be deemed the Coordinating Center.  
 
DF/HCC Quality Assurance Office for Clinical Trials: A group within DF/HCC 
responsible for registering human subjects for trials, ensuring high -quality standards are 
used for data collection and the ongoing management of clinical trials, auditing, and data 
and safety monitoring. QACT also coordinates quality assurance efforts related to multi - 
center clinical research.  
 
2. GENERAL  ROLES  AND  RESPONSIBILITIES  
 
For DF/HCC Multi -Center Protocols, the DF/HCC Sponsor, the Coordinating Cente r, and 
the Participating Institutions are expected to adhere to the following general  
responsibilities:  
 
2.1 DF/HCC  Sponsor  
 
The DF/HCC Sponsor, Irene Ghobrial, MD will accept responsibility for all aspects of  
conducting a DF/HCC Multi -Center protocol which in cludes but is not limited to:  
• Oversee the coordination, development, submission, and approval of the protocol 
as well as subsequent amendments.  
• Ensure that the investigators, study team members, and Participating Institutions  
are qualified and appropriately resourced to conduct the protocol.  
• Include the Multi -Center Data and Safety Monitoring Plan as an appendix to the  
protocol.  
• Ensure  all Participating  Institutions  are using  the correct  version  of the protocol.  
• Ensure that each participating investigator and study team member receives 
adequate protocol training and/or a Site Initiation Visit prior to enrolling 
participants and throughout tr ial’s conduct as needed.  
• Ensure the protocol will be provided to each participating site in a language 
understandable to all applicable site personnel when English is not the primary 
language.  
• Monitor  progress  and overall  conduct  of the study  at all Partic ipating  Institutions.  
• Ensure all DFCI Institutional Review Board (IRB), DF/HCC and other applicable 
reporting requirements are met.  
• Review  data and maintain  timely  submission  of data for study  analysis.  
• Ensure compliance with all requirements as set forth in the Code of Federal 
Regulations, applicable DF/HCC requirements, HIPAA requirements, and the 
approved protocol.  
• Commit to the provision that the protocol will not be rewritten or modified by 
anyone other than the DF/HCC Sponsor.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
91  
 • Identify  and qualify  Participating  Institutions  and obtain  accrual  commitments 
prior to extending the protocol to that site.  
• Monitor  accrual  and address  Participating  Institutions  that are not meeting  their 
accrual requirements.  
 
2.2 Coordinating  Center  
 
The general responsibilities  of the  Coordinating Center  may include  but are  not limited to: 
• Assist  in protocol  development.  
• Review  registration  materials  for eligibility  and register  participants  from 
Participating Institutions with DF/HCC QACT.  
• Distribute  protocol  and informed  consent  document  updates  to Participating 
Institutions as needed.  
• Oversee  the data collection  process  from  Participating  Institutions.  
• Maintain documentation of Serious Adve rse Event (SAE) reports and 
deviations/violation  submitted  by Participating  Institutions  and provide  to the 
DF/HCC Sponsor for timely review.  
• Distribute serious adverse events reported to the DF/HCC Sponsor that fall under 
the DFCI IRB Adverse Event Report ing Policy to all Participating Institutions.  
• Provide  Participating  Institutions  with information  regarding  DF/HCC 
requirements that they will be expected to comply with.  
• Carry  out plan to monitor  Participating  Institutions  either  by on-site or remote 
monitoring.  
• Maintain  Regulatory  documents  of all Participating  Institutions  which  includes  but 
is not limited to the following: local IRB approvals/notifications from all 
Participating Institutions, confirmation of Federalwide Assurances (FWAs) for all 
sites,  all SAE submissions, Screening Logs for all sites, IRB approved consents 
for all sites  
• Conduct  regular  communications  with all Participating  Institutions  (conference 
calls, emails, etc) and maintain documentation all relevant communications.  
 
2.3 Participating  Institution  
 
Each Participating Institution is expected to comply with all applicable federal regulations 
and DF/HCC requirements, the protocol and HIPAA requirements.  
 
The general  responsibilities  for each Participating  Institution  may include  but are not 
limited to:  
• Document  the delegation  of research  specific  activities  to study  personnel.  
• Commit  to the  accrual of participants  to the protocol.  
• Submit  protocol  and/or  amendments  to their local  IRB. 
• Maintain  regulatory  files as per sponso r requirements.  
• Provide the Coordinating Center with regulatory documents or source documents 
as requested.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
92  
 • Participate in protocol training prior to enrolling participants and throughout the  
trial as required (i.e. teleconferences).  
• Update  Coordinating  Center  with research  staff changes  on a timely  basis.  
• Register participants through the Coordinating Center prior to beginning research 
related activities.  
• Submit Serious Adverse Event (SAE) reports to local IRB per local requirements 
and to the Coordinating Center, in accordance with DF/HCC requirements.  
• Submit protocol deviations and violations to local IRB per local requirements and 
to the DF/HCC Sponsor in accordance with DF/HCC requirements.  
• Order,  store  and dispense  investigational  agents  and/or  other  protocol  mandated 
drugs per federal guidelines and pr otocol requirements.  
• Have  office  space,  office  equipment,  and internet  access  that meet  HIPAA 
standards.  
• Participate  in any quality  assurance  activities  and meet  with monitors  or auditors  at 
the conclusion of a visit to review findings.  
• Promptly  provide  follow -up and/or  corrective  action  plans  for any monitoring 
queries or audit findings.  
 
3. DF/HCC  REQUIREMENTS  FOR  MULTI -CENTER  PROTOCOLS  
 
The following section will clarify DF/HCC Requirements and further detail the expectations for 
participating in a DF/HCC  Multi -Center protocol.  
 
3.1 Protocol Distribution  
 
The Coordinating Center will distribute the final DFCI IRB approved protocol and any 
subsequent amended protocols to all Participating Institutions.  
 
3.2 Protocol  Revisions  and Closures  
 
The Participating Institutions will receive notification of protocol revi sions and closures 
from the Coordinating Center.  It is the individual Participating Institution’s responsibility 
to notify its IRB of these revisions.  
 
• Non life -threatening revisions: Participating Institutions will receive written 
notification of protocol  revisions regarding non life -threatening events from the 
Coordinating Center. Non -life-threatening protocol revisions must be IRB 
approved and implemented within 90 days from receipt of the notification.  
 
• Revisions for life -threatening causes: Participati ng Institutions will receive 
immediate  notification  from  the Coordinating  Center  concerning  protocol  revisions 
required to protect lives with follow -up by fax, mail, e -mail, etc.  Life-threatening 
protocol revisions will be implemented immediately followed by IRB request for 
approval.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
93  
 • Protocol closures and temporary holds: Participating Institutions will receive 
notification of protocol closures and temporary holds from the Coordinating 
Center. Closures and holds will be effective immediately.  In addition, the 
Coordinating Center, will update the Participating Institutions on an ongoing basis 
about protocol accrual data so that they will be aware of imminent protocol 
closures.  
 
3.3 Informed  Consent  Requirements  
 
The DF/HCC approved informed consent  document will serve as a template for the 
informed consent for Participating Institutions. The Participating Institution consent form 
must  follow  the consent  template  as closely  as possible  and should  adhere  to specifications 
outlined in the DF/HCC Guidan ce Document on Model Consent Language for PI -Initiated 
Multi -Center Protocols.  This document will be provided separately to each Participating 
Institution.  
 
Participating Institutions are to send their version of the informed consent document and 
HIPAA aut horization, if a separate document, to the Coordinating Center for review and 
approval prior to submission to their local IRB. The approved consent form must also be 
submitted to the Coordinating Center after approval by the local IRB for all consent 
versi ons. 
 
The Principal Investigator (PI) at each Participating Institution will identify the physician 
members of the study team who will be obtaining consent and signing the consent form  
for therapeutic protocols. Participating institutions must follow the DF/HCC requirement 
that only attending physicians obtain informed consent and re -consent to interventional 
trials (i.e. drug and/or device trials).  
3.4 IRB Documentation  
 
The following  must be  on file with  the Coordinating Center:  
• Initial  approval  letter  of the Participating  Institution's  IRB. 
• Copy of the Informed Consent Form(s) approved by the Participating Institution’s 
IRB. 
• Participating  Institution’s  IRB approval  for all amendments.  
• Annual  approval  letters  by the Participating  Institution's  IRB. 
 
3.5 IRB Re-Appr oval 
 
Verification of IRB re -approval from the Participating Institutions is required in order to 
continue research activities.  There is no grace period for continuing approvals.  
 
The Coordinating  Center  will not register  participants  if a re-approval  letter is not received 
from the Participating Institution on or before the anniversary of the previous approval 
date. 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
94  
 3.6 Participant  Confidentiality  and Authorization  Statement  
 
In 1996, congress passed the first federal law covering the privacy of health information 
known as the Health Insurance Portability and Accountability Act ( HIPPA). Any 
information, related to the physical or mental health of an individual is called Protect ed 
Health Information (PHI). HIPAA outlines how and under what circumstances PHI can be 
used or disclosed.  
 
In order for covered entities to use or disclose protected health information during the 
course of a study, the study participant must sign an autho rization statement.  This 
authorization statement may or may not be separate from the informed consent document. 
The Coordinating Center, with the approval from the DFCI IRB, will provide a consent 
template, with information regarding authorization for the disclosure of protected health 
information.  
 
The DF/HCC Sponsor will use all efforts to limit its use of protected health information in 
its trials. However, because of the nature of these trials, certain protected health 
information must be collected. DF/ HCC has chosen to use authorizations, signed by the 
participant in the trial, rather than limited data sets with data use agreements.  
3.6.1 DF/HCC  Multi -Center  Protocol  Confidentiality  
All documents, investigative reports, or information relating to the particip ant are strictly 
confidential.  Whenever  reasonably  feasible,  any participant  specific  reports  (i.e. Pathology 
Reports, MRI Reports, Operative Reports, etc.) submitted to the Coordinating Center 
should be de -identified. It is recommended that the assigned D F/HCC QACT case number 
(as described below) be used for all participant specific documents. Participant initials  
may be included or retained for cross verification of identification.  
3.7 DF/HCC  Multi -Center  Protocol  Registration  Policy  
 
3.7.1 Participant  Registratio n 
 
See Sections  4.3 and 4.4 of the protocol.  
 
3.7.2 Initiation  of Therapy  
 
Participants must be registered with the DF/HCC QACT before  receiving treatment. 
Treatment may not be initiated until the Participating Institution receives confirmation of 
the participant’s registration from the Coordinating Center. The DF/HCC Sponsor and 
DFCI IRB must be notified of any violations to this policy . 
 
3.7.3 Eligibility  Exceptions  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
95  
 The DF/HCC QACT will make no exceptions to the eligibility requirements for a protocol 
without DFCI IRB approval. The DF/HCC QACT requires each institution to fully  
comply with this requirement.  
 
3.8 DF/HCC  Protocol  Case  Number  
 
At the time of registration, QACT requires the following identifiers for all subjects: 
initials, date of birth, gender, race and ethnicity. Once eligibility has been established and 
the participant successfully registered, the participant is assig ned a unique protocol case 
number.  Participating Institutions should submit all de -identified subsequent 
communication and documents to the Coordinating Center, using this case number to 
identify the subject.  
 
3.8.1 Protocol  Deviations,  Exceptions  and Violations  
 
Federal Regulations require an IRB to review proposed changes in a research activity to 
ensure that researchers do not initiate changes in approved research without IRB review 
and approval, except when necessary to eliminate apparent immediate hazards to  the 
participant. DF/HCC requires all departures from the defined procedures set forth in the 
IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is responsible 
for reporting to the DFCI IRB.  
 
For reporting purposes, DF/HCC uses the ter ms “violation”, “deviation” and “exception” 
to describe departures from a protocol. All Participating Institutions must adhere to these 
requirements for reporting to the DF/HCC Sponsor and will follow their institutional 
policy for reporting to their local  IRB.  
 
3.8.2 Definitions  
 
Protocol Deviation : Any departure from the defined procedures set forth in the IRB - 
approved protocol which is prospectively approved prior to its implementation.  
 
Protocol  Exception : Any protocol  deviation  that relates  to the eligibility  criteria,  e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria.  
 
Protocol  Violation : Any protocol  deviation  that was not prospectively  approved  by the 
IRB prior to its initiation or implementation.  
 
3.8.3 Reporting Procedures  
 
DF/HCC Sponsor:  is responsible for ensuring that clear documentation is available in the 
medical  record  and/or  regulatory  documents  to describe  all protocol  exceptions,  deviations 
and violations. The DF/HCC Sponsor will also be responsible for ensu ring that all  
protocol violations/deviations are promptly reported per DFCI IRB guidelines.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
96  
 Participating Institutions : Protocol deviations require prospective approval from the DFCI 
IRB. The Participating Institution must submit the deviation request to the Coordinating 
Center who will then submit the deviation request to the DFCI IRB. Upon DFCI IRB 
approval the deviatio n is submitted to the Participating Institution IRB, per institutional 
policy. A copy of the Participating Institution’s IRB report and determination will be 
forwarded to the Coordinating Center within 10 business days after the original 
submission.  
 
All protocol  violations  must be  sent to the  Coordinating  Center in  a timely manner.  
 
Coordinating Center:  Upon receipt of the violation/deviation report from the Participating 
Institution, the Coordinating Center will submit the report to the DF/HCC Sponsor for  
review. Subsequently, the Participating Institution’s IRB violation/deviation report will be 
submitted to the DFCI IRB for review per DFCI IRB reporting guidelines. DF/HCC will 
forward all violation reports to CTEP via an internal DF/HCC process, as appli cable.  
 
3.9 Safety  Assessments  and Toxicity  Monitoring  
 
The study teams at all participating institutions are responsible for protecting the safety, 
rights and well -being of study participants. Recording and reporting of adverse events that 
occur during the course of a study help ensure the continuing safety of  study participants.  
 
All participants  receiving  investigational  agents  and/or  other  protocol  mandated  treatment 
will be evaluated for safety. The safety parameters include all laboratory tests and 
hematological abnormalities, physical examination findings , and spontaneous reports of 
adverse events reported by participants.  All toxicities encountered during the study will 
be evaluated according to the NCI criteria specified in the protocol. Life -threatening 
toxicities must be reported immediately to the DF/ HCC Sponsor via the Coordinating 
Center.  
 
Additional  safety  assessments  and toxicity  monitoring  will be outlined  in the protocol.  
 
3.9.1 Guidelines  for Reporting  Serious  Adverse  Events  
 
Guidelines for reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) are  
detailed in Section 7 of the protocol.  
 
Participating  Institutions  must  report  the SAEs  to the DF/HCC  Sponsor  and the 
Coordinating Center following the DFCI IRB Adverse Event Reporting Policy . 
 
The Coordinating Center will maintain documentation of all Participating Institution 
Adverse Event reports and be responsible for communicating to all participating 
investigators, any observations reportable under the DFCI IRB Reporting Requirements. 
Participating Institutions will review and submit to thei r IRB according to their 
institutional policies and procedures  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
97  
 3.9.2 Guidelines  for Processing  IND Safety  Reports  
 
The DF/HCC  Sponsor  will review  all IND Safety  Reports  and ensure  that all IND Safety 
Reports are distributed to the Participating Institutions. Participating Institutions will 
review and submit to their IRB according to their institutional policies and procedures.  
 
3.10 Data  Management  
 
The DF/HCC QACT develops case report forms (CRF/eCR Fs), for use with the protocol. 
These forms are designed to collect data for each study. The DF/HCC QACT provides a 
web based training for eCRF users.  
 
3.10.1  Data  Forms  Review  
 
Data submissions are monitored for timeliness and completeness of submission. 
Partici pating Institutions are notified of their data submission delinquencies in accordance 
with the following:  
 
Incomplete  or Questionable  Data 
If study forms are received with missing or questionable data, the submitting institution 
will receive a written or e lectronic query from the DF/HCC QACT Data Analyst, 
Coordinating Center or designee.  Responses to all queries should be completed and 
submitted within 14 calendar days.  Responses may be returned on the written query or on 
an amended paper case report form, or in the case of electronic queries, within the 
electronic data capture (eDC) system. In the case of a written query for data submitted on  
a paper case report form, the query must be attached to the specific data being re - 
submitted in response.  
 
Missing  Forms  
If study forms are not submitted on schedule, the Participating Institution will receive a 
Missing Form Report from the Coordinating Center noting the missing forms.  These 
reports are compiled by the DF/HCC QACT and distributed on a monthly basis.  
 
4. REQUISITIONING  INVESTIGATIONAL  DRUG  
 
The ordering of investigational agent is specified in Section 8 of the protocol. 
Participating  Institutions  should  order  their own agent  regardless  of the supplier.  
If the agent is commercially available, check with the local Director of Pharmacy and/or  
the Research Pharmacy to ensure that the agent is in stock. If the agent is not stocked, 
ensure that the agent can be ordered once the protocol is approved by the loca l IRB.  
 
If the agent is investigational, ensure that the pharmacy will be able to receive and store the 
agent  according  to state and federal  requirements.  The local  IRB should  be kept informed  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
98  
 of who will supply the agent so that any regulato ry responsibilities can be met in a timely 
fashion.  
 
5. MONITORING: QUALITY CONTROL  
 
The quality control process for a clinical trial requires verification of protocol compliance 
and data accuracy. The Coordinating Center, with the aid of the QACT provides qu ality 
control oversight for the protocol.  
 
5.1 Ongoing  Monitoring of Protocol Compliance  
 
The Participating  Institutions  will be required  to submit  subject  source  documents  to the 
DF/HCC Lead Institution or designee for monitoring. Also, the Participating Institution 
may be subject to on -site monitoring conducted by the DF/HCC Lead Institution.  
 
The DF/HCC Lead Institution will implement on -site as well as virtual monitoring 
activities to ensure that Participating Institutions are complying with regulatory and 
protocol requirements, data quality, and subject safety.  At a minimum, the DF/HCC Lead 
Institute, or designee, will monitor each participating site twice a year while patients are 
receiving treatment. Should a Participating Institution be monitored once and then not 
accrue  any additional  patients  or participant  visits,  then a second  monitorin g visit may not 
be necessary.  
 
Monitoring practices may include but are not limited to; source verification, review and 
analysis of the following: eligibility requirements of all participants, informed consent 
procedures,  adverse  events  and all associated  documentation,  study  drug administration  / 
treatment, regulatory records and site trial master files, protocol deviations,  pharmacy 
records,  response  assessments,  and data management.  Additionally,  regular  and ongoing 
communication with Participating Insti tutions will be accomplished by holding all site 
teleconferences at least monthly. The Lead Institution will keep in close touch with the 
Participating Institutions via email and phone. Source documents from Participating 
Institutions, will be collected at  specific data points that support the primary and or 
secondary endpoints.  
 
On-Site Monitoring: On-site monitoring will occur at least once per year. Participating 
Institutions  will be required  to provide  access  to participants’  complete  medical  record  and 
source documents for source documentation verification during the on -site visit. In 
addition, upon request from a monitor or auditor, Participating Institutions should provide 
access to regulatory documents, pharmacy records, local policies rela ted to the conduct of 
research, and any other trial -related documentation maintained by the participating site. If 
there are concerns for protocol compliance, issues that impact subject safety or the 
integrity of the study are found, or trends identified b ased on areas of need, additional 
monitoring visits may be scheduled. On site monitoring visits can be supplemented with 
virtual monitoring assessments, provided that the minimum monitoring frequencies are 
adhered to.  
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
99  
 Virtual  Monitoring: The Coordinating Center will  request  source documentation from 
Participating Institutions as needed to complete monitoring activities. Participating 
Institutions  will be asked  to forward  de-identified  copies  of participants’  medical  record 
and source documents  to the Coordinating Center to aid in source documentation 
verification.  
5.2 Monitoring Reports  
 
The DF/HCC Sponsor will review all monitoring reports for on -site and remote  
monitoring of Participating Institutions to ensure protocol compliance. The DF/HCC 
Sponsor may increase the monitoring activities at Participating Institutions that are unable 
to comply with the protocol, DF/HCC Sponsor requirements or federal and local 
regulations. Participating Institutions may also be subject to an audit as determined by  the 
DF/HCC Sponsor.  
 
5.3 Accrual  Monitoring  
 
Prior to extending a protocol to an external site, the DF/HCC Sponsor will establish 
accrual  requirements  for each participating  institution.  Accrual  will be monitored  for each 
participating institution by the DF/H CC Sponsor or designee. Sites that are not meeting 
their accrual expectations may be subject to termination. Due to the small patient 
population, the accrual minimum requirement is at least 1 patient every two years.  
 
6. AUDITING:  QUALITY  ASSURANCE  
 
Auditing  is a method  of Quality  Assurance.  Its main  focus  is to measure  whether  standards 
and procedures were followed. Auditing is the systematic and independent examination of 
all trial related activities and documents.  Audits determine if evaluated acti vities were 
appropriately conducted and whether data was generated, recorded and analyzed, and 
accurately reported per the protocol, Standard Operating Procedures (SOPs), and the Code 
of Federal Regulations (CFR).  
 
6.1 Audit  Plan:  DF/HCC  Sponsored  Trials  
 
One on-site audit will be scheduled by the QACT, assuming at least three participants  
have been treated on protocol at the site, or at the discretion of the DF/HCC sponsor. 
Approximately 3 -4 participants would be audited at the site over a 2 day period.  If 
violations which impact participant safety or the integrity of the study are found, more 
participant records may be audited.  
 
6.2 Audit  Notification  
 
It is the Participating Institution’s responsibility to notify the Coordinating Center of all 
scheduled audit dat es (internal or NCI) and re -audit dates (if applicable), which involve 
this protocol.  All institutions  will forward  a copy  of final audit  and/or  re-audit  reports  and 
Protocol  #: 14 -338 
Version  Date:  4.9.2021  
CONFIDENTIAL  
This document is  confidential. Do  not disclose or use  except as authorized.  
100  
 corrective action plans (if applicable) to the Coordinating Center, within 1 2 weeks after  
the audit date.  
 
6.3 Audit  Reports  
 
The DF/HCC Sponsor will review all final audit reports and corrective action plans if 
applicable. The Coordinating Center, must forward these reports to the DF/HCC QACT 
per DF/HCC policy for review by the DF/HCC Audit Committee. Based upon the audit 
assess ments the DF/HCC Audit Committee could accept or conditionally accept the audit 
rating and final report. Conditional approval could require the DF/HCC Sponsor to 
implement recommendations or require further follow -up. For unacceptable audits, the 
DF/HCC Au dit Committee would forward the final audit report and corrective action plan 
to the DFCI IRB as applicable.  
 
6.4 Participating  Institution  Performance  
 
The DF/HCC Sponsor and DFCI IRB is charged with considering the totality of an 
institution’s performance in  considering institutional participation in the protocol.  
 
6.4.1 Corrective  Actions  
 
Participating Institutions that fail to meet the performance goals of accrual, submission of 
timely and accurate data, adherence to protocol requirements, and compliance with state 
and federal regulations, may be recommended for a six -month probation perio d. Such 
institutions must respond with a corrective action plan and must demonstrate during the 
probation period that deficiencies have been corrected, as evidenced by the improved 
performance measures. Participating Institutions that fail to demonstrate s ignificant 
improvement will be considered by the DF/HCC Sponsor for revocation of participation.  
A DF/HCC Sponsor and/or the DFCI IRB may terminate a site’s participation if it is 
determined that a site is not fulfilling its responsibilities as described a bove.  